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Abstract 
Functional amyloid-forming peptides can be found in nature, including stored in secretory 
granules as hormones. In contrast to toxic amyloid-forming peptides, the fibrillisation process 
for functional amyloids is typically “reversible”, a mechanism that may be related to the lack 
of toxicity for these amyloids. The mechanism of fibrillisation for functional amyloids has been 
reported to be dependent on changes to environmental conditions such as pH, temperature and 
solvent conditions. Some molecules are known to act as aggregation enhancers for functional 
amyloids, including, metal ions, heparin and lipid bilayer while others inhibit fibrillisation. 
Lipid membranes have been shown to significantly affect fibrillisation, and membrane-
mediated fibrillisation has been well characterised for toxic amyloid species such as the 
amyloid-beta peptide involved in Alzheimer’s disease.  Depending on the lipid composition 
and physicochemical properties of the membrane, lipid membranes can both promote or inhibit 
fibril growth. The following parameters, including a surface charge on the membrane, 
membrane fluidity, chain packing, and lipid solubility have been shown to drive changes in the 
electrostatic and hydrophobic interactions between the peptide and the membrane, and hence 
the rate of fibrillisation. However, essentially nothing is known about the membrane-mediated 
assembly of functional amyloid-forming peptides.  
In this thesis, the effect of the lipid membrane on fibrillisation of five different peptide 
hormones (Somatostatin, Oxytocin, Vasopressin, Substance P and Deslorelin) was 
investigated. In general, liposomes were used as model membranes.  In Chapter 1, the effect of 
liposomes of different lipid composition on the fibrillisation of SST was investigated.  SST 
reliably self-assembles into amyloid fibrils above a critical concentration (>5% w/w). 
Interactions of SST with the lipid bilayer were characterised using synchrotron radiation 
circular dichroism and intrinsic tryptophan fluorescence. The kinetics of fibrillisation was 
determined using a Thioflavin T assay, while the morphology of fibrils formed was directly 
visualised using atomic force microscopy (AFM). Reciprocal effects of the peptide and the 
growing fibril on the lipid bilayer were investigated using synchrotron small-angle x-ray 
scattering (SAXS).   
In Chapter 4 a similar suite of techniques was used to determine the effect of the lipid 
membrane on the fibrillisation of two additional cyclic peptides, the neurohypophysial 
hormone-like peptides, vasopressin (AVP-9) and oxytocin (OT-9).  These two nine-amino acid 
peptides are likely to form aggregates due to mutations and are known to form functional 
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amyloids in secretory granules. They are part of a family of structurally and functionally related 
peptide hormones with a conserved intramolecular ring, allowing us to determine whether 
substitutions in amino acids can impact the interactions of these peptides with the membrane 
and subsequent fibrillisation.   
In Chapter 5 the effect of linear vs cyclic peptides was determined using two linear peptides, 
substance P (SP), and Deslorelin (Des).  Substance P has been reported to form fibrils and has 
also been observed to self-assemble into nanotubes.  Deslorelin is an analogue of LHRH, which 
has also been shown to adopt nanotubes in solution.   
Finally, in Chapter 6, the anti-amyloidogenic effect of the polyphenol resveratrol, and its 
derivatives, Trimethoxy stilbene (TMS) and trans-stilbene (TS) was investigated using 
Somatostatin. Several studies have reported the anti-amyloidogenic effect of resveratrol on 
toxic amyloids such as Aβ and HIAPP. To our knowledge, this is the first study conducted on 
the effect of stilbenes on functional amyloids (somatostatin). All three stilbenes were shown to 
inhibit fibril formation in solution.  When doped in a bilayer, this effect changes, particularly 
for TS, which actually promoted fibril growth.   
This body of work has significantly added to our understanding of the effect of the lipid bilayer 
on the fibrillisation of functional amyloids, about which almost nothing is known to date.  The 
trends observed not only assist in our fundamental understanding of how such peptide 
hormones are stored in vivo, but also adds to our understanding of fundamental peptide-lipid 
interactions, and the differences in toxicity between toxic and functional amyloids.   
 
 
 
 
 
 
  
VIII 
 
Table of Contents 
 
Declaration .............................................................................................................................................. II 
Acknowledgements ................................................................................................................................ III 
Conference presentations ........................................................................................................................ V 
Abstract .................................................................................................................................................. VI 
Table of Contents ................................................................................................................................. VIII 
List of figures and tables ....................................................................................................................... XII 
Abbreviations ................................................................................................................................... XXVIII 
Explanatory notes .............................................................................................................................. XXXII 
1. The role of the lipid bilayer and molecular additives on fibrillisation of functional amyloid-forming 
peptides ................................................................................................................................................... 1 
1.1 Introduction ..................................................................................................................................... 1 
1.2 Common structural features and mechanism of amyloid formation ................................................. 2 
1.2.1 Toxic Amyloids ......................................................................................................................... 2 
1.2.2 Functional Amyloids .................................................................................................................. 5 
1.3 Molecular aggregation modifiers ...................................................................................................... 8 
1.3.1 Impact of Metal Ions .................................................................................................................. 8 
1.3.2 Impact of Heparin/Glycosaminoglycans (GAGs) ...................................................................... 8 
1.3.3 Effects of Resveratrol (RSV) ..................................................................................................... 9 
1.4 Membrane-based aggregation modifiers ......................................................................................... 10 
1.4.1 Ganglioside clusters, Cholesterol and Sphingomyelin ............................................................. 12 
1.4.2 Charged lipids .......................................................................................................................... 13 
1.4.3 Neutral lipid ............................................................................................................................. 15 
1.4.4 Physicochemical properties of the lipid bilayer ....................................................................... 16 
1.5 Effect of amyloid-forming peptides on the structure of the lipid bilayer ........................................ 18 
1.6 Model Lipid Bilayers ...................................................................................................................... 20 
1.6.1 Bulk Lamellar Phase ................................................................................................................ 21 
1.6.2 Liposomes ................................................................................................................................ 22 
1.7 Effect of lipid bilayer composition on the fibrillisation of functional amyloid-forming peptides .. 23 
2. Materials and Methods ................................................................................................................... 29 
2.1 Materials ......................................................................................................................................... 29 
2.1.1 Lipids ....................................................................................................................................... 29 
2.1.2 Non-lipid materials .................................................................................................................. 29 
2.1.3 Peptides .................................................................................................................................... 29 
  
IX 
 
2.2 Methods........................................................................................................................................... 30 
2.2.1 Liposome Preparation .............................................................................................................. 30 
2.2.2 Thioflavin T (ThT) Binding Assay .......................................................................................... 30 
2.2.3 Tryptophan Fluorescence ......................................................................................................... 31 
2.2.4 Atomic Force Microscopy (AFM) ........................................................................................... 31 
2.2.5 Circular Dichroism (CD) ......................................................................................................... 32 
2.2.6 Synchrotron Circular Dichroism (SR-CD) (ASTRID II facility in Aarhus Denmark) sample 
measurements and characterisation ................................................................................................... 33 
3. Effect of lipid composition on fibrillisation of the functional amyloid-forming peptide 
Somatostatin-14 (SST-14) ................................................................................................................... 35 
3.1 Introduction ..................................................................................................................................... 35 
3.2 Materials and Methods .................................................................................................................... 38 
3.2.1 Liposome preparation and analysis .......................................................................................... 38 
3.2.2 Small Angle X-ray Diffraction (SAXD) on bulk lamellar sample, preparation and data 
analysis .............................................................................................................................................. 38 
3.2.3 Small Angle X-ray Scattering (SAXS) .................................................................................... 39 
3.2.4 Preparation of Functional amyloid-forming peptides (FAFP’s) .............................................. 40 
3.2.5 Thioflavin T (ThT) Binding Assay .......................................................................................... 40 
3.2.6 Time-resolved kinetic studies using Dynamic Light Scattering (DLS) ................................... 40 
3.2.7 Atomic Force Microscopy (AFM) ........................................................................................... 40 
3.2.8 Tryptophan Fluorescence ......................................................................................................... 40 
3.2.9 Synchrotron Circular Dichroism (SR-CD) (ASTRID II facility in Aarhus Denmark) sample 
measurements and characterisation ................................................................................................... 40 
3.3 Results ............................................................................................................................................. 41 
3.3.1 Interaction with the lipid bilayer changes the secondary structure of SST-14 and the kinetics 
of fibril growth .................................................................................................................................. 41 
3.3.2 The peptide and bilayer interaction reveals no significant changes to bilayer size and shape . 48 
3.3.3 The interaction between the peptide and the lipid bilayer do not significantly alter the bilayer 
structure ............................................................................................................................................ 49 
3.3.4 Clear morphological differences are observed between fibrils formed in the buffer and those 
incubated with liposomes .................................................................................................................. 54 
3.4 Discussions ..................................................................................................................................... 58 
4. The interaction between the cyclic neurohypophysial hormone-like peptides Vasopressin 
(AVP-9) and Oxytocin (OT-9) and model membranes .................................................................... 62 
4.1 Introduction ..................................................................................................................................... 62 
4.2 Materials and Methods .................................................................................................................... 64 
4.2.1 Liposome preparation .............................................................................................................. 64 
4.2.2 Preparation of Functional amyloid-forming peptides (FAFP’s) .............................................. 64 
  
X 
 
4.2.3 Thioflavin T (ThT) Binding Assay .......................................................................................... 64 
4.2.4 Atomic Force Microscopy (AFM) ........................................................................................... 64 
4.2.5 Circular Dichroism (CD) ......................................................................................................... 64 
4.3 Results ............................................................................................................................................. 65 
4.3.1 Effect of the lipid bilayer on the secondary structure of cyclic neurohypophysial hormones . 65 
4.3.2 Effect of the lipid bilayer on the kinetics of fibril growth of OT-9 ......................................... 69 
4.3.3 Effect of the lipid bilayer on the kinetics of fibril growth for AVP ......................................... 74 
4.3.4 AFM a surface technique used to study aggregate deposited from solution both in the absence 
and presence of liposomes ................................................................................................................ 76 
4.4 Discussion ....................................................................................................................................... 78 
5. Effect of lipid composition on fibrillisation in linear functional amyloid-forming peptides, 
Substance P-11 (SP-11) and Deslorelin-10 (Des-10) ......................................................................... 83 
5.1 Introduction ..................................................................................................................................... 83 
5.2 Materials and Methods .................................................................................................................... 85 
5.2.1 Liposome preparation .............................................................................................................. 85 
5.2.2 Preparation of Functional amyloid-forming peptides (FAFP’s) .............................................. 85 
5.2.3 Thioflavin T (ThT) Binding Assay .......................................................................................... 86 
5.2.4 Atomic Force Microscopy (AFM) ........................................................................................... 86 
5.2.5 Circular Dichroism (CD) ......................................................................................................... 86 
5.2.6 Synchrotron Circular Dichroism (SR-CD) (ASTRID II facility in Aarhus Denmark) sample 
measurements and characterisation ................................................................................................... 86 
5.3 Results ............................................................................................................................................. 86 
5.3.1 Interaction with the lipid bilayer changes the secondary structure of SP-11 and Des-10 ........ 86 
5.3.2 Effect of the lipid bilayer on the kinetics of aggregation for SP-11 and .................................. 91 
Des-10 ............................................................................................................................................... 91 
5.3.3 Clear morphological differences are observed between aggregates formed in the buffer and 
those incubated with liposomes ........................................................................................................ 97 
5.4 Discussion ....................................................................................................................................... 99 
6. Effects of Stilbenes on functional amyloid-forming peptide Somatostatin-14 (SST-14)......... 103 
6.1 Introduction ................................................................................................................................... 103 
6.2 Materials and Methods .................................................................................................................. 106 
6.2.1 Liposome preparation ............................................................................................................ 106 
6.2.2 Preparation of stilbenes and liposome doped with stilbenes (RSV, TMS and TS) ................ 106 
6.2.3 Preparation of Functional amyloid-forming peptides (FAFP’s) ............................................ 106 
6.2.4 Thioflavin T (ThT) Binding Assay ........................................................................................ 106 
6.2.5 Tryptophan Fluorescence ....................................................................................................... 107 
6.2.6 Circular Dichroism (CD) ....................................................................................................... 107 
  
XI 
 
6.2.7 Atomic Force Microscopy (AFM) ......................................................................................... 107 
6.3 Results ........................................................................................................................................... 107 
6.3.1 Addition of RSV to liposomes ............................................................................................... 107 
6.3.2 SST-14 interaction with the lipid bilayer doped with RSV ................................................... 109 
6.3.3 Effect of RSV on fibrillisation of SST-14 ............................................................................. 113 
6.3.4 SST-14 interaction with the lipid bilayer doped with tri-methoxy RSV and trans-stilbene .. 118 
6.3.5 Effect of the stilbenes TMS and TS on fibrillisation of SST-14 ............................................ 121 
6.3.6 SST-14 interaction with anionic charged lipid bilayer doped with tri-methoxy RSV and trans-
stilbene ............................................................................................................................................ 127 
6.3.7 Clear morphological differences are observed between fibrils formed in the buffer and RSV 
doped with lipid vesicles ................................................................................................................. 130 
6.4 Discussion ................................................................................................................................. 132 
7. Conclusion and Future work ....................................................................................................... 136 
References ........................................................................................................................................... 139 
Appendix ............................................................................................................................................. 160 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
XII 
 
List of figures and tables 
Figure Title Page 
1.1 Shows amyloid-forming proteins that form β-sheets are linked 
to various human diseases (adopted from (1))  
1 
1.2 A schematic representation of the aggregation process for 
Toxic amyloids. Aggregation proceeds by aggregation from 
the monomeric state to a fibrillar structure through oligomeric 
intermediates (adapted from (2)) 
3 
1.3 The geometric isomers of RSV (adapted from (3)) 9 
1.4 Shows a typical biological membrane (adapted from (4)) 10 
1.5 Shows the model of Aβ-fibril formation on ganglioside clusters 
in lipid rafts (adopted from (5)) 
12 
1.6 Shows the two types of oligomers and its ability to interact with 
the membrane (adopted from (6)) 
13 
1.7 Schematic representation of interactions of amyloidogenic 
IAPP (black lines) with SPBs (Supported Planar bilayers), 
depicting significant reduction in the fluidity of membrane 
(adapted from (adapted from (7)) 
15 
1.8  Schematic illustration for the mechanism of TasA interacting 
with the membrane (adopted from (8)) 
15 
1.9 Schematic of Aβ interacting with lipids and phase separation 
in the bilayer shows nonhomogeneity (adopted from (9)) 
16 
1.10  Illustration of Aβ interacting with gel phase and fluid phase 
(adapted from (10)) 
17 
1.11 Illustration of three possible mechanism of Aβ encouraged 
membrane damage (adopted from (11)) 
19 
1.12 (A-C) Shows the clustered liposomes distorted by short fibrils. 
(D) A 3D model of a distorted liposome (blue), surrounding 
20 
  
XIII 
 
fibrils visualised by cryo-electron tomography (cET) (adopted 
from (12)) 
1.13 Shows the polymorphic phases and corresponding dynamic 
molecular shapes of a component of phospholipids (adopted 
from (13-16)) 
21 
1.14 Shows a typical lamellar phase or phospholipid bilayer (lipids-
grey and water-red) (adopted from (17)) 
22 
1.15 A structure of a liposome (adapted from (18)) 23 
1.16 Shows the structure of five different lipid molecules (adapted 
from (10)) 
24 
1.17 Schematic representation of fluid (left) and gel (right) phase 
bilayer (adapted from (10))  
25 
1.18 Shows the structure of anionic lipids and cholesterol (adapted 
from (5, 19)) 
25 
3.1 Shows the process of nucleation-dependent fibril formation for 
Toxic vs Functional amyloids (adapted from (5)) 
36 
3.2 Shows the amino acid sequence and disulphide link for SST-
14 (adapted from (20))  
38 
3.3 (a) SR-CD spectra for SST-14 co-incubated in vesicles after 3 
hours and (b) SR-CD spectra for SST-14 co-incubated in 
vesicles after 72 hours 
41 
3.4 SST-14 environment in the bilayer measured by Tryptophan 
Fluorescence 
43 
3.5 (a) Thioflavin T (ThT) assay of SST-14 incubated in NaCl, (b) 
ThT assay of SST-14 and SST-14 at 5 % (w/w) co-incubated 
with unsaturated and saturated vesicle with increase in chain 
length impacting SST fibrillisation, (c) ThT assay of SST-14 
and SST-14 co-incubated in DOPC, DOPC vesicle doped with 
46 
  
XIV 
 
cholesterol, DMPC, DMPC doped with cholesterol, DOPC 
doped with DOPS and DMPC doped with DMPS 
3.6 Size distribution of vesicles of various compositions co-
incuated with SST-14 (5% w/w) for 1 week as determined by 
DLS  a) DOPC, b) DMPC, c) DOPC doped with cholesterol 
and d) DOPC doped with DOPS 
48 
3.7 Shows the hydrodynamic size of the vesicles with SST-14 over 
1 week period 
49 
3.8 Shows the 1D diffraction pattern of Intensity vs q for bulk 
lipids at varying SST concentration. Small angle X-ray 
scattering data were obtained ~7 h after setup of the plates.  
50 
3.9 The 1D diffraction pattern of Intensity vs q for bulk lipids at 
varying SST concentration. Small angle X-ray scattering data 
were obtained ~7 h after setup of the plates.  
51 
3.10 Small angle X-ray scattering (SAXS) of Multilamellar vesicles 
(MLVs) co-incubated with SST, (a) DOPC vesicle co-
incubated with SST and (b) DOPC vesicle doped with 
cholesterol co-incubated with SST, (c) DMPC vesicles co-
incubated with SST 
53 
3.11 Atomic Force Microscopy Analysis of 5% (w/w) SST fibrils 
and SST fibrils co-incubated with DMPC lipid vesicles, (a-b) 
topographic images of (a) SST fibrils displaying typical 
amyloid-like unbranched twisted fibrillar structure, (b) SST co-
incubated with DMPC vesicles, the formed fibrils display a 
more heterogeneous structure and evidence of the lipid coating 
of the fibrils is highlighted by the arrows, (c-d) statistical 
analysis (approximately 500 fibrils) of fibrillar species formed 
and (e-f) Persistance length calculations, for (e) SST and (f) 
SST+DMPC, very little difference, slight increase in stiffness 
for the SST + DMPC fibril 
56 
  
XV 
 
3.12 High Resolution AFM images of the change in fibril 
nanostructure between SST and SST + DMPC fibrils (a-b) 
topographical AFM images of (a) SST and (b) SST + DMPC 
fibrils, (c-d) line section through one individual fibril (c) SST 
and (d) SST + DMPC. (e-f) Direct Fourier Transform analysis 
of pitch of multiple fibrils (g-h) Auto-Correlation Function 
analysis of twist angle of multiple fibrils 
57 
3.13 An illustration of SST-14 fibril interacting with fluid DMPC 
bilayer, inspired by AFM image (Figure. 3.9b) 
60 
4.1 The amino acid sequences for neurohypophysial hormones (a. 
AVP and b. OT) (adapted from (21)) 
62 
4.2 Secondary structures of OT-9, AVP-9 and AVP:OT (1:1) at 1 
mg mL-1 analysed using Circular Dichroism (CD) 
65 
4.3 (a) CD spectra for 1 mg mL-1 (0.01% w/w) OT-9 co-incubated 
with saturated lipid vesicles after 3 hours, (b) after 72 hours, 
(c) CD spectra for 1 mg mL-1 OT-9 co-incubated with vesicles 
doped with various lipid compositions after 3 hours and (d) 
after 72 hours   
67 
4.4 (a) CD spectra for 1 mg mL-1 (0.01% w/w) AVP-9 co-
incubated in saturated lipid vesicles after 3 hours, (b) after 72 
hours, (c) CD spectra for 1 mg mL-1 AVP-9 co-incubated in 
vesicles doped with various lipid compositions after 3 hours 
and (d) after 72 hours 
68 
4.5 (a) CD spectra for 1 mg mL-1 (0.01% w/w) AVP:OT (1:1) co-
incubated in saturated lipid vesicles after 3 hours, (b) after 72 
hours, (c) CD spectra for 1 mg mL-1 AVP:OT (1:1) co-
incubated in vesicles doped with various lipid compositions 
after 3 hours, (b) after 72 hours 
69 
4.6 (a) Thioflavin T (ThT) assay for OT-9 in buffer over a 1-week 
period, (b) ThT assay for OT-9 at 0.5% (w/w) co-incubated 
71 
  
XVI 
 
with unsaturated (DOPC) and saturated (DLPC, DMPC, DPPC 
and DSPC) vesicles with increase in chain length, (c) ThT 
assay for OT-9 at 0.5% (w/w) co-incubated with unsaturated 
and saturated vesicle doped with cholesterol and (d) ThT assay 
for OT-9 at 0.5% (w/w) co-incubated with unsaturated and 
saturated vesicle doped with charged lipids (DMPS/DOPS)  
4.7 (a) ThT assay for vasopressin (AVP-9) in buffer over a 1-week 
period, (b) ThT assay for AVP-9 at 5% (w/w) co-incubated 
with unsaturated and saturated vesicle with an increase in chain 
length, (c) ThT assay for AVP-9 at 5% (w/w) co-incubated 
with unsaturated and saturated vesicle doped with cholesterol 
and (d) ThT assay for AVP-9 at 5% (w/w) co-incubated with 
unsaturated and saturated vesicle doped with charge 
75 
4.8 ThT assay for AVP-9 at 5% (w/w) co-incubated with saturated 
vesicle doped with an increase in the concentration of the 
charged lipid DMPS (5 – 35 mol%) 
76 
4.9 Topographic images of (a) short OT fibrils at 0.5% (w/w) in 
aqueous solution and (b) image of a single OT fibril  
77 
4.10 Topographic image showing no OT fibrils detected with 
DMPC 
77 
4.11 Topographic images of (a) 5 % (w/w) AVP in aqueous solution 
and (b) AVP incubated with DMPC+DMPS vesicles 
78 
5.1 An illustration of the linear structure and amino acid sequence 
of (a) SP and (b) Deslorelin similar to LHRH, (adapted from 
(22) (23)) 
84 
5.2 Secondary structures of SP-11 at 0.3 mg mL-1 (0.03 % w/w) 
analysed using Synchrotron Circular Dichroism (SR-CD), and 
Des-9 at 0.3 mg mL-1 analysed using Circular Dichroism (CD) 
87 
  
XVII 
 
5.3 (a) SR-CD spectra for SP-11 at 0.3 mg mL-1 (0.03 % w/w) co-
incubated in vesicles after 3 hours, (b) SR-CD spectra for SP-
11 co-incubated in vesicles after 72 hours  
88 
5.4 (a) CD spectra for Des-9 at 2 mg mL-1 (0.2% w/w) co-
incubated in vesicles after 3 hours, (b) CD spectra for Des-9 
co-incubated in vesicles after 72 hours 
90 
5.5 ThT assay performed over 1-week period for (a) Substance P 
(SP-11) in NaCl, (b) 10% w/w or 5 mol% SP-11, co-incubated 
with unsaturated and saturated vesicle with an increase in chain 
length, (c) SP (5 mol%) co-incubated with DMPC, DMPC 
doped with cholesterol and (d) SP (5 mol%) co-incubated with 
DOPC, DOPC vesicle doped with cholesterol and DOPC 
doped with DOPS  
92 
5.6 ThT assay performed over 1-week period for (a) Deslorelin 
(Des-9) in NaCl, (b) 10% w/w or 5 mol% Des-9, co-incubated 
with unsaturated and saturated vesicle with an increase in chain 
length, (c) Des (5 mol%) co-incubated with DMPC, DMPC 
doped with cholesterol and (d) Des-9 (5 mol%) co-incubated 
with DOPC, DOPC vesicle doped with cholesterol and DOPC 
doped with DOPS 
95 
5.7 Atomic force microscopy (AFM) analysis of SP fibrils at 10% 
(w/w) and SP fibrils co-incubated with DMPC lipid vesicles, 
(a-b) topographic images of (a) SP fibrils displaying needle-
like fibrillar structure and (b) SP co-incubated with DMPC 
vesicles 
97 
5.8 Topographic images of (a) Des fibrils at 10% (w/w) in the 
absence of DMPC vesicles assemblies can be seen better in the 
adhesion and (b) deformation channels 
98 
5.9 Topographic images of Des fibrils in DMPC displaying a 
regular looking amyloid (a) with periodic twisting structure (b) 
the twists can be clearly seen in the deformation channel   
98 
  
XVIII 
 
5.10 Illustrations of (a) an electron micrograph image of triptorelin 
in water (24) and (b) nanotube self-assembly (25)   
100 
6.1 Shows the structure of stilbenes (a) RSV (RSV) (26), (b) 
TMS (TMS) (27) and (c) TS (27) 
104 
6.2 Diagram showing RSV location in the bilayer of DPPC/Chol 
(adapted from (28)) 
104 
6.3 Shows the Dynamic light scattering (DLS) curves for pure 
saturated chain vesicles and saturated vesicles doped with 5 
mol% RSV (a) DLPC, (b) DMPC, (c) DPPC and (d) DSPC 
108 
6.4 DLS curve for pure DMPC+Chol vesicle and vesicle doped 
with 5 mol% RSV 
109 
6.5 DLS curve for (a) Pure DOPC+DOPS vesicle and vesicle 
doped with 5 mol% RSV and (b) Pure DMPC+DMPS vesicle 
and vesicle doped with 5 mol% RSV 
109 
6.6 (a) CD spectra for SST-14 0.01% w/w (0.1 mg mL-1) co-
incubated in saturated vesicles doped with 5 mol% RSV, (b) 
CD spectra for SST-14 co-incubated in DMPC bilayer doped 
with cholesterol and 5 mol% RSV and (c) CD spectra for SST-
14 co-incubated in bilayers (DMPC & DOPC) doped with 
anionic charge (DMPS & DOPS) and 5 mol% RSV 
111 
6.7 SST-14 environment in bilayer and bilayer doped with RSV, 
measured by Tryptophan Fluorescence 
112 
6.8 Shows the ThT assay curves for 5% (w/w) SST-14 incubated 
in buffer (NaCl) vs stilbenes co-dissolved using DMSO 
114 
6.9 Shows the ThT assay curves for 5% (w/w) SST-14 co-
incubated in saturated chain lipids doped with 5 mol% RSV (a) 
DLPC, (b) DMPC, (c) DPPC vesicles and (d) DSPC   
115 
  
XIX 
 
6.10 Shows the ThT assay curves for 5% (w/w) SST-14 co-
incubated in the buffer and DMPC/Chol vesicles doped with 5 
mol% RSV 
116 
6.11 Illustrations of: (a) ThT assay curves for 5% (w/w) SST-14 co-
incubated in buffer and DOPC/DOPS vesicles doped with 5 
mol% RSV (b) ThT assay curves for 5% (w/w) SST-14 co-
incubated in buffer and DMPC/DMPS vesicles doped with 5 
mol% RSV 
117 
6.12 Shows the Dynamic light scattering (DLS) curves for pure 
saturated chain vesicles and saturated vesicles doped with 5 
mol% stilbenes (a) DLPC, (b) DMPC, (c) DPPC and (d) DSPC 
119 
6.13 SST-14 environment in bilayer and bilayer doped with 
stilbenes, measured by Tryptophan Fluorescence 
120 
6.14 Shows the ThT assay curves for 5% (w/w) SST-14 incubated 
in buffer (NaCl) vs stilbenes co-dissolved using DMSO 
122 
6.15 Shows the ThT assay curves for 5% (w/w) SST-14 co-
incubated in saturated chain lipids doped with 5 mol% stilbenes 
(a) DLPC, (b) DMPC, (c) DPPC vesicles and (d) DSPC   
123 
6.16 DLS curve for pure DMPC+Chol vesicle and vesicle doped 
with 5 mol% stilbenes 
125 
6.17 Shows the ThT assay curves for 5% (w/w) SST-14 co-
incubated in the buffer and DMPC/Chol vesicles doped with 5 
mol% stilbenes 
126 
6.18 DLS curve for (a) Pure DOPC+DOPS vesicle and vesicle 
doped with 5 mol% stilbenes and (b) Pure DMPC+DMPS 
vesicle and vesicle doped with 5 mol% stilbenes 
127 
6.19 Illustrations of: (a) ThT assay curves for 5% (w/w) SST-14 co-
incubated in buffer and DOPC/DOPS vesicles doped with 5 
mol% stilbenes (b) ThT assay curves for 5% (w/w) SST-14 co-
128 
  
XX 
 
incubated in buffer and DMPC/DMPS vesicles doped with 5 
mol% stilbenes 
6.20 AFM analysis of SST-14 fibrils at 10% (w/w) with RSV, 
topographic images of (a) SST-14 with 5 mol% RSV 
displaying little or fibrils and (b) SST-14 co-incubated with 
DMPC vesicles doped with 5 mol% RSV displaying much 
shorter fibrils 
130 
6.21 AFM analysis of SST-14 fibrils at 10% (w/w) with TS, 
topographic images of (a) SST-14 with 5 mol% TS displaying 
little or no fibrils and (b) SST-14 with DMPC vesicles doped 
with 5 mol% TS displaying neat long fibrils 
131 
6.22 AFM analysis of SST-14 fibrils at 10% (w/w) with TMS, 
topographic images of (a) SST-14 with 5 mol% TMS 
displaying little or no fibrils and (b) SST-14 with DMPC 
vesicles doped with 5 mol% TMS displaying neat long fibrils  
132 
6.23 Diagrammatic illustrations of how RSV inhibits SST 
fibrillisation by disturbing the lipid monolayer by a dual effect 
approach (adapted from (29))  
133 
S8.1 
 
Shows the DLS curves for liposomes doped with various lipid 
compositions 
160 
S8.2 ThT curve fit for SST (5% w/w) in NaCl 164 
S8.3 ThT curve fit for SST (5% w/w) in DOPC 165 
S8.4 ThT curve fit for SST (5% w/w) in DLPC 165 
S8.5 ThT curve fit for SST (5% w/w) in DMPC 166 
S8.6 ThT curve fit for SST (5% w/w) in DPPC 166 
S8.7 ThT curve fit for SST (5% w/w) in DSPC 167 
S8.8 ThT curve fit for SST (5% w/w) in DOPC+Chol 167 
  
XXI 
 
S8.9 ThT curve fit for SST (5% w/w) in DMPC+Chol 168 
S8.10 ThT curve fit for SST (5% w/w) in DOPC+DOPS 168 
S8.11 ThT curve fit for SST (5% w/w) in DMPC+DMPS 169 
S8.12 ThT curve fit for OT (0.1% w/w) in NaCl 169 
S8.13 ThT curve fit for OT (0.5% w/w) in NaCl 170 
S8.14 ThT curve fit for OT (5% w/w) in NaCl 170 
S8.15 ThT curve fit for OT (0.5% w/w) in DOPC 171 
S8.16 ThT curve fit for OT (0.5% w/w) in DOPC+Chol 171 
S8.17 ThT curve fit for OT (0.5% w/w) in DOPC+DOPS 172 
S8.18 ThT curve fit for OT (0.5% w/w) in DLPC 172 
S8.19 ThT curve fit for OT (0.5% w/w) in DMPC 173 
S8.20 ThT curve fit for OT (0.5% w/w) in DMPC+Chol 173 
S8.21 ThT curve fit for OT (0.5% w/w) in DMPC+DMPS 174 
S8.22 ThT curve fit for OT (0.5% w/w) in DPPC 174 
S8.23 ThT curve fit for OT (0.5% w/w) in DSPC 175 
S8.24 ThT curve fit for AVP (5% w/w) in 95DMPC+5DMPS 175 
S8.25 ThT curve fit for AVP (5% w/w) in 85DMPC+15DMPS 176 
S8.26 ThT curve fit for AVP (5% w/w) in 75DMPC+25DMPS 176 
S8.27 ThT curve fit for AVP (5% w/w) in 65DMPC+35DMPS 177 
S8.28 ThT curve fit for Des (10% w/w) in DOPC 177 
S8.29 ThT curve fit for Des (10% w/w) in DOPC+Chol 178 
S8.30 ThT curve fit for Des (10% w/w) in DOPC+DOPS 178 
S8.31 ThT curve fit for Des (10% w/w) in DLPC 179 
S8.32 ThT curve fit for Des (10% w/w) in DMPC 179 
  
XXII 
 
S8.33 ThT curve fit for Des (10% w/w) in DPPC 180 
S8.34 ThT curve fit for Des (10% w/w) in DSPC 180 
S8.35 ThT curve fit for Des (10% w/w) in DMPC+Chol 181 
S8.36 ThT curve fit for SP (10% w/w) in DLPC 181 
S8.37 ThT curve fit for SP (10% w/w) in DMPC 182 
S8.38 ThT curve fit for SP (10% w/w) in DPPC 182 
S8.39 ThT curve fit for SP (10% w/w) in DSPC 183 
S8.40 ThT curve fit for SP (10% w/w) in DOPC+Chol 183 
S8.41 ThT curve fit for SP (10% w/w) in DMPC+DMPS 184 
S8.42 ThT curve fit for SST (5% w/w) in RSV (RSV) 184 
S8.43 ThT curve fit for SST (5% w/w) in TS (TS) 185 
S8.44 ThT curve fit for SST (5% w/w) in trimethoxy RSV (TMS) 185 
S8.45 ThT curve fit for SST (5% w/w) in DLPC+RSV 186 
S8.46 ThT curve fit for SST (5% w/w) in DLPC+TMS 186 
S8.47 ThT curve fit for SST (5% w/w) in DLPC+TS 187 
S8.48 ThT curve fit for SST (5% w/w) in DMPC+RSV 187 
S8.49 ThT curve fit for SST (5% w/w) in DMPC+TS 188 
S8.50 ThT curve fit for SST (5% w/w) in DMPC+TMS 188 
S8.51 ThT curve fit for SST (5% w/w) in DMPC+Chol+RSV 189 
S8.52 ThT curve fit for SST (5% w/w) in DMPC+Chol+TS 189 
S8.53 ThT curve fit for SST (5% w/w) in DMPC+Chol+TMS 190 
S8.54 ThT curve fit for SST (5% w/w) in DMPC+DMPS+RSV 190 
S8.55 ThT curve fit for SST (5% w/w) in DMPC+DMPS+TS 191 
S8.56 ThT curve fit for SST (5% w/w) in DMPC+DMPS+TMS 191 
  
XXIII 
 
S8.57 ThT curve fit for SST (5% w/w) in DOPC+DOPS+TS 192 
S8.58 ThT curve fit for SST (5% w/w) in DOPC+DOPS+TMS 192 
S8.59 ThT curve fit for SST (5% w/w) in DPPC+RSV 193 
S8.60 ThT curve fit for SST (5% w/w) in DPPC+TS 193 
S8.61 ThT curve fit for SST (5% w/w) in DPPC+TMS 194 
S8.62 ThT curve fit for SST (5% w/w) in DSPC+RSV 194 
S8.63 ThT curve fit for SST (5% w/w) in DSPC+TS 195 
S8.64 ThT curve fit for SST (5% w/w) in DSPC+TMS 
 
195 
  
XXIV 
 
 
Tables 
 
Title 
 
Page 
1.1 Shows the diseases resulting from protein misfolding and 
subsequent aggregation into amyloid nanofibrils (30, 31) 
4 
1.2 Shows a list of functional amyloids in prokaryotic and 
eukaryotic organisms (2, 31, 32) 
5 
1.3 Includes a summary of model membranes involved in 
fibrillisation of amyloidogenic proteins and peptides (33) 
11 
3.1 The secondary structure of selected samples of SST-14 co-
incubated with liposomes, analysed using Dichroweb with 
Contin-LL algorithm method. *Quantitative analysis was 
performed for DOPC+SST, DOPC+DOPS+SST (3 and 72 
hours) and DMPC+SST (72 hours) since NRMSD > 0.250 (in 
appendix Table S8.3) 
42 
3.2 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST-14 at 
5% (w/w) in NaCl and vesicles doped with various lipid 
compositions over 1 week period 
47 
3.3 Shows the effect of SST addition (0.01 to 2.5% w/w) on D-
spacing of the lamellar phase of DMPC 
50 
3.4 Shows the effect of SST addition (0.01 to 2.5% w/w) on D-
spacing of the lamellar phase of DSPC 
51 
3.5 Lattice parameter or D-spacing for SST co-incubated with 
vesicle 
52 
4.1 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for OT-9 in the 
buffer over 1 week 
 
72 
  
XXV 
 
4.2 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for OT-9 at 
0.5% (w/w) in buffer and vesicles doped with various lipid 
compositions over 1 week 
73 
4.3 Shows the position, polarity, charge and hydrophobic amino 
acid residues for OT and AVP 
74 
4.4 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for AVP-9 at 
5% (w/w) in DMPC vesicles doped with DMPS at (5-35 mol%) 
76 
5.1 The secondary structure of SP-11 in liposomes analysed using 
Dichroweb with Contin-LL algorithm method 
89 
5.2 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SP at 10% 
(w/w) in NaCl and vesicles doped with various lipid 
compositions over 1 week 
93 
5.3 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for Des at 10% 
(w/w) in NaCl and vesicles doped with various lipid 
compositions over 1 week 
96 
6.1 Shows the topological polar surface area (tPSA) and partition 
coefficient (clogP) values for stilbenes    
105 
6.2 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) co-incubated in the buffer, RSV, saturated chain lipids 
and saturated chain lipids doped with 5 mol% RSV 
116 
6.3 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) co-incubated in the buffer and DMPC/Chol vesicles 
doped with 5 mol% RSV 
117 
  
XXVI 
 
6.4 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) co-incubated in the buffer and DOPC/DOPS and 
DMPC/DMPS vesicles doped with 5 mol% RSV 
118 
6.5 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) in buffer vs stilbenes 
122 
6.6 
        
Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) co-incubated in the buffer, stilbenes, saturated chain 
lipids and saturated chain lipids doped with 5 mol% stilbenes 
124 
6.7 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) co-incubated in the buffer and DMPC/Chol vesicles 
doped with 5 mol% stilbenes 
126 
6.8 Shows the lag phase, half-time, aggregation rate constant and 
the final fluorescence intensity of plateau phase for SST at 5% 
(w/w) co-incubated in the buffer and DOPC/DOPS and 
DMPC/DMPS vesicles doped with 5 mol% stilbenes 
129 
S8.1 Analysis of hydrophobicity, net charge, and % charged amino 
acids of SST-14 using PEPTIDE 2.0 (34) 
160 
S8.2 Shows the hydrodynamic size of liposomes doped with various 
compositions 
161 
S8.3 Quantitative analysis of the CD spectra for SST incubated in 
liposomes 
161 
S8.4 Shows the effect of concentration on kagg, half-time and lag 
phase for SST in NaCl 
162 
S8.5 Quantitative analysis of the CD spectra for SP incubated in 
liposomes after 72-hours 
162 
  
XXVII 
 
S8.6 Shows the hydrodynamic size of saturated lipid vesicles with 
the presence and absence of stilbenes at 5 mol% 
163 
S8.7 Shows the hydrodynamic size of DMPC+Chol vesicles with 
the presence and absence of stilbenes at 5 mol% 
163 
S8.8 Shows the hydrodynamic size of anionic charged vesicles with 
the presence and absence of stilbenes at 5 mol% 
164 
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
XXVIII 
 
Abbreviations 
Instruments & Techniques: 
CD – Circular Dichroism 
SRCD – Synchrotron Circular Dichroism  
SAXS – Small-angle X-ray scattering 
SAXD – Small-angle X-ray diffraction 
WAXS – Wide-angle X-ray scattering 
AFM – Atomic force microscopy 
cTEM – Cryo-transmission electron microscopy 
ThT – Thioflavin T  
DLS – Dynamic light scattering 
FTIR – Fourier-transform infrared spectroscopy 
SPR – Surface plasmon resonance 
XRD – X-ray diffraction 
ACF – Autocorrelation function 
DFT – Direct fourier transform 
MDS – Molecular dynamic simulations 
ESR – Electron spin resonance spectroscopy 
NMR – Nuclear magnetic resonance spectroscopy     
Lipid Derivatives: 
Tc – Phase transition temperature 
Lα – Liquid crystalline/fluid/liquid disordered bilayer phase 
Lo – liquid-ordered phase  
Lβ – Gel/solid ordered bilayer phase 
  
XXIX 
 
MLV – Multi-lamellar vesicles 
LUV – Large unilamellar vesicles 
SLB – Supported lipid bilayer 
PI – Phosphatidylinositol  
PIP – Phosphatidylinositol phosphate  
PIP2 – Phosphatidylinositol bisphosphate 
PE – Phosphatidylethanolamine 
PA – Phosphatidic acid 
PG – Phosphatidylglycerol   
CL – Cardiolipin  
SM – sphingomyelin  
GM1 – Gangliosides  
Unsaturated Lipids: (Total number of carbon atoms : Total number of double bonds) 
DOPC (18:1) – 1,2-dioleoyl-sn-glycero-3-phosphocholine   
POPC (16:0-18:1) – 1-palmitoyl-2-oleoyl-glycero-3-phosphocholine 
Saturated Lipids: 
DLPC (12:0) – 1,2-dilauroyl-sn-glycero-3-phosphocholine  
DSPC (18:0) – 1,2-distearoyl-sn-glycero-3-phosphocholine 
DPPC (16:0) – 1,2-dipalmitoyl-sn-glycero-3-phosphocholine  
DMPC (14:0) – 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
Anionic lipids 
DOPS (18:1) – 1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
DMPS (14:0) – 1,2-dimyristoyl-sn-glycero-3-phospho-L-serine 
POPS (16:0-18:1) – 1-palmitoyl-2-oleoyl-glycero-3-phospho-L-serine 
  
XXX 
 
Sterols: 
CHOL – cholesterol 
Non-lipid derivatives: 
Polyphenols: 
RSV – Resveratrol (3,5,4’-trihydroxy-trans-stilbene) 
TS – Trans-stilbene 
TMS – Trimethoxy trans-stilbene or (3,5,4’-trimethoxy resveratrol) 
Buffers: 
NaCl – Sodium Chloride 
DMSO – Dimethyl sulfoxide 
PBS – Phosphate buffered saline 
List of amino acids: 
Pyr (Z) – Pyroglutamic acid 
His (H) – Histidine  
Trp (W) – Tryptophan  
Ser (S) – Serine  
Tyr (Y) – Tyrosine  
Asp (D) – Aspartic acid 
Leu (L) – Leucine  
Arg (R) – Arginine  
Pro (P) – Proline  
Phe (F) – Phenylalanine  
Lys (K) – Lysine  
Gln (Q) – Glutamine  
  
XXXI 
 
Met (M) – Methionine  
Cys (C) – Cysteine  
Thr (T) – Threonine  
Gly (G) – Glycine  
Asn (N) – Asparagine  
Ala (A) – Alanine  
Non-pathological or functional amyloid-forming peptides (FAFP’s): 
Cyclic peptides: 
SST-14 (aa) – Somatostatin (14 amino acids) 
OT-9 (aa) – Oxytocin acetate (9 amino acids) 
AVP-9 (aa) – Arginine Vasopressin acetate (9 amino acids) 
Linear peptides: 
SP-11 (aa) – Substance P acetate (11 amino acids) 
Des-10 (aa) – Deslorelin acetate (10 amino acids)  
Pathological or toxic amyloids: 
AD – Alzheimer’s disease 
Aβ – Amyloid-beta 
IAPP – Islet amyloid polypeptide  
HIAPP – Human Islet amyloid polypeptide  
AS or αs – Alpha-synuclein 
Prion proteins – PrP  
 
 
 
  
XXXII 
 
Explanatory notes 
The purpose of these notes is to briefly define the measures taken throughout the preparation 
of this thesis. They relate to spelling conventions, units of measurements, the expression of 
analytical results and referencing of literature sources: 
1. Australian or British spelling is adopted in the text, for example, fibrillisation (rather 
than fibrillization), words ending with -ise (rather than -ize) and few other technical 
terms. 
 
2. Mostly, results are presented in SI units 
 
3. In-text citations are presented in the Vancouver style and are assigned to each reference 
for example, (35) shown below and applied throughout (see the page. 136) 
 
34. Campolongo P, Ratano P, Ciotti MT, Florenzano F, Nori SL, Marolda R, et al. Systemic 
administration of substance P recovers beta amyloid-induced cognitive deficits in rat: involvement of 
Kv potassium channels. PLoS One. 2013;8(11):e78036. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
XXXIII 
 
 
 
CHAPTER 1 
 
 
 
 
 
 
 
 
  
1 
 
1. The role of the lipid bilayer and molecular additives on fibrillisation of 
functional amyloid-forming peptides 
1.1 Introduction  
 
Figure 1.1. Shows amyloid-forming proteins that form β-sheets are linked to various human 
diseases (adopted from (1))  
Failure of a peptide or protein to adopt, or retain, its intrinsic functional conformational state 
can lead to aggregation into amyloid fibrils, for instance, the twist and internal lateral packing 
of β-sheets (red lines) (Figure 1.1), which is linked to several devastating disorders, including 
type II diabetes mellitus, Alzheimer’s Disease, Parkinson’s Disease, Creutzfeldt-Jakob disease 
and dialysis-related amyloidosis (DRA) (36-38). These neurotic disorders are commonly 
referred to as protein misfolding diseases (31). Peptides can assemble into amyloid fibrils 
through a process of nucleated polymerisation (aggregation); with breakage of fibrils providing 
new ends for elongation (39). This accumulation of fibrils is predicted to have a huge impact 
on the structure and function of the cell membrane; hence, amyloid proteins have pathological 
significances (5). The occurrence of amyloid plaques relates to senile plaques (neuritic) 
disintegration and cell death (40). The role of amyloid protein fibrils in neurodegenerative 
disease has been the topic of significant research (5, 41). While the details of the molecular 
mechanism of membrane penetration remain unconfirmed, several models have been proposed.  
Oligomers of amyloid peptides have been shown to interact with lipid membranes, resulting in 
a nonspecific ion leakage (42). Peptides can also transform into annular protofibrils that can 
form ion channel-like structures in the cell membrane (43). Therefore, it is of great significance 
to recognise both the exact steps behind fibril formation from the monomer state and the precise 
molecular mechanism of toxicity in these diseases (44).  
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1.2 Common structural features and mechanism of amyloid formation  
1.2.1 Toxic Amyloids 
Amyloids were first discovered in 1906 when Alois Alzheimer observed proteinaceous 
deposits in the brain tissue from patients with Alzheimer’s disease (45, 46). The fibrils appear 
as thin filaments visible by electron microscopy, with a diameter of 10 to 100’s of nm in length 
(47). Since then numerous proteins and polypeptides have been found to self-assemble into 
amyloid fibrils under certain conditions. They are associated not only with dozens of 
devastating diseases but are integral to many biological processes such as hormone storage, 
signal transduction, and cell surface adhesion (48). Separate from the context of their parent 
proteins, synthesised peptide segments can self-assemble into amyloid-like fibrils in vitro as 
well (49, 50). Fibrils formed by diverse proteins and peptides all share a common cross-β 
structure, composed of interdigitated β-sheets termed “the zipper-like fibril spine” (51). The 
ability to form amyloid aggregates is a basic property of the polypeptide chain, as the amyloid 
aggregate structure is based on β-sheets stabilised by hydrogen bonds which contain the 
polypeptide backbone (31). The aggregation mechanism of amyloid-forming peptides is a 
nucleation dependent process consisting of a lag phase followed by an exponential growth 
phase. During this process, protein monomers self-assemble into oligomers, followed by 
assembly into more intricate structures (38). Initially, during the lag period or phase, there is a 
transition of soluble protein species into β-sheet nuclei usually involving a large number of 
metastable oligomers. However, some proteins such as, insulin is biologically active mainly in 
its monomeric form (52). Certain nuclei then undergo elongation and proliferation until 
attaining a measurable aggregate concentration, thereby terminating the lag phase as shown in 
(Figure 1.2) (53). Fibrillisation is therefore slow until a critical oligomeric size capable of 
nucleating fibril formation is reached. Once a fibril is formed, it cannot revert to a soluble 
intermediate oligomeric species (54). A rise in the concentration of fibrils has been shown to 
reduce the lag period and promote fibrillisation (55-57). 
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Figure 1.2. A schematic representation of the aggregation process for Toxic amyloids. 
Aggregation proceeds by aggregation from the monomeric state to a fibrillar structure through 
oligomeric intermediates (adapted from (2)) 
The characteristic features of amyloid nanofibrils can be observed using Electron Microscopy 
(EM) or Atomic Force Microscopy (AFM). Fibrils are typically comprised of protofilaments, 
each approximately 2-5 nm in diameter (58). These protofilaments spiral to form rope-like 
fibrils that are normally 7-13 nm wide (58-60) or associate in a lateral manner to form long 
ribbons that are 2-5 nm thick and up to 30 nm wide (61-63). X-ray fibre diffraction data have 
shown that in each protofilament the protein or peptide molecules are organised in such a way 
that polypeptide chains form β-strands (60). Specific dyes like Thioflavin-T (ThT), Thioflavin-
S and Congo Red (CR), have the ability to adhere to fibrils (50, 64) resulting in green 
birefringence under cross-polarised microscopy (2, 31, 65-67). It is reported that dyes, such as 
ThT, adheres to the surface-chain grooves formed from layers of laminated β-sheets (68). 
For toxic amyloid-forming peptides, some of which are shown in (Table 1.1) (31), a large body 
of research suggests that formation of amyloid fibrils and their mechanism of cytotoxicity are 
membrane linked processes (33). According to Murphy (69), several studies demonstrate that 
the lipid bilayer actively changes fibril kinetics. For example, the lipid bilayer facilitated 
nucleation of Amyloid-beta (Aβ) fibrils in one study, with the effect depending on the chemical 
composition of the lipids (70). It is generally believed that oligomeric aggregates are the most 
toxic species with a disruptive effect on membrane permeability (71). However, in some 
instances, the mature fibrils may also induce cell damage by disordering the membrane lipids 
(72). 
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Table 1.1. Shows the diseases resulting from protein misfolding and subsequent aggregation 
into amyloid nanofibrils (30, 31, 73) 
Disease Amyloid-forming peptide/protein 
Corpora amylacea Kappa-casein 
Diabetes mellitus type II Islet amyloid polyprotein (IAPP/Amylin) 
AL amyloidosis Immunoglobin light chains or fragments 
Familial Mediterranean fever Fragments of serum amyloid A protein 
Senile systemic amyloidosis Wild-type transthyretin 
Lysozyme amyloidosis Mutants of lysozyme 
Fibrinogen amyloidosis Variants of fibrinogen α-chain 
Haemodialysis-related amyloidosis Β2-microglobulin 
Type II diabetes 
Amylin also called islet amyloid polypeptide 
(IAPP) 
Medullary carcinoma of the thyroid Calcitonin 
Atrial amyloidosis Atrial natriuretic factor 
Pituitary prolactinoma Prolactin 
Cataract γ-Crystallins 
Pulmonary alveolar proteinosis Lung surfactant protein C 
Aortic medial amyloidosis Medin 
Atherosclerosis Apolipoprotein AI 
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1.2.2 Functional Amyloids 
Increasing numbers of proteins with no connection to protein deposition diseases form fibrillar 
aggregates under some in vitro conditions (36). Many of these are peptide hormones, which 
are proposed to be stored as amyloids within endocrine secretory granules (Table 1.2). These 
aggregates have the morphological, structural and dye-binding properties that allow them to be 
categorised as amyloid fibrils (74, 75). This basic ability has been exploited by living 
organisms for specific purposes since some of the organisms have been known to convert one 
or more of their endogenous proteins into amyloid fibrils that possess functional rather than 
disease associated properties (36, 76). A list of such “functional” amyloid-forming proteins is 
given in (Table 1.2) with additional functional amyloids listed in the supporting information 
(Table S1) (77). Experimental evidence for the formation of amyloids by these proteins is 
provided by Electron Micrograph (EM), CR, ThT, Circular dichroism (CD), Fourier transform 
infrared (FTIR), Nuclear magnetic resonance (NMR), X-ray diffraction (XRD) and Atomic 
force microscopy (AFM) (31, 75, 78-80).  
Table 1.2. Shows a list of functional amyloids in prokaryotic and eukaryotic organisms (2, 31, 
32) 
Organisms Non-disease 
related amyloid-
forming protein 
Biological function Refs 
Escherichia coli 
 
Curli formation of 
biofilms 
(67) 
Streptomyces 
coelicolor 
Chaplins modulation of water 
surface tension 
(development of 
aerial structures) 
(81) 
Podospora 
anserine 
 
HET-s regulation of 
heterokaryon 
formation 
(82-93) 
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Saccharomyces 
cerevisiae 
 
Sup35p 
 
regulation of stop 
codon read-through 
 
 
Schizophyllum 
commune 
Hydrophobins fungal coat 
formation 
(94) 
Silk worm Chorion protein protecting the oocyte 
and developing 
embryo from 
environmental 
hazards 
(95) 
Spider Spidroin protein intermediate in the 
biosynthesis of 
spider silk 
(96) 
Mammalians Pmel17 assisting with 
melanin production 
(97) 
 
 
 
Homo sapiens 
 
Somatostatin-14 regulates growth 
hormone secretion 
(98, 99) 
Oxytocin-9 stimulation of 
uterine contraction 
and production of 
prostaglandins 
(99, 
100) 
Vasopressin-9 regulates water 
content in blood 
(99, 
101) 
Deslorelin-10 -a 
synthetic 
analogue of 
luteinising 
hormone (LH) 
controls 
reproduction by 
suppressing the 
release of 
gonadotrophin-
(102, 
103) 
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releasing hormone 
(GnRH) 
Substance P-11 responsible for 
transmission of pain 
(104) 
 
Amyloid fibres that appear to have a functional role have been observed in bacteria, 
invertebrates, and humans (105). For instance, Pmel 17 is a functional amyloid that has a vital 
role in the biosynthesis of the pigment melanin; this process is generally tightly regulated to 
avoid toxicity (32).  However, the unregulated release of functional amyloid seeds could 
propagate pathological amyloidogenesis (97). It has been shown that injection of functional 
amyloid fibres, for example, curli (Escherichia coli) and Sup35p (Saccharomyces cerevisiae), 
into a chronic inflammatory amyloid protein amyloid A, proliferates amyloid formation and 
development of disease in a reactive amyloidogenesis mouse model (97, 106). This absence of 
cytotoxicity in functional amyloids is thought to be potentially related to their ability to reverse 
fibrillisation (32, 107-109). However, the broader principles of regulation of functional 
amyloidogenesis, and the possible relationship between functional and toxic amyloid formation 
has not been well characterised to date.   
The kinetics and mechanism of amyloid formation can be influenced by interactions with 
biomolecules and biosurfaces, particularly lipid membranes.  These interactions can either 
promote or inhibit fibrillisation. While the vast majority of the published literature in this area, 
deals with the effect on fibrillisation of toxic amyloids, some studies have shown that 
molecules, such as glycosaminoglycans, can impact fibrillisation for functional amyloid-
forming peptides (110).  The biological aggregation modifiers reviewed in the following 
sections have been divided into molecular (Section 1.3) and lipid membrane-based (Section 
1.4).    
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1.3 Molecular aggregation modifiers 
1.3.1 Impact of Metal Ions 
Growing evidence supports the binding of metal ions to amyloid species found in the brain of 
patients suffering from various disease-related amyloid conditions. High concentrations of 
metal ions such as Cu2+, Zn2+ and Fe3+ have been reported to be bound to Aβ peptides (111, 
112). Binding of transition metal ions, including Cu2+ and Zn2+, have been reported to induce 
Aβ fibrillisation in parts of the neuron which release high concentrations of metal ions such as 
the synaptic cleft (113, 114). More specifically in the hippocampus, a region of the brain 
involved in memory and also one of the first regions to be affected by early onset stages of AD 
(115). Evidence shows deposits of zinc in pancreatic β-cells found in patients with IAPP and 
iron deposits were reported in the Lewy bodies formed in Parkinson’s disease (116, 117). The 
nature of the metal ions, Cu(II) was reported to significantly reduce the lag phase and promote 
the rate of fibril formation for α-synuclein (118). However, Cu(II) was shown to inhibit IAPP 
fibrillisation, instead of promoting the formation of toxic oligomers via an alternate aggregation 
pathway (119). For Aβ peptides, Cu (II) is reported to increase the rate of fibril formation by 
decreasing the lag phase (120, 121). Aβ protofibrils were also detected in the presence of large 
concentrations of iron, while manganese did not show any binding affinity to Aβ (122, 123). It 
is reported that Zn2+ can prevent fibrillisation by stabilising the hexamer (124).  Thus, transient 
metal binding to amyloidogenic peptides and fast exchange rates of the metal ions within intra 
and intermolecular peptide binding sites are currently a growing field in biometal-amyloid 
interactions (125).   
1.3.2 Impact of Heparin/Glycosaminoglycans (GAGs) 
Polyelectrolytes like GAGs belong to a family of sulfated and intricate polysaccharide 
molecules that repeat to form heparin (126). Heparin is an anticoagulant known to boost 
amyloid fibrillisation in vitro (127), including for the toxic Aβ peptides (128-130), Tau protein 
(131, 132), α-synuclein (133), gelsolin (134, 135), IAPP (136). Heparin also enhances 
fibrillisation for a range of neuropeptide hormones which form functional amyloids (77). From 
a kinetic standpoint, heparin significantly reduces the lag phase and increases the rate of the 
growth phase for many amyloidogenic systems studied. Heparin binds to α-synuclein and not 
only accelerates the speed of fibrillisation but also increases the fibril yield (133). The 
mechanism by which heparin acts is primarily through electrostatic interactions, thereby 
concentrating the oligomers and increasing the degree of order within the aggregates which 
favours the fibrillisation process (137). It has been reported that a considerable number of 
  
9 
 
neuropeptide hormones require heparin to induce functional fibrillogenesis in vitro (77). The 
strong effect of heparin dominates the intermolecular interactions and the morphology of the 
end structures. 
The binding affinity of GAGs to amyloid fibrils occurs principally through electrostatic 
interactions involving the anionic polyelectrolyte charge and cationic side chain residues of the 
aggregating protein (138). In addition to biochemical molecules, there is also growing 
interested in lipid-protein interaction within the membrane that is known to induce amyloid 
aggregation. 
1.3.3 Effects of Resveratrol (RSV) 
3,5,4’-trihydroxy-trans-stilbene (RSV), is a polyphenolic substance predominantly found in 
grapes, red wine, berries and other plant types (139). RSV has been shown to exhibit several 
biological activities, for instance, anti-inflammatory, antioxidants, anticarcinogenic properties 
etc. (3, 140). Current evidence suggests that RSV plays a significant part in the prevention and 
treatment of AD (141-143). RSV exists in two isomers and contains two aromatic rings (Figure 
1.3), the trans-RSV, which is most commonly studied than cis-RSV; several studies have 
shown that trans form is more stable and effective than the inactive cis form (144, 145). 
 
(trans-RSV) (cis-RSV) 
Figure 1.3. The geometric isomers of resveratrol (adapted from (3))              
The results obtained from research carried out Feng et al. 2009, showed that resveratrol inhibits 
Aβ42 cytotoxicity and fibril formation, but does not prevent Aβ42 oligomer formation (143). 
Surface plasmon resonance (SPR) and proton nuclear magnetic resonance (1H NMR) 
experiments by Fang Ge et al. 2012, showed that RSV could bind to both monomer or fibrillar 
Aβ(1-42) (146). In vivo effects of RSV in PC12 cells have shown to protect cells from Aβ25-35 
induced toxicity (139). RSV has relatively poor solubility in biological fluids hence lipid 
carriers are used for drug delivery. In this research, liposomes are chosen due to their 
biocompatibility and diverse choice of physio-chemical properties (28). The interaction 
between RSV and functional amyloids have not been explored, until now (Chapter 6).  
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1.4 Membrane-based aggregation modifiers 
Amyloid-forming peptides can interact with the lipid bilayer environment of the cell 
membrane, with a knock-on effect on fibrillisation.  Cell membranes consist of a fundamental 
lipid bilayer structure, a thin membrane consisting of two lipid monolayers stacked back to 
back.  The fluid mosaic model (Figure 1.4) of the lipid membrane, according to Singer and 
Nicholson, is a two-dimensional fluid in which membrane proteins and other molecules like 
phospholipids and cholesterol are embedded (147). These sheet-like structures play a crucial 
role in inhibiting proteins, ions and other molecules from dispersing into surrounding 
territories. Apart from being the gate of the cells, lipid bilayers are regular binding sites, for 
several amphipathic molecules, proteins, and peptides and control numerous indispensable 
biological functions, including cell fusion (148) and ion transport (149).  
 
Figure 1.4. Shows a typical biological membrane (adapted from (4)) 
Lipid membranes are especially vital to amyloid formation under physiological conditions, as 
these are abundant in living organisms. Model membrane surfaces of several types have been 
shown to accelerate amyloid fibrilization and summary included in (Table 1.3). It is believed 
that the interaction is between the membrane and peptide monomers, or smaller oligomers, 
rather than mature fibrils. For example, experimental evidence suggests that the monomeric 
form of Human islet amyloid polypeptide (hIAPP) inserts into phospholipid monolayers, 
whereas fibrillar hIAPP does not insert (72, 150). The membrane may impact the aggregation 
mechanism is several ways. For example, local increases in peptide concentration driven by 
hydrophobic and/or electrostatic interactions of the peptide with the bilayer may increase the 
rate of fibrillisation. Changes to peptide conformation upon binding to the bilayer may also 
promote the peptide-peptide contacts necessary for fibrillisation to occur.   
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Table 1.3. Includes a summary of model membranes involved in fibrillisation of amyloidogenic 
proteins and peptides (33) 
Disease Protein or 
peptide 
Membrane 
systems* 
Summary 
Parkinson’s α-synuclein PA/PC, PG/PC, 
PS/PC, PG/PE 
vesicles 
α-helical conformation in bilayer and 
disruption of bilayer due to the formation 
of fibrils (151-155) 
Alzheimer’s Aβ peptide 
and Tau 
PC/PG vesicles, 
PA, PS, PI, PIP, 
PIP2, CL, PC, PE, 
SM, Chol, DG, 
gangliosides, 
sonicated lipid 
suspensions 
α-helical conformation reported in bilayer 
and accelerated the formation of 
aggregates in ganglioside vesicles and 
acidic phospholipids. No fibril formation 
reported in neutral lipids  (156-160) 
Type II diabetes IAPP PG/PC vesicles, 
liposomes from 
pancreas lipids 
and PC, PS/PC 
vesicles, rat 
insulinoma 
tumour cells 
IAPP fibrillisation is observed in a mixed 
bilayer such as PG/PC and reported 
disruption to liposome structure (161, 
162) 
Spongiform 
encephalopathies 
Prion protein PG, PC, 
PC/Chol/SM 
vesicles 
Formation of fibrils reported, however, 
the disruptive effect is observed mostly in 
POPG membrane (163) 
Familial 
polyneuropathy, 
systemic 
amyloidosis 
Transthyretin PC/PS, PC/PG 
vesicles 
Anionic bilayers induced rapid formation 
of fibrils (164) 
Thyroid 
carcinoma 
Calcitonin PC, PC/Chol, 
PC/PS, 
Membranes consisting of cholesterol and 
ganglioside induced aggregation (165) 
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PC/ganglioside 
vesicles 
 
As for molecular aggregation modifiers, the vast majority of the published literature on the 
effect of lipid membranes on fibrillisation deals with toxic amyloid-forming peptides, including 
the Aβ peptide, α-synuclein and islet amyloid precursor protein (IAPP). Lipid membranes 
generally appear to promote, rather than inhibit, fibril growth via interactions with the bilayer. 
Shen et al. have shown that Aβ misfolds in the presence of surfaces of varying hydrophobicity, 
and fibrillises at much lower concentrations than those required in bulk. The surface is 
proposed to permit binding, diffusion and interaction of monomers (166). 
Interactions with the membrane can also affect protein conformation. In the case of α-
synuclein, interaction with lipids results in an increase in α-helical content and subsequent 
aggregation. The helical conformation is shown to be more stable in the presence of membranes 
(167). Similarly, binding of human islet amyloid polypeptide (hIAPP) to membranes 
containing negatively charged lipids led to the conversion to α-helical form and eventually to 
β-sheets (168). Current published data show that interactions of hIAPP with membranes results 
in the formation of the monomeric helical form within the headgroup region, with a subsequent 
transition to β-aggregates at higher protein concentrations (169). 
1.4.1 Ganglioside clusters, Cholesterol and Sphingomyelin 
The ganglioside (GM1) and cholesterol content, as well as the overall fluidity of the membrane, 
have been shown to anchor amyloidogenic proteins to membranes, inducing the adoption of β 
sheet formation and affecting fibrillisation rates (5). Studies have also reported, Aβ 
amyloidogenesis process is accelerated in the presence of sphingomyelin (SM), ganglioside 
and cholesterol (Figure 1.5) (170-175).  
 
Figure 1.5. Shows the model of Aβ-fibril formation on ganglioside clusters in lipid rafts 
(adopted from (5))   
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The fibrillisation depends on the concentration of cholesterol within the bilayer. Cholesterol 
has been reported to both induce (176) and constrain (177) the interaction between (Aβ 1-40) 
and model membranes. This enhanced binding of Aβ and aggressive peptide aggregation with 
cholesterol has been reported numerous times (5, 178-181). In fact, it has been proposed by 
Matsuzaki that cholesterol forms sites on the cell membrane that are chosen for Aβ after 
separating from the amyloid precursor protein (APP) and initiating its fibril formation 
(182).Cholesterol can also affect acyl chain order, depending on the concentration, which can 
impact the peptide binding and membrane-mediated fibrillisation process. Evidence from 
published data also reports that liposomes containing cholesterol accelerate fibril (β-sheet) 
formation of Aβ (181, 183, 184). A published report has suggested that the toxicity of 
oligomers can depend on its hydrophobic property (Figure 1.6) (6).     
 
Figure 1.6. Shows the two types of oligomers and its ability to interact with the membrane 
(adopted from (6)) 
1.4.2 Charged lipids 
Anionic lipids seem to be particularly significant in a membrane-assisted conformational 
change, and electrostatic interactions can play a part in protein-lipid interactions. Previous 
studies have concluded that hIAPP and α-synuclein require anionic lipids such as 
phosphatidylserine (PS) for protein binding (152, 161, 167, 168, 185). Studies by Zhao et al. 
indicated that a range of different proteins formed fibrils in the presence of charged liposomes 
containing PS (164). 
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Electrostatic interactions between most cationic amyloid-forming peptides and anionic lipid 
headgroups is a frequent observation, and this can also facilitate the binding of the peptide to 
the membrane (179, 186-188). By means of neutron and X-ray scattering techniques, Lee and 
co-workers have been able to reveal that Aβ40 inserts more readily into anionic DPPG bilayers, 
compared to neutral DPPC lipid bilayers (5). Anionic liposomes containing PG headgroup have 
also been shown to promote a β-sheet conformation in Aβ40 in addition to peptide 
oligomerisation (189); similar observations have been reported with IAPP (185) and α-
synuclein (154, 190, 191). Increasing the anionic content of the headgroup in mixed vesicles 
have shown to accelerate binding of α-synuclein monomers (192) and oligomers (193). It is 
proposed that interactions between β-amyloid and anionic membranes result in monomeric 
peptide and that further incubation leads to oligomer formation in the membrane (194, 195). 
The addition of oligomers to negatively charged lipid vesicles results in fast content release in 
a bulk permeabilisation assay; in contrast, a much slower loss of content was observed after 
adding oligomers to vesicles that mimic mitochondrial membranes (196). Even following long 
incubation, oligomers are unable to induce leakage in artificial plasma membranes with CD 
experiments confirming minimal changes to the secondary structure (197). Addition of 0.1M 
NaCl to screen electrostatic interactions demonstrated that the interaction was mainly 
electrostatic, rather than hydrophobic (198). 
Studies show that binding of β-amyloid (1-40) to a supported anionic lipid membrane resulted 
in a tight binding followed by oligomer formation in the membrane thereby causing a 
significant decrease in membrane fluidity as shown in Figure 1.7 below (7, 194). Recently, a 
functional amyloid TasA, which is a major matrix protein found in biofilms of the soil 
bacterium Bacillus subtilis, demonstrated higher ThT activity with negatively charged lipids 
compared to neutral membranes. A diagrammatic illustration of its interaction with the 
membrane is shown in (Figure 1.8) (8).    
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Figure 1.7. Schematic representation of interactions of amyloidogenic IAPP (black lines) with 
SPBs (Supported Planar bilayers), depicting significant reduction in the fluidity of membrane 
(adapted from (7))          
 
Figure 1.8. Schematic illustration for the mechanism of TasA interacting with the membrane 
(adopted from (8)) 
1.4.3 Neutral lipid 
Phosphatidylcholine (PC) and sphingomyelin (SM) are zwitterionic phospholipids in 
mammalian cells. Most published data suggest that Aβ (1-40) monomer do no interact with PC 
(175, 199-202) or SM (158, 175). Although amyloid interactions have been reported with 
neutral 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) (Figure 1.9) (9) with time in a 
similar way on the surface of negatively charged 1,2-dioleoyl-sn-glycero-3-phosphoglycerol 
(DOPG) membrane (203). 
IAPP 
Planar 
bilayer 
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Figure 1.9. Schematic of Aβ interacting with lipids and phase separation in the bilayer shows 
nonhomogeneity (adopted from (9)) 
1.4.4 Physicochemical properties of the lipid bilayer  
As summarised in Table 1.3, while fibrillisation in vitro has been reported mainly for 
negatively charged membranes, enhancement of fibrillisation has also been observed for lipid 
mixtures composed of phosphatidylcholine (PC) and phosphatidylethanolamine (PE) with 
cholesterol or gangliosides, and ‘rafts’ consisting of sphingomyelin and cholesterol. 
Consequently, it is difficult to ascribe the promotion of protein fibrillisation to a specific class 
of lipids. In addition, physicochemical properties of the lipid bilayer, such as bilayer thickness, 
fluidity and surface charge, are likely to play a critical role in influencing the mode and extent 
of the membrane binding of these proteins, in addition to the adoption of an aggregation-prone 
protein conformation. Lipid-protein interactions may also differ significantly, contingent on 
the structural characteristic of the proteins or peptides in question and these interactions may 
either promote or inhibit fibril growth. Any change to physicochemical properties upon peptide 
incorporation, such as membrane thickness and lipidic phase, may be characterised using a 
range of techniques including X-ray diffraction and neutron reflectivity experiments (5, 204). 
The membrane fluidity, which is related to the level of order in the acyl chains, is one of the 
most prevalent features of a membrane and it is vital for its biological viability (205). The 
bilayer thickness is also an important parameter; for a certain lipid head group, the thickness 
of a liquid-disordered bilayer is determined both by the number of carbons, and the position 
and number of double bonds in the acyl chains (206, 207). The fluidity depends on both the 
temperature and the lipid composition within the bilayer, as is readily confirmed in studies of 
artificial bilayers (208). A model bilayer made from a single type of phospholipid varies from 
a fluid state to a two-dimensional gel or crystalline state at the melting point, Tm (209). This 
phase transition temperature is typically lower for shorter chains, or chains containing one or 
more unsaturated double bonds (210). Shorter chains are associated with weaker hydrophobic 
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and Van der Waals interactions between the hydrocarbon chains, while the presence of 
unsaturation creates kinks in the hydrocarbon chains, reducing packing efficiency and 
promoting the retention of membrane fluidity at lower temperatures (211). Yeasts, Bacteria 
and other organisms can maintain the fluidity of their membrane by adjusting the fatty acid 
composition of their membrane lipids with that of their environment (212). 
Enhancement of Aβ fibrillation has been demonstrated in fluid phase membranes due to 
increased mobility, whereas mobility is restricted in a gel phase with concomitant retardation 
in fibrillation (Figure 1.10) (10). Whereas α-synuclein (AS) bound to membranes in gel phase 
(DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol (DPPG), indicated deeper 
insertion of the protein into the bilayer due to the electrostatic interaction between positively 
charged N-terminal of α-synuclein and negatively charged surface of the lipid (213). The 
deepest immersion of C-terminus was observed in the presence of rigid neutral DPPC probably 
due to the absence of electrostatic repulsion (214). To allow measurement of a higher order of 
Bragg peaks, the membranes were studied in their gel states using high-resolution X-ray 
diffraction (215).  
 
Figure 1.10. Illustration of Aβ interacting with gel phase and fluid phase (adapted from (10)) 
The physicochemical properties of the bilayer can be impacted by the lipid composition. For 
example, the eukaryotic plasma membrane contains significant levels of cholesterol, up to one 
molecule for every phospholipid molecule (211). The cholesterol molecule is reported to orient 
with their hydroxyl groups close to the polar head groups of the phospholipid molecules (216). 
In this position, their rigid, platelike steroid rings interact with and partially restrain the 
hydrocarbon chains nearby to the polar head groups, which can decrease membrane fluidity, 
increase local bilayer rigidity, and decrease the permeability of the bilayer to small water-
soluble molecules (217).   
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In addition, anionic phospholipids in cellular membranes can regulate electrostatic potential in 
the membrane, and drive interaction between peripheral proteins (218). It has been reported 
that the ordering of PC chains and stiffness of the bilayer increases with an increase in negative 
PS content (219). Several amyloid studies have been investigated using negatively charged 
lipid molecules since it is known to induce severe aggregation or fibril formation via 
electrostatic interactions (220).  
1.5 Effect of amyloid-forming peptides on the structure of the lipid bilayer 
It is generally accepted that the interaction between toxic amyloid aggregates and membrane 
can induce disruption of the barrier function of the membrane (164). However, the interaction 
between non-toxic or functional amyloid-forming peptides and lipid membranes are in fact not 
well explored (5).   
It has been reported in many published papers that peptides including antimicrobial peptides 
(gramicidin) and α-helical peptides (alamethicin) can disturb the bilayer architecture by 
inducing a transition to a non-lamellar phase, e.g. the hexagonal (HII) phase.  Such a phase 
transition results from fundamental changes to bilayer curvature induced by binding of the 
peptide (221). It has been suggested that Aβ can also drive changes in membrane curvature 
which cause a lamellar to a non-lamellar phase transition and that the specific transition can 
differ depending upon the relative concentration of lipids in the bilayer (221, 222). Studies on 
liposomes exposed to IAPP shows that the membrane-peptide interaction causes pores in the 
membrane, as the oligomeric state of the peptide expands and it is known to be stable for days 
(223). This result agrees with the hypothesis that antimicrobial peptides and amyloids share a 
mutual pore-forming ability.  
Experimental findings suggest that there can be more than one mechanism involved for 
amyloid peptides interacting with the membrane, thereby leading to events concomitant with 
amyloid diseases.  
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Figure 1.11. Illustration of three possible mechanism of Aβ encouraged membrane damage 
(adopted from (11)) 
There are three proposed models for toxic peptide interaction with membranes (Figure 1.11). 
1. The carpet model, where carpeting of the peptide on one side of the membrane surface, 
causing asymmetric pressure between two sides and leakage of small molecules. 2. Formation 
of stable pores and ion channels (by forming Ca2+ channels in lipid bilayers upon incorporating 
Aβ40). 3. Detergent-like effects, where membrane association of the amyloid-forming peptides 
in the form of micelle-like structures (183). 
Studies carried out by Atomic force microscopy (AFM) on supported bilayer lipid membranes 
subjected to amyloidogenic peptide (HypF), either in its monomeric or in the oligomeric 
aggregation form, have revealed that the amyloid-like peptide can disrupt the bilayer causing 
membrane thinning (224). Alternatively, amyloid fibrils, proliferating at membranes, may 
remove lipids by interacting with an outer leaflet (225). Using experimental surface-sensitive 
techniques, Reynolds et al. and co-workers were able to conclude that α-synuclein monomers 
massively disrupted the membrane by removing lipids followed by membrane thinning and 
subsequently, the membrane integrity is lost (37). In summary, published data shows that both 
oligomers and fibrils can disturb the order of the membrane and can give rise to cell disruption.  
Sparr et al. indicated that hIAPP interacts with liposomes during amyloid formation, inducing 
uptake of lipids and resulting in the loss of the barrier properties of the membrane (162). hIAPP 
fibrils were shown to grow in an ordered manner on the surface of distorted lipid vesicles. 
Relating the similarity of the kinetic profiles of dye leakage and thioflavin T (ThT) 
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fluorescence, the authors suggested that fibril growth is associated with membrane damage 
through a process that also implicates alterations in membrane curvature and lipid packing (72). 
A similar behaviour was described by Milanesi et al. in an experiment performed exposing 
liposomes to β2-microglobulin fibrils formed in vitro. The result from this experiment shows 
that fibril tips extract lipids from the membrane at the point of contact, causing distortions in 
the liposome shape (Figure 1.12) (12).  
 
Figure 1.12. (A-C) Shows the clustered liposomes distorted by short fibrils. (D) A 3D model 
of a distorted liposome (blue), surrounding fibrils visualised by cryo-electron tomography 
(cET) (adopted from (12)) 
1.6 Model Lipid Bilayers 
Determining the effect of the cell membrane on the amyloid formation and determining the 
converse effect of amyloid formation on the structure of the cell membrane, can be difficult 
due to the inherent complexity of cell membranes, and difficulties in working with biological 
cell-lines. Therefore, model membranes, where membrane parameters may be more easily 
controlled, are typically used to determine the effect of specific membrane properties on 
amyloid fibrillogenesis. Model systems, which can be based on lipid monolayers or bilayers, 
include the bulk lipid lamellar phase, liposomes (or multi-lamellar vesicles) and supported lipid 
bilayers.  All these model membranes have shown to impact fibrillogenesis of toxic amyloid-
forming peptides, although their effect on functional amyloid-forming peptides remains 
essentially uncharacterised. 
A monolayer is one of the simplest ways to mimic the outer leaflet of a biological membrane. 
The hydrophobic tails of the lipid chains are in contact with air (interface), and the polar lipid 
headgroups are directed towards the aqueous phase (5). Several studies have investigated 
fibrillisation in the presence of lipid monolayers (5, 150, 224, 226).  X-ray reflectivity study 
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has shown fibril nucleation in IAPP only occurs in the presence of DOPC/DOPG monolayers, 
but not with pure neutral DOPC monolayers (29).   
Supported lipid bilayers (SLBs) are made via Langmuir transfer or fusion of vesicle onto a 
suitable surface (227, 228). Literature has shown progressive accumulation of oligomers and 
fibrils of Aβ1-42 using a SLB (194, 229). Due to the positive charge of the peptide and fluid 
phase of the lipid bilayer is known to induce aggregation (203).  
1.6.1 Bulk Lamellar Phase 
The lipids of the cell membrane can self-assemble into numerous structures (Figure 1.13) of 
which the bulk lamellar phase is most applicable to biomembranes. The lamellar phase consists 
of a 1-D stack of lipid bilayers, separated by water layers (Figure 1.14).  However, some cell 
membrane lipids do not adopt the lamellar phase but instead, form more curved non-lamellar 
phases. Such phases, which include the hexagonal and bicontinuous cubic phases, might relate 
to temporary events in biomembrane, such as fusion, fission and pore formation (230, 231). 
However, in this thesis, we focus on the lamellar phase and liposome systems.   
 
 
Figure 1.13. Shows the polymorphic phases and corresponding dynamic molecular shapes of a 
component of phospholipids (adopted from (13-16)) 
 
Types of Lipids Lipid Phases 
Diagram 
Lipid Shapes 
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Figure 1.14: Shows a typical lamellar phase or phospholipid bilayer (lipids-grey and water-red) 
(adopted from (17))  
1.6.2 Liposomes 
Liposomes are vesicles with an aqueous core entrapped by one or more than one lipid bilayer 
(Figure 1.15). Liposome properties vary significantly with lipid composition, size, surface 
charge and method of preparation (sonication vs extrusion) (232). Moreover, the choice of the 
bilayer components controls the ‘rigidity’ or ‘fluidity’ and the charge of the bilayer. For 
example, unsaturated phosphatidylcholine molecules from natural sources (soybean and egg) 
give much more permeable and disordered bilayers, whereas saturated phospholipids with long 
acyl chains (DPPC or DSPC) form a rather stiff and impermeable bilayer structure (233-235). 
Mostly, liposomes are spherical with particle size ranging from 30 nm to several micrometres 
and can be classified as: (1) multilamellar vesicles (MLV) and (2) unilamellar vesicles. 
Unilamellar vesicles can be further divided into two categories: (1) large unilamellar vesicles 
(LUV) and small unilamellar vesicles (SUV) (236). In unilamellar liposomes, the vesicle 
consists of a single phospholipid bilayer sphere enclosing the aqueous solution. In 
multilamellar liposomes, vesicles are arranged in an onion ring-like fashion (232). These 
vesicles can transport hydrophilic, hydrophobic and lipophilic compounds to their designated 
target sites without causing any decomposition of the entrapped molecules (237). Such 
characteristics make them a perfect delivery vehicle in a broad range of pharmaceutical 
applications (238) and a model membrane in several amyloid research studies (5, 239, 240). 
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Figure 1.15. A structure of a liposome (adapted from (18)) 
1.7 Effect of lipid bilayer composition on the fibrillisation of functional amyloid-
forming peptides  
In this thesis, I investigate the effect of model lipid membranes, mainly focused on liposomes, 
on the fibrillisation of functional amyloid-forming peptides. In contrast to the extremely large 
body of literature investigating the effect of model lipid membranes on amyloid aggregation in 
disease-related peptides (5, 241, 242), almost no studies to date have investigated the effect of 
the lipid bilayer on the fibrillisation of functional amyloid-forming peptides.    
Five different functional amyloid-forming peptides (Somatostatin-14, Oxytocin-9, 
Vasopressin-9, Deslorelin-9 and Substance P-11) has been studied. Specifically, the effect of 
lipid chain length and unsaturation, charged lipids, cholesterol and addition of polyphenol 
additives such as resveratrol, trans-methoxy stilbene and trans-stilbene which are known to 
inhibit or influence amyloid aggregation for toxic amyloids have been investigated.  
In this thesis, model membranes used to determine the effect of the lipid bilayer on the kinetics 
and mechanism of fibrillisation were typically multi-lamellar vesicles or liposomes. The bulk 
lamellar phase was also used in SAXS studies to determine any reciprocal effects on the 
structure of the lipid bilayer.   
Five different lipid molecules, which either form a fluid or gel phase at room temperature, were 
used to form the lipid bilayer. These were: 1,2-dilauroyl-sn-glycero-3-phosphocholine 
(DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-
dioleoyl-sn-glycero-3-phosphocholine (DOPC) as shown in (Figure 1.16). These five lipids 
have the same phosphatidylcholine headgroup but differ in the architecture of the hydrophobic 
  
24 
 
alkyl tails. The phase transition temperature (Tc) of the lipids are: DLPC (-57 
oC), DOPC (-47 
oC), DMPC (23 oC), DPPC (41 oC) and DSPC (55 oC) indicating that DLPC, DMPC and DOPC 
are fluid at room temperature (although we note that DMPC is close to the del-fluid transition) 
(10). This is in agreement with Total Internal Reflection Fluorescence Microscopy (TIRFM) 
studies performed on the lipids, show that lipid molecules within DLPC, DOPC and DMPC 
spreads rapidly (243), and with molecular dynamics (MD) studies (209, 244).  DMPC is best-
characterised model lipid due to its phase transition behaviour between fluid and gel, 
contributing higher structural resolution (70). A highly fluid membrane would be made up of 
well-spaced lipids with a greater degree of freedom in acyl tail motion, while a gel membrane 
would be more rigid (such as DPPC and DSPC)  (70) (Figure 1.17). 
(DOPC C18:1) 
(DLPC C12:0) 
(DMPC C14:0) 
(DPPC C16:0) 
(DSPC C18:0) 
Figure 1.16. Shows the structure of five different lipid molecules (adapted from (10))  
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Figure 1.17. Schematic representation of fluid (left) and gel (right) phase bilayer (adapted from 
(10))  
To investigate the interaction between membrane surface charge and the fibrillisation of 
functional amyloids, we investigated the model membranes doped with anionic lipids including 
1,2-dioleoyl-sn-glycero-3-phosphoserine (DOPS) and 1,2-dimyristoyl-sn-glycero-3-
phosphoserine (DMPS), since ‘PS’ is an excellent substitute for naturally occurring brain PS. 
The effect of membrane fluidity was investigated using cholesterol (Chol) (Figure 1.18) as a 
membrane additive. Evidence suggests that cholesterol in the membrane increases stiffness (5) 
and also induce liquid-ordered phase domain (Lo), which creates the likelihood of favourable 
interface of ligands with distinct phase (245, 246).    
(DOPS C18:1) 
(DMPS C14:0) 
(Cholesterol) 
Figure 1.18. Shows the structure of anionic lipids and cholesterol (adapted from (5, 19))  
  
26 
 
The functional amyloid-forming peptides studies include the peptide hormone Somatostatin 
(SST-14), which is involved in regulating the central nervous system (CNS) and endocrine 
system (ES), has a cyclic structure resulting from a disulphide bridge between Cysteine (Cys) 
(Cys3-Cys14) (247). It has been reported to form amyloid fibrils in vitro (77, 248, 249). 
Recently, Dharmadana et al. have demonstrated that aggregation enhancers, such as heparin, 
commonly used to increase the aggregation rate result for amyloid-forming peptides result in 
clear morphological differences in the resulting fibrils for SST (98). Two additional cyclic 
functional amyloid-forming peptides are investigated in Chapter 3, Oxytocin (OT) and 
Arginine Vasopressin (AVP). Both peptides are neurohypophysial hormones, which are 
involved in sexual behaviours and social recognition, and are implicated in neuropsychiatric 
disorders including intellectual disability (ID), autism spectrum disorders (ASDs) and bipolar 
disorder (BD) (250, 251). Studies have concluded that neurohypophysial hormones contain 
sequences which are likely to form pathological aggregates due to mutations. Such aggregation 
of peptide hormones into secretory granules corresponds to the formation of functional 
amyloids (77). Immunohistochemical studies conducted on mouse pituitary tissue has 
confirmed that oxytocin and vasopressin, are stored as amyloid-like aggregates in their 
secretory granules, located in the posterior lobe of the pituitary (99, 100). 
In order to compare the effects of peptide structure (cyclic vs linear) in inducing amyloid 
aggregation, we additional studied the following linear peptides in Chapter 5, Substance P (SP) 
(252) and Deslorelin (DES) (253). SP belongs to a neuropeptide group called tachykinins, and 
it is made up of 11 amino acids (254, 255). It has a cationic charge of +3 at neutral pH (256), 
and Its activity spans across the central and peripheral nervous system (257), involved in 
different functions such as pain transmission (254), regulation of blood flow (258) and 
gastrointestinal motility (259). Evidence, reports reduced levels of SP, is capable of 
antiapoptotic and neuroprotective properties, have been found in the brain and spinal fluid of 
Alzheimer’s disease (AD) patients (35). Literature evidence suggests that SP plays an 
important role in preventing brain ageing-related memory decline (255, 260-262). Recently, 
SP is also shown to form nanotubes (Durga et al. 2018) through Cryo-Transmission Electron 
Microscope (Cryo-TEM), and Fourier-Transform Infrared spectroscopy (FTIR) and this study 
would illustrate structural characteristics of peptide self-assembly process. The secondary 
structure of SP has been reported from unfolded to aggregates or β-sheets (254) and X-ray, and 
neutron diffraction studies have also revealed β-sheet for aggregated SP (263). Deslorelin (Des) 
is nonapeptide synthetic analogue of gonadotropin-releasing hormone (GnRH). Des regulates 
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the follicle stimulating hormone (FSH) and luteinising hormone (LH) (264, 265). However, no 
evidence of β-sheets or aggregates reported to date. 
Finally, in Chapter 6, the effects of RSV doped in liposomes of various lipid compositions on 
the aggregation profile of SST-14 was investigated. RSV is a natural product found in red wine, 
which has been shown to have an inhibitory effect on the aggregation of toxic amyloid species 
reported in the literature (266, 267). Also, this effect was further compared with two additional 
stilbenes analogues of RSV, TMS and TS however, no literature is available reporting the 
effects of these analogues of stilbenes with amyloids, until now.    
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CHAPTER 2 
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2. Materials and Methods 
This chapter provides an overview of the experimental protocols used for the research 
presented in this thesis, and all experiments were performed at room temperature 25oC. All 
experiments are limited on a certain amount of physical restrictions be it instrumentation 
failure, human error, time and current state of knowledge.  
2.1 Materials 
2.1.1 Lipids  
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phospho-L-
serine (DOPS-sodium salt), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-
distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) and 1,2-
dimyristoyl-sn-glycero-3-phospho-L-serine (DMPS-sodium salt)  of >99% purity were 
purchased from Avanti polar lipids, INC, United States of America (USA). Cholesterol ≥99% 
purity was purchased from Sigma-Aldrich (Australia). 
2.1.2 Non-lipid materials  
Thioflavin T (ThT), Sodium Chloride (NaCl) and Phosphate buffered saline (PBS), and 
Dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (Australia). Resveratrol 
(RSV) 3,4,5-Trihydroxy-trans-stilbene of >99%, HPLC grade was purchased from AK 
Scientific, INC (USA), 3,4,5-Trimethoxy-trans-stilbene (TMS) of >99% purity was purchased 
from SAPPHIRE Bioscience Pty. Ltd. (Australia), and trans-stilbene (TS) was synthesised and 
supplied by A/Prof. Helmut Hugel, School of Science, RMIT. The partition coefficient (LogP) 
and topological surface area (tPSA) for stilbenes were calculated using Molinspirataion 
Cheminformatics (MC) software (268) (included in Table 6.1, Chapter 6). 
2.1.3 Peptides  
Somatostatin (SST, AGCKNFFWKTFTSC, Cys3-Cys14 and molecular weight (MW) 1637.9 
Da) and Vasopressin acetate (AVP, CYFQNCPRG-NH2, Cys
1-Cys6 and MW 1084.2 Da), 
purity of 98.0%, were purchased from polypeptide group the USA. Substance P acetate (SP, 
RPKPQQFFGLM-NH2 and MW 1347.6 Da), purity of 97.39%, was purchased from CHEM 
PEP INC USA. Oxytocin acetate (OT, CYIQNCPLG-NH2, Cys1-Cys6 and MW 1007.2 Da), 
purity of 98.15% and Deslorelin acetate (Des, XHWSYdWLRP-NHEt, MW 1282.5 Da), purity 
of 99.14%, were purchased from MIMOTOPES, Melbourne, Australia. The % hydrophobicity, 
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% charged amino acid residue, and a net charge for all functional amyloid-forming peptides 
was analysed using peptide 2.0 (34), (table included in appendix S8.1).  
2.2 Methods  
2.2.1 Liposome Preparation  
Multilamellar vesicles (MLV) with compositions (100 mol% DOPC, 100 mol% DLPC, 100 
mol% DMPC, 100 mol% DPPC, 100 mol% DSPC, 70 mol% DOPC/30 mol % Chol, 70 mol% 
DMPC/30 mol% Chol, 65 mol% DOPC/35 mol% DOPS, 65 mol% DMPC/35 mol% DMPS 
were combined in appropriate ratios and prepared by dissolving lipids in chloroform. The 
solution was gently dried under a stream of N2, and the film was then thoroughly dried under 
high vacuum overnight to remove any traces of residual solvent. The obtained dried film 
rehydrated with buffer (150 mM NaCl), to yield a final concentration of 20 mM and dispersed 
by sonication for 30 seconds using a 130 W (Vibra-Cell, VCX 130, Sonics, Newton, CT, USA) 
with 35% amplitude, pulse for 5 secs on/off. The lipid suspension was extruded 10 times 
through a 0.1 µm or 100 nm polycarbonate Nucleopore membrane filter (Whatman) fixed on a 
mini extruder (Avanti Polar Lipids, Inc.) to obtain MLV with an average diameter of 100 nm. 
Polydispersity Index (PDI) and particle size measured using Dynamic Light Scattering (DLS) 
technique, with instrument Zetasizer Nano ZS in PC2 lab at the Micro Nano Research Facility 
(MNRF) at RMIT (City campus). The hydrodynamic size data was analysed using zeta sizer 
software, and file exported .csv and plotted intensity vs size (nm) (include in appendix Figure 
S8.1 and Table S8.2). DLS measurements are very sensitive to temperature and solvent 
viscosity. Therefore, the temperature must be kept constant and solvent viscosity must be 
known for a reliable DLS experiment (270). 
2.2.2 Thioflavin T (ThT) Binding Assay  
Peptides were prepared in 25 µM ThT and liposomes doped with various lipid compositions 
(specified in 2.2.1). Therefore the peptide aggregation was measured in a series of 
concentration as described in each Chapter. The initial fluorescence (t = 0) was immediately 
recorded after sample preparation and at different time points throughout 168 hours or 1-week. 
The fluorescence intensity made in 6 replicates using PerkinElmer plate reader (excitation 
wavelength at 440 nm, emission wavelength at 482 nm respectively). The fluorescence 
intensity recorded from 200 µL samples contained into 96 microwell plates (Greiner Bio-one). 
The data is background subtracted and expressed as mean ± Standard Deviation (SD). To 
calculate aggregation rate constant kagg, the relative ThT fluorescence intensity as a function of 
  
31 
 
time was fitted to the following exponential equations (1) and (2). Equation 1 (one-phase 
association) was used when no lag phase was recorded, where y0 is the relative fluorescence 
intensity at t = 0, Plateau is the fluorescence intensity value at infinite t, k is the aggregation 
rate constant. Equation 2 (plateau followed by a one-phase association) was used when the lag 
phase was recorded, where t0 is the time at which fluorescence intensity increases after a lag 
phase (271). 
(1) 𝐹 (𝑡) = 𝑦0 + (Plateau − 𝑦0) × (1 − 𝑒−𝐾𝑡)  
(2) 𝐹 (𝑡) = (Plateau − 𝑦0) × (1 − 𝑒−𝐾(𝑡−𝑡0)) 
The half-time or (t1/2) for each sample obtained from the midpoint of ThT fluorescence a region 
that represents the pre and post-aggregation stage (272). Limitations, ThT assay does not 
recognise amyloid fibrils per se, but binds to the molecular groove found typically on the 
amyloid fibril surface and becomes activated. ThT is also unable to detect early aggregates i.e. 
oligomers and protofibrils (273).  
2.2.3 Tryptophan Fluorescence 
Fluorescence emission spectra were measured using FluoroMax (Horiba) spectrofluorimeter at 
an excitation wavelength of 290 nm and emission scan ranging 295 to 500 nm. The sample 
concentration described in Chapter 3 and 6 were excited at 290 nm and emission scan ranging 
295 to 500 nm. The excitation and emission slit width were both set to 5 nm. The background 
fluorescence of buffer or liposomes was subtracted out from the sample reading. The data was 
exported as a .csv file and plotted λmax versus sample (lipid + peptide). Fluorescence emission 
maxima (λmax) were calculated by averaging the mean of three measurements that exhibited 
the highest signal. The shift in the wavelength indicates the hydrophobicity and hydrophilicity 
of the peptide, blue shift denotes lower wavelength, or hydrophobic and red shift depicts higher 
wavelength or hydrophilic.      
2.2.4 Atomic Force Microscopy (AFM)  
All AFM imaging was performed in soft tapping mode in PBS to ensure that the fidelity of the 
lipid bilayers investigated was not affected by dehydration. The samples (as described in each 
Chapter) were pipetted onto a disk of freshly cleaved mica and left for 10 min, at which time 
the disk was gently washed in PBS before mounting on the AFM in a fluid cell (Bruker). The 
concentration of fibrils and lipids described in the subsequent Chapters. Imaging was 
performed on a Multimode 8 AFM using a Nanoscope V controller (Bruker) using an ultra-
sharp silicon nitride cantilever optimised for fluid imaging (SCANASSYST FLUID +, Bruker). 
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The tips possessed a nominal end radius of 2 nm, and a resonant frequency of 150 kHz (in air). 
All images were flattened using the first order flattening algorithm in the Nanoscope analysis 
software and no further image manipulation occurred. Statistical analysis of the AFM images 
was performed in the software FiberApp (274) from data sets of around 500 individual fibrils. 
In some cases, fibril numbers were too low (<500) to perform statistical analysis. Note that all 
the samples were prepared at RMIT and the imaging was performed at Swinburne University. 
Limitations of AFM, relatively slow scan time, can lead to thermal drift on the sample and 
time-resolved kinetic studies of fibril formation is not feasible using this technique and the 
resolution can be impacted if the probe is not sharp enough (275).     
2.2.5 Circular Dichroism (CD) 
CD spectroscopy was performed on Jasco J-1500, spectrophotometer. Measurements were 
conducted in the 280-190 nm region and measured every 1 nm at a scan speed of 50 nm/min 
using 2s equilibration time per step. Each spectrum is the average of 6 scans and was smoothed 
with a 7-point Savitsky-Golay filter to increase the signal-to-noise ratio. The mesophase was 
prepared by mixing peptides with liposomes at a ratio of 1:33, the final concentration of 6 mM 
vesicles and appropriate concentration was selected for functional amyloid-forming peptides 
(as described in Chapter 4, 5 and 6), to obtain a good signal to noise ratio with a high tension 
(HT) ≥ 800. The peptide only spectra were collected in 1 mm path quartz cuvette according to 
Beer’s Law equation: 𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 𝑒 𝑥 𝐿 𝑥 𝑐; (e) molar extinction; (L) path length of cell 
holder and (c) concentration of solution. While the peptides co-incubated in lipids were 
recorded in a 0.1 mm path length sandwich cuvette (due to high scattering). Each sample was 
recorded after 3-hour and 72-hour incubation in buffer or lipid mesophase, in which the 
spectrum of a blank sample of the related lipid mesophase without peptide was deducted from 
that with incorporated peptide. A quantitative approach was taken to predict the secondary 
conformation of peptides due to high normalised root mean square errors (NMRSD) >0.250. 
Limitations, secondary structure cannot be accurately determined for the majority of proteins 
whose 3D structures have been solved and restriction to detect protein structures in far UV 
range (i.e. below 180 nm) (276). Difficult to detect peptide conformational changes in smaller 
aliquots, especially in amyloid fibril studies. 
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2.2.6 Synchrotron Circular Dichroism (SR-CD) (ASTRID II facility in Aarhus 
Denmark) sample measurements and characterisation 
The measurements were conducted in the 170-280 nm region using the CD beamline of the 
synchrotron radiation source ASTRID2 at ISA, a centre for storage ring facilities at University 
of Aarhus (Denmark). Suprasil Quartz cells (Hellma GmbH & Co., Germany) of 0.1 mm path 
length, requiring a ~30 µL sample volume, were used in a temperature-regulated sample holder. 
The measurements were obtained at 1 nm increments in wavelength, 2.15 s averaging time, 
and 6 scans for each baseline and sample data. Data were smoothed with a 7-point Savitzky-
Golay filter (277). Liposomes in the absence of peptide were used as the baseline. The spectra 
are presented as molar ellipticity (M-1 cm-1), calculated with the mean residue weight (MRW) 
of the peptide, using the equation 𝑀𝑅𝑊 =
𝑀𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒
𝑁−1
; N = number of amino 
acids” (278), the path lengths of CD cells measured (102.3 and 97.7 µm). The data analysis 
performed using the online the DICHROWEB server (279) using CONTIN-LL algorithm. 
DICHROWEB analysis for samples with high NMRSD >0.250, a similar approach as 
described in section 2.2.5 was taken to predict the secondary conformation of peptides, 
included in appendix Table S8.3 and S8.5). Limitations, samples such as proteins can be 
damaged by radiation over longer exposure.    
 
 
  
34 
 
 
 
CHAPTER 3 
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3. Effect of lipid composition on fibrillisation of the functional amyloid-forming 
peptide Somatostatin-14 (SST-14)  
3.1 Introduction 
The ability of amyloid-forming peptides to self-assemble into larger aggregates, characterised 
by a β-sheet rich structure, is a trademark of several neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease and type II diabetes mellitus (280). Recently, 
neuropeptide hormones, including somatostatin, oxytocin, and vasopressin have been shown 
to self-assemble into fibrils with similar morphological features to those found in toxic 
amyloids (99).  These so-called “functional amyloids” are stored as amyloids within endocrine 
secretory granules and possess physiologically normal functions in living systems (5). 
The mechanism of amyloid fibril growth has been proposed for human amyloidogenic peptides, 
including islet amyloid polypeptide (IAPP) and Amyloid-β peptide (Aβ), and as described in 
Chapter 1, normally occurs through a nucleation-dependent polymerisation process made up 
of two phases: a nucleation (lag phase) and an extension (growth phase) (Figure 3.1) (281). 
During the lag phase, peptide monomers undergo a conformational shift to a β-sheet 
conformation, with subsequent self-assembly into oligomers and higher-order protofibrils (5, 
282). This conformational change is unfavourable thermodynamically and a rate-limiting step 
of the fibrillisation process. Once the nucleus has formed, the further addition of monomers to 
the nucleus results in the extension and growth of amyloid fibrils (281). The mechanism of 
amyloid formation is thought to be similar for functional amyloids, although (unlike for toxic 
amyloids) amyloid formation is a reversible process (5, 98).   
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Figure 3.1. Shows the process of nucleation-dependent fibril formation for Toxic vs Functional 
amyloids (adapted from (5))   
Numerous studies have shown that membrane surfaces can accelerate fibril growth for toxic 
amyloids. Several mechanisms have been proposed for this effect (5, 158, 283). Peptide-
binding to the membrane can induce a conformational change to the peptide, promoting fibril 
growth (245). A conformational change to a α-helical structure has been observed for Aβ, IAPP 
and α-synuclein following binding to the membrane (152, 284-287). Local increases in peptide 
concentration (referred to as “molecular crowding”) can then facilitate aggregation (5). It has 
also been suggested that the dielectric constant of the solvent is locally reduced in the 
microenvironment of the membrane and that this can promote the formation of intermolecular 
hydrogen-bonding or hydrophobic interactions between the peptides (283). The fibrillisation 
process can, in turn, significantly impact the structural integrity of the lipid membrane, via 
membrane thinning and pore formation, an effect which is strongly correlated with toxicity for 
toxic amyloids (288).   
Research shows that the rate of fibril formation in toxic amyloidogenic peptides is influenced 
by a range of membrane parameters, such as lipid composition, surface charge and intrinsic 
membrane curvature (5). Anionic lipids have been shown to accelerate fibril growth for a range 
of cationic amyloid-forming peptides including Aβ (215, 288), IAPP (289) and α-synuclein 
(290), presumably due to increased electrostatic interactions (291). Neutron and X-ray 
scattering studies by Lee and co-workers demonstrated that Aβ40 inserts more readily into 
anionic DPPG bilayers compared to neutral DPPC lipid bilayers (5). Liposomes containing the 
anionic PG lipid were also found to promote a β-sheet conformation for Aβ40 (189), IAPP 
(185) and α-synuclein (154, 190, 191). α-synuclein bound to membranes in gel phase (DPPC/ 
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DPPG), indicated a deeper penetration of the peptide within the bilayer as a result of peptide-
lipid bilayer interaction (37, 153, 197, 290). An increase in surface curvature of the membrane 
has also been linked with increased binding and aggregation rates (292). 
Cholesterol along with sphingomyelin and ganglioside lipids, which form ordered lipid-raft 
microdomains have been shown to enhance peptide binding and subsequent fibrillisation for 
Aβ, IAPP and prion proteins (170-175, 293). In contrast, α-synuclein however, preferentially 
binds to disordered bilayers. Binding to such domains has been shown to result in a 
conformational change for α-synuclein, from random coil to α-helix (at low peptide-lipid ratio) 
(294-296) and to β-sheets (at high peptide-lipid ratio) (297).   
Recently, a study on TasA, a model functional amyloid protein from the soil bacterium Bacillus 
subtilus, suggested, for the first time, that lipid membranes may play a similar role in the 
fibrillogenesis of functional amyloids (8). The interaction of TasA with a bacterial model 
membrane composed of a ternary mixture of PE, PG and cardiolipin resulted in disordered 
aggregates, displaying clear morphological differences to the fibrils formed in contact with a 
PC, Cholesterol and Sphingomyelin mixture designed to mimic a eukaryotic cell membrane. 
This initial study (and the body of literature on toxic amyloids) tentatively suggests that the 
ability of amyloidogenic proteins and peptides to interact with eukaryotic membranes is a 
ubiquitous feature which tends to promote amyloid assembly (8). However, in contrast to the 
vast body of literature on toxic amyloid-forming peptides, this study remains, to the best of our 
knowledge, the only investigation into the effect of eukaryotic lipid membranes on fibrillisation 
of functional amyloids.   
In Chapter 3, the effect of the lipid membrane composition on the formation of fibrils has been 
investigated for the functional amyloid-forming peptide SST-14 using multi-lamellar vesicles 
(MLVs). The peptide hormone SST-14, which is involved in regulating the central nervous 
system (CNS) and endocrine system (ES), has a cyclic structure resulting from a disulphide 
bridge (Cys3-Cys14) (Figure 3.2) (247).  
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Figure 3.2. Shows the amino acid sequence and disulphide link for SST-14 (adapted from (20))  
It has been reported to form amyloid fibrils in vitro (77, 248, 249). Recently, Dharmadana et 
al. have demonstrated that aggregation enhancers, such as heparin, commonly used to increase 
the aggregation rate for amyloid-forming peptides result in clear morphological differences in 
the resulting fibrils for SST (98). The fibrillisation of SST was characterised in the presence of 
liposomes of various lipid compositions.  Saturated lipids with chain lengths from C12 to C18 
were investigated, as well as the singly unsaturated C18 lipid DOPC.  The effect of cholesterol 
and the anionic lipids DMPS and DOPS were also investigated. Results are rationalised in 
terms of the effect of membrane parameters including membrane surface charge and fluidity, 
hydrocarbon chain packing, and lipid solubility on the fibrillisation of functional amyloid-
forming peptides.   
3.2 Materials and Methods 
3.2.1 Liposome preparation and analysis 
The liposome preparation and analysis are described in Chapter 2, section 2.2.1.  
3.2.2 Small Angle X-ray Diffraction (SAXD) on bulk lamellar sample, 
preparation and data analysis   
Self-assembled lipid mesophase (gel phase) of 100 mol% DMPC and 100 mol% DSPC 
prepared from a chloroform solution. The solution was dried under fume hood overnight to 
evaporate and remove any residual solvent and lyophilised for 24 hours. Approximately, 80 
wt% of Milli-Q water was added to dried films followed by 0.01% w/w to 2.5% w/w SST at a 
ratio of (1:97). Mol% is defined as 100 𝑋 
𝑚𝑜𝑙 𝑆𝑆𝑇
𝑚𝑜𝑙 𝑆𝑆𝑇+𝑚𝑜𝑙 𝑙𝑖𝑝𝑖𝑑
. The peptide and self-assembled 
lamellar phase (gels) allowed to equilibrate overnight before SAXD experiments. SAXS 
experiments were run at the SAXS/WAXS beamline of the Australian Synchrotron. A beam 
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current of 10.0 keV was used with dimensions 200 µm x 300 µm and a typical flux of 1 x 1013 
photons s-1. The sample to detector distance was 1.5 m, with an exposure time of 1 s. Two-
dimensional diffraction patterns were recorded on a Pilatus 1 M detector, which offers 
minimum noise and collection of data over a large area. The samples were deposited in gel 
plates which consist of 40 wells and kapton tape was used to retain moisture in the samples. 
The 2D diffraction images are converted to 1D files of intensity vs q using the scatterbrain 
program. This was used in combination with IDL-based AXcess software package, developed 
at Imperial College London, which permits individual analysis of X-ray images. Calibration of 
the program is carried out with a known standard (silver behenate, d = 58.38 A). Followed by 
assigning the sample peaks, the program then calculates the d-spacing or lattice parameter for 
a specified phase. The D-spacing of more than one or co-existing phases are calculated 
separately using the equation: 𝑞 =
2𝜋
𝐷
. 
3.2.3 Small Angle X-ray Scattering (SAXS) 
Liposomes used in this experiment and preparation is described in Chapter 2, section 2.2.1 with 
the same ratios but only selected vesicles were used (DOPC, DOPC/Chol and DMPC). The 
beamline and its configurations are similar to 3.2.2, with changes to the sample and plate set-
up. The peptide (SST-14) co-incubated at 5% w/w or 2 mol% in buffer (150 mM NaCl) and 
liposomes at a similar ratio to bulk samples (3.2.2) and the final concentration of vesicles were 
6 mM. 100 µl of sample was deposited in 96 well polymerase chain reaction (PCR) plates. The 
plate was sealed with a silicon rubber lid to prevent evaporation and pre-cut to allow smooth 
penetration of the sample loading needle. The plates were positioned in the plate holder and 
standard safety, the procedure is administered before X-rays were directed on to the samples. 
An auto-loader set-up was used and the plate holder custom built can accommodate 2 plates of 
dimensions (85 x 127 mm, 96 or 384 well) and is fixed in front of the beam, coordinates mapped 
for samples and an automated scan of each well is initiated with an approximate run time ~1 
hour per plate. The scatterbrain software developed by SAXS/WAXS beamline scientists (Dr. 
Stephen Mudie and Dr. Nigel Kirby) was used to perform averaging, buffer subtraction and 
preliminary analysis on samples. The data was exported as a .csv file and plotted as intensity 
vs q, and the D-spacing equation was used in 3.2.2 to calculate D-spacing (D) or lattice 
parameter. Limitations are radiation damage to samples e.g. proteins and spatial averaging can 
occur due to random orientation of dissolved samples, which leads to loss of information (298).  
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3.2.4 Preparation of Functional amyloid-forming peptides (FAFP’s) 
150 mM NaCl was added to a weighed fraction of SST-14. The solution was vortexed for a 
few seconds for smaller aliquots or a minute for bigger aliquots to produce solutions having a 
final concentration ranging from 0.01% w/w to 5% w/w. 
3.2.5 Thioflavin T (ThT) Binding Assay  
The concentration of SST-14 in the buffer is described in 3.2.4 and 5% w/w or 2 mol% is used 
in liposomes (preparation and analysis described in Chapter 2, section 2.2.1). ThT assay 
protocol is described in Chapter 2, section 2.2.2. 
3.2.6 Time-resolved kinetic studies using Dynamic Light Scattering (DLS) 
5% w/w SST was co-incubated in liposomes at an appropriate ratio (1:97) with selected 
vesicles (DOPC, DMPC, DOPC/Chol and DOPC/DOPS). The liposome preparation and DLS 
protocol and analysis are described in Chapter 2, section 2.2.1.  
3.2.7 Atomic Force Microscopy (AFM)  
5 % (w/w) solution of SST fibrils or fibrils + liposomes (SST + DMPC) at ratio (1:97). Imaging 
and analysis are carried out as described in Chapter 2, section 2.2.4. 
3.2.8 Tryptophan Fluorescence 
The peptide (SST-14) prepared at 0.01% w/w in buffer (NaCl) and co-incubated in liposomes 
doped with various lipid compositions at a ratio (1:97) (described in Chapter 2, section 2.2.1). 
The experimental protocol and analysis are described in Chapter 2 section 2.2.3. 
3.2.9 Synchrotron Circular Dichroism (SR-CD) (ASTRID II facility in Aarhus 
Denmark) sample measurements and characterisation 
A weighed fraction of 0.03% w/w or 0.3 mg mL-1 SST was dissolved in buffer (MilliQ water) 
and co-incubated in selected liposomes (DOPC, DMPC, DOPC/Chol and DOPC/DOPS (lipid 
at an appropriate ratio (1:97) as described in Chapter 2, section 2.2.1 with a minor change to 
this protocol for liposome preparation (Milli-Q water instead of 150 mM NaCl to rehydrate 
vesicles). The experimental parameter and SRCD spectra analysis are described in Chapter 2, 
section 2.2.6. 
  
  
41 
 
3.3 Results 
3.3.1 Interaction with the lipid bilayer changes the secondary structure of SST-
14 and the kinetics of fibril growth 
The secondary structure of SST-14 was studied using synchrotron circular dichroism (CD) in 
the presence and absence of liposomes. Note that a typical peptide concentration for CD 
experiments was used, 0.3 mg mL-1, or (0.03 % w/w) which is below the minimum SST-14 
concentration at which amyloid fibril formation is observed (59). The CD spectrum of SST-14 
in water contains a large minimum at 201 nm, consistent with a secondary structure which is a 
mostly random coil (Figure 3.3a). A shoulder at around 195 nm indicates the presence of β-
sheet structures, presumably due to intra-peptide hydrogen bonds constrained by the cyclic 
molecular structure and potentially to inter-peptide networks within small soluble oligomers. 
This is confirmed by analysis of the spectrum using Dichroweb, which yields 54% random coil 
and 42% β-sheets and turns (Table 1), in agreement with previous ATR-FTIR and CD studies 
on SST-14 in water (299). 
 
Figure 3.3. (a) SR-CD spectra for SST-14 co-incubated in vesicles after 3 hours and (b) SR-
CD spectra for SST-14 co-incubated in vesicles after 72 hours 
 
 
 
a) b) 
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Table 3.1. Secondary structure of selected samples of SST-14 co-incubated with liposomes, 
analysed using Dichroweb with Contin-LL algorithm method. *Quantitative analysis was 
performed for DOPC+SST, DOPC+DOPS+SST (3 and 72 hours) and DMPC+SST (72 hours) 
due to NRMSD > 0.250 (in appendix Table S8.3) 
 
Following three hours incubation with liposomes of various compositions, a shift in the CD 
spectrum was observed for all samples relative to pure SST (Figure 3.3a). The minimum at 201 
nm becomes less intense and moves to higher wavelength, while the shoulder feature at 195 
nm becomes more pronounced, consistent with an increase in β-sheets and a concomitant 
reduction in the proportion of the structure that is the random coil. The effect is dependent on 
the lipid composition and is most pronounced for the lipid bilayer doped with the anionic lipid 
DOPS, presumably due to an electrostatic interaction with the positively charged peptide. 
Dichroweb analysis, which was only possible for selected samples due to large errors in data-
fitting (NRMSD > 0.250), confirmed a significant reduction in the percentage of random coil 
structures and increased in β-sheets and turns (Table 3.1). This effect appears to become more 
pronounced with time, particularly for the anionic lipid bilayer, which displays a characteristic 
β-sheet rich spectrum of a strong negative peak at around 210 nm and a maximum of 
comparable intensity at 195 nm after 72 hours, with no residual trace of random coil structures 
visually observed in the spectrum (Figure 3.3b). 
Intrinsic tryptophan fluorescence measurements, (Figure 3.4), provide information on the 
environment around the single tryptophan (Trp) residue in SST-14.  In buffer, λmax has a value 
of approximately 357nm.  Following incubation with liposomes of various lipid compositions, 
a characteristic blue shift of λmax to lower wavelength is typically observed. This is 
Samples 
Helix
% 
Sheet
% 
Turns
% 
Unordered
% 
NRMSD Ref Set 
After 3 hours 
Pure SST 4 27 15 54 0.209 7 
DMPC+SST 15 39 26 6 0.191 7 
70DOPC:30CHOL+SST 8 53 31 3 0.161 7 
After 72 hours 
Pure SST 5 26 14 55 0.219 7 
70DOPC:30CHOL+SST 1 45 27 26 0.120 7 
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characteristic of the presence of a more hydrophobic environment around the tryptophan 
residue, consistent with some penetration of the SST into the liposomal lipid bilayer. The 
magnitude of this blue shift is larger for liposomes formed from the unsaturated lipid DOPC, 
and smaller for liposomes formed from saturated chain lipids, indicating greater penetration of 
the peptide into the unsaturated bilayer. Addition of the anionic PS lipid resulted in an increased 
blue shift relative to the analogous uncharged bilayer for unsaturated and saturated chain 
liposomes, suggesting that the electrostatic interaction has also promoted deeper penetration 
into the bilayer. The effect of cholesterol was not consistent; an increased blue shift was 
observed for DOPC, but a reduced blue shift for DMPC.   
 
Figure 3.4. SST-14 environment in buffer (control) and in bilayer measured by Tryptophan 
Fluorescence 
The fluorescent dye Thioflavin T (ThT) specifically binds to β-sheets or fibrils, which results 
in an increase in its fluorescence intensity. ThT fluorescence binding assays were used to 
monitor the kinetics of SST-14 amyloid fibrils formation in the presence of liposomes. The 
increase in ThT relative fluorescence with time is plotted in (Figure 3.5a) for SST-14 at various 
concentrations in the presence of NaCl. In the absence of the lipid bilayer, ThT binding was 
detected for SST concentrations of > 2.5% (w/w). An initial lag phase of 12 hours, 
characterised by a weak increase in ThT fluorescence, was followed by a strong growth phase. 
This growth phase can be used to calculate the rate constant for aggregation (kagg) by fitting a 
mono-exponential decay (characteristic of first-order kinetics) to the data, as described in (98). 
The kagg values for SST-14 in NaCl was obtained for concentrations 2.5 and 5% w/w, i.e. 
0.0037 s-1 to 0.019 s-1 (in appendix Table S8.4). 
  
44 
 
The increase in ThT relative fluorescence for SST-14 (2 mol%) incubated with liposomes of 
various lipid compositions, including saturated chain lipids of various lengths (DLPC (C12); 
DMPC (C14); DPPC (C16) and DSPC (C18)) and the unsaturated lipid DOPC (C18:1) is 
shown in (Figure 3.5b). The values of lag phase, kagg, t1/2, and final fluorescence intensity of 
the plateau phase were extracted from the ThT curves are provided in Table 3.2. Incubation 
with saturated chain lipids increased the value of kagg, relative to that observed in the buffer, in 
all cases, with no strong correlation between kagg and the alkyl chain length (Table 3.2). These 
results show that the presence of saturated lipids accelerates the SST-14 aggregation process. 
Saturated chain lipids also reduced the lag period relative to that seen in NaCl and resulted in 
slightly higher fluorescence plateau values, supporting that fibril nucleation occurs earlier and 
more aggregates are formed in the presence of these liposomes. However, the half-time ( for 
SST fibrils in DLPC liposomes (t1/2 = 6.3 hours) was much shorter compared to other saturated 
chain lipids, (Table 3.2), consistent with a previous study which showed accelerated Aβ 
aggregation with short-chain lipid (300). The most significant effect is observed with the 
saturated chain lipid DMPC which has a significantly highly fluorescence plateau value (Table 
3.2) than any other saturated chain lipid, suggesting the greatest number of fibrils are formed 
with this combination.   
In contrast, the unsaturated chain lipid DOPC appeared to slow down fibril aggregation, with 
both an increase in the lag period, a reduction in the t1/2 value, and a reduction in the value of 
kagg (Table 3.2). The fluorescence plateau value was also much lower in the presence of DOPC, 
suggesting many fewer aggregates are formed. The reduction in aggregation may be linked to 
the deeper penetration in the DOPC bilayer suggested by the tryptophan fluorescence results 
presented above and is discussed further in the discussion.   
The effect of the addition of cholesterol to the DOPC and DMPC lipid bilayers on fibrillisation 
was also investigated (Figure 3.5c). In a saturated chain bilayer (DMPC), cholesterol appeared 
to significantly increase the fluorescence intensity of the final plateau, with a slight decrease 
of the kagg value (0.04 s
-1 vs 0.03 with cholesterol). The t1/2 value (23h) was slightly longer than 
that for pure DMPC (13h) (Table 3.2). This result supports that more peptide fibrils are formed 
in the presence of cholesterol in the saturated bilayer. In the unsaturated DOPC lipid bilayer, 
while addition of cholesterol did not significantly increase the plateau value, it did reduce the 
lag phase from 48 hours to 24 hours and slightly increased the kagg value from 0.024 to 0.029, 
suggesting that the kinetics of the fibril formation process is affected, but not the number of 
fibrils.  
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The greatest impact on fibril growth was observed for the charged lipids DOPS and DMPS, in 
agreement with numerous studies on the strong electrostatic interaction between cationic 
peptides and anionic lipid membranes (5, 37, 214, 301). The effect of charge was also observed 
in a recent study on the functional amyloid TasA, which interacted more strongly with a 
charged lipid membrane composed of PE/PG/CL (302). We note that the lag period was 
reduced, and kagg and final fluorescence plateau values increased significantly when the bilayer 
was doped with 35 mol% anionic lipids, which is also in agreement with the shortest half-time 
values (Table 3.2). While the rate of growth was similar for both anionic liposomes, the volume 
of fibrils formed was significantly greater for the anionic DMPC/DMPS liposomes. 
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Figure 3.5. (a) Thioflavin T (ThT) assay of SST-14 incubated in NaCl, (b) ThT assay of SST-
14 and SST-14 at 5 % (w/w) co-incubated with unsaturated and saturated vesicle with increase 
in chain length impacting SST fibrillisation, (c) ThT assay of SST-14 and SST-14 co-incubated 
in DOPC, DOPC vesicle doped with cholesterol, DMPC, DMPC doped with cholesterol, 
DOPC doped with DOPS and DMPC doped with DMPS 
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Table 3.2. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST-14 at 5% (w/w) in NaCl and vesicles doped with various 
lipid compositions over 1 week period 
Conditions Lag phase 
(hours) 
t50 or (t1/2) 
(hours)3 
kagg (s-1)1or2 Final 
fluorescence 
intensity of 
plateau phase 
(x106) 
 Buffer 
NaCl 12 51 0.01862 2.7 
 Unsaturated 
DOPC 48 85 0.02382 1.4 
 Effect of chain length or bilayer thickness 
DLPC 0 6.3 0.05891 3.8 
DMPC 0 13 0.03801 6.2 
DPPC 24 41 0.06312 4.9 
DSPC 12 28 0.05112 4.8 
 Effect of Cholesterol 
70DOPC+30CHOL 24 36 0.02872 3.3 
70DMPC+30CHOL 0 23 0.03021 11.0 
 Effect of Charge 
65DOPC+35DOPS 0 2.6 0.3251 5.6 
65DMPC+35DMPS 0 0.3 0.2191 12.3 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
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3.3.2 The peptide and bilayer interaction reveals no significant changes to bilayer 
size and shape 
The average size distribution is almost the same which indicates that the vesicles do not change 
significantly with the presence of the peptide (Figure 3.6). The broadness of the peaks is 
observed to be unchanged which further suggests that the interaction between peptide and lipid 
had not occurred. Therefore, following (Figure 3.7) shows the hydrodynamic size change with 
respect to time (hours), and the results clearly suggest no change in the overall hydrodynamic 
size.    
 
Figure 3.6. Size distribution of vesicles of various compositions co-incuated with SST-14 (5% 
w/w) for 1 week as determined by DLS  a) DOPC, b) DMPC, c) DOPC doped with cholesterol 
and d) DOPC doped with DOPS 
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Figure 3.7. Shows the hydrodynamic size of the vesicles with SST-14 over 1 week period 
3.3.3 The interaction between the peptide and the lipid bilayer do not significantly 
alter the bilayer structure 
The effect of SST on the bulk lamellar structure was investigated for DMPC and DSPC phases 
using Synchrotron Small-Angle X-ray diffraction (SAXD). The well-defined lamellar peaks 
are characteristic of a bilayer structure. Upon incubating SST with DMPC (Figure 3.8) or 
DSPC (Figure 3.9), no changes to the lamellar peaks and D-spacing (Table 3.3 and Table 3.4), 
which indicates that the sharp lamellar peaks were retained at all concentrations, which 
suggests that the bilayer structure is unpertubed. 
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Figure 3.8. Shows the 1D diffraction pattern of Intensity vs q for bulk lipids at varying SST 
concentration. Small angle X-ray scattering data were obtained ~7 h after setup of the plates.  
Table 3.3. Shows the effect of SST addition (0.01 to 2.5% w/w) on D-spacing of the lamellar 
phase of DMPC 
Lipids mol% Peptide % w/w Phase D-spacing (A) 
100 DMPC No peptide Lα1 62 
100 DMPC 0.01 Lα1 62 
100 DMPC 0.05 Lα1 62 
100 DMPC 0.1 Lα1 62 
100 DMPC 0.5 Lα1 62 
100 DMPC 1 Lα1 61 
100 DMPC 2.5 Lα1 62 
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Figure 3.9. The 1D diffraction pattern of Intensity vs q for bulk lipids at varying SST 
concentration. Small angle X-ray scattering data were obtained ~7 h after setup of the plates.  
Table 3.4. Shows the effect of SST addition (0.01 to 2.5% w/w) on D-spacing of the lamellar 
phase of DSPC 
Lipids mol% Peptide % w/w Phase D-spacing (A) 
100 DSPC No peptide Lα1 67 
100 DSPC 0.01 Lα1 67 
100 DSPC 0.05 Lα1 67 
100 DSPC 0.1 Lα1 68 
100 DSPC 0.5 Lα1 69 
100 DSPC 1 Lα1 68 
100 DSPC 2.5 Lα1 67 
 
The effect of SST on the lipid bilayer structure of multi-lamellar vesicles (MLVs) was 
investigated.  Liposomes formed by DMPC, DOPC and DOPC+Chol mixtures displayed x-ray 
scattering patterns consistent with the formation of multi-lamellar liposomes, (Figure 3.10). 
Two clear correlation peaks are seen in each case corresponding to lattice parameter or D-
spacings of 64 Å, 62 Å and 65 Å (Table 3.5) respectively, in good agreement with the lamellar 
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phase formed by these systems (303-305). Upon addition of peptide (peptide : lipid ratio = 
1:97), a decrease in the scattered intensity was observed.  However, two clear correlation peaks 
are still observed for DOPC and DOPC+Chol suggesting that the bilayer structure of the 
liposomes has not been impacted significantly, despite CD and tryptophan fluorescence studies 
showing significant interaction between the peptide and these bilayers. For DMPC liposomes 
the second correlation peak has been replaced by a single broad peak in the scattering pattern, 
(Figure 3.8c), indicating that the multi-lamellar structure has been compromised, suggesting a 
phase transition from lamellar to micelles. 
 
Table 3.5. Lattice parameter or D-spacing for SST co-incubated with vesicle 
 
 
 
 
 
 
 
Liposomes SST (Mol%) Peptide : lipid D-spacing 
DOPC 0 0 62 
70DPC+30CHOL 0 0 65 
DMPC 0 0 64 
DOPC+SST 1 1:97 60 
70DOPC+30CHOL+SST 1 1:97 63 
DMPC+SST 1 1:97 0 
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Figure 3.10. Small angle X-ray scattering (SAXS) of Multilamellar vesicles (MLVs) co-
incubated with SST, (a) DOPC vesicle co-incubated with SST and (b) DOPC vesicle doped 
with cholesterol co-incubated with SST, (c) DMPC vesicles co-incubated with SST 
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3.3.4 Clear morphological differences are observed between fibrils formed in the 
buffer and those incubated with liposomes 
Results so far suggest that the addition of liposomes formed from DMPC lipids (compared to 
other zwitterionic lipids studied) result in faster fibrillisation kinetics for SST-14 and a 
significant increase in total volume of fibrils formed. SAXS results suggest that the bilayer 
structure of DMPC liposomes is impacted by this interaction. We, therefore, used DMPC 
liposomes to perform a comparative analysis of the fibrils formed in the presence of liposomes, 
with those formed in the buffer using Atomic Force Microscopy. Analysis was carried out on 
SST fibrils and SST fibrils co-incubated with DMPC lipid vesicles (1:97), (Figure 3.11). Clear 
differences in SST fibril morphology were observed between samples formed in NaCl and in 
the presence of liposomes. SST fibrils form typical amyloid-like unbranched twisted fibrillar 
structures, (Figure 3.11a). 
In contrast, the fibrils formed by SST co-incubated with DMPC vesicles, (Figure 3.11b), 
displayed a more heterogeneous structure, likely due to an uneven coating of lipids decorating 
the fibrils. Evidence of the lipid coating of the fibrils is highlighted by the arrows in (Figure 
3.11b). The distribution in height (Figure 3.11c) and length (Figure 3.11d) of individual  SST 
and SST-DMPC fibrils were determined by a statistical analysis of more than 500 fibrils using 
the open source software FiberApp (306). The contour length distributions show that the bare 
fibrils display a relatively broad single population of contour lengths centred around 1000 nm, 
with a small additional population of very long fibrils (> 8000 nm). The distribution of contour 
lengths for fibrils coated with DMPC, on the other hand, is very heterogeneous with seemingly 
multiple sub-populations co-existing. From the histograms in (Figure 3.11c) it is obvious that 
the fibrils coated with DMPC have a tendency to be longer with large populations with contour 
lengths > 5000 nm, this tendency for longer fibrils to be formed in the presence of DMPC is 
consistent with the increase in kinetics and overall fluorescence levels in the ThT analysis 
(Figure 3.5b).  
The height distribution statistics (Figure 3.11d) indicate that fibrils formed in the absence of 
lipids have a relatively small distribution of heights with a single population centred around 2-
3 nm. Fibrils formed in the presence of DMPC liposomes displayed a more heterogeneous 
distribution of heights with what appears to be two populations centred around 3.5 and 6.5 nm.  
Presumably, these two populations relate to partially lipid coated fibrils (with a mean diameter 
only 0.5 nm larger than the bare fibrils) and a second population of lipid coated fibrils (with an 
average fibril diameter around 3.5-4.5 nm larger than the uncoated fibrils). This 3 nm increase 
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in fibril height is too small to correspond to a full bilayer surrounding the fibril (typically a full 
bilayer is approximately 5 nm in width, multiplied by two to account for the coating of the top 
and the bottom of the fibril), suggesting that upon co-aggregation of the SST and the DMPC 
lipids the bilayer structure is disrupted and something approximating the height of a lipid 
monolayer (~2.5 nm) is surrounding the fibrils on all sides (in agreement with the suggested 
bilayer disruption from the SAXS). Persistance length calculations suggest that SST-DMPC 
fibrils display a slight increase in stiffness (Figure 3.11e, f).   
The high-resolution AFM images of the fibrils formed in NaCl display a commonly observed 
mature amyloid twisted fibril structure (Figure 3.12a) (307). However, in the presence of the 
DMPC lipids, this twisted morphology seems to be obscured (Figure 3.12b). The representative 
height profiles of bare SST and SST + DMPC fibrils confirm this is showing a very regular 
periodicity for the bare fibrils (Figure 3.9c), and no obvious periodicity for the DMPC coated 
fibrils. Through Direct Fourier Transform (DFT) (Figure 3.12e, f) and autocorrelation function 
(ACF) (Figure 3.12g, h) analysis of the populations of fibrils we can very accurately calculate 
the peak to peak distance of these periodic structures. For the bare fibrils, DFT analysis 
provides a pitch of 64.4 nm while ACF shows 63 nm for the bare SST fibrils, and as expected 
no periodicity is detected when the DMPC liposomes are added.   
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Figure 3.11. Atomic Force Microscopy Analysis of 5% (w/w) SST fibrils and SST fibrils co-
incubated with DMPC lipid vesicles, (a-b) topographic images of (a) SST fibrils displaying 
typical amyloid-like unbranched twisted fibrillar structure, (b) SST co-incubated with DMPC 
vesicles, the formed fibrils display a more heterogeneous structure and evidence of the lipid 
coating of the fibrils is highlighted by the arrows, (c-d) statistical analysis (approximately 500 
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fibrils) of fibrillar species formed and (e-f) Persistance length calculations, for (e) SST and (f) 
SST+DMPC, very little difference, slight increase in stiffness for the SST + DMPC fibrils 
 
 
Figure 3.12. High Resolution AFM images of the change in fibril nanostructure between SST 
and SST + DMPC fibrils (a-b) topographical AFM images of (a) SST and (b) SST + DMPC 
fibrils, (c-d) line section through one individual fibril (c) SST and (d) SST + DMPC. (e-f) 
Direct Fourier Transform analysis of pitch of multiple fibrils (g-h) Auto-Correlation Function 
analysis of twist angle of multiple fibrils 
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3.4 Discussions 
Co-incubation of the SST-14 peptide with lipid membranes results in clear differences in the 
rate of fibrillisation, and the volume and morphology of the formed fibrils. The effect is 
dependent on the lipid bilayer composition. As expected, the addition of an anionic lipid into 
the bilayer strongly promoted fibril growth, with both a fast rate of fibrillisation and a large 
volume of formed fibrils. This is consistent with the known effect of anionic lipids on toxic 
amyloid-forming peptides and results from increased electrostatic interaction between the 
cationic peptide and the anionic membrane (5, 153, 160, 284, 308). More unexpectedly the 
effect of chain unsaturation in the lipid also had a significant effect. In all cases, lipids having 
saturated hydrocarbon chains both increased the aggregation rate and resulted in a greater 
number of fibrils formed. We note that the fastest aggregation rates (shortest t1/2 times) were 
observed for the short-chain lipids, DLPC (C12:0) and DMPC (C14:0), although all four 
saturated chain lipids display similar kagg values during the fibril growth phase. Interestingly, a 
fast aggregation rate does not always correlate with the greatest volume of fibrils formed; while 
the fluorescence plateau value is correspondingly high for DMPC, it is low for DLPC. These 
data are in agreement with a recent study on α-synuclein, which also showed the fastest 
aggregation rates for the charged analogues DLPS and DMPS (309). The authors rationalised 
this effect in terms of the relatively high solubility of these short-hydrocarbon chains (in 
general the free energy of solubilisation of lipids in water is proportional to chain length). They 
suggested that the mechanism of membrane-mediated fibrillisation may, therefore, involve not 
just binding of the peptide to the membrane, but a reciprocal transfer of lipids to the local 
environment of the peptide. They noted the physiological relevance of this effect due to the 
generation of short-chain lipids from the peroxidation of poly-unsaturated lipids, which is 
known to be damaging to cells. It is interesting to note an identical effect for the uncharged 
lipids investigated here, suggesting that the effect of lipid solubility may be comparable to the 
known effect of charge.  
Both CD and intrinsic tryptophan fluorescence studies confirm the interaction between the 
peptide and the lipid bilayer, although the strength of this interaction is not fully correlated 
with the effect on fibrillisation. The change in secondary structure of the peptide in the presence 
of the liposomes indicates interaction is associated with changes to the secondary structure of 
the peptide consistent with a reduction in random coil structure and an increase in β-sheets and 
is most pronounced for the charged lipid bilayer DOPC:35%DOPS. Tryptophan fluorescence 
studies indicate that the peptide resides in a more hydrophobic environment in the presence of 
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liposomes, confirming that the peptide inserts, at least partially, into the bilayer.  The blue shift 
is most pronounced for the unsaturated bilayer DOPC, and more minor for the saturated chain 
bilayers suggesting that SST inserts more deeply into the unsaturated bilayer. The deeper 
penetration into the DOPC bilayer is consistent with recent studies suggesting that the increased 
lateral bilayer pressure associated with the saturated hydrocarbon chains can hinder peptide 
insertion (310) and may inhibit aggregation by blocking potential aggregation sites for the 
peptide. 
We also note clear differences in peptide-membrane interactions between gel (DPPC, DSPC) 
and fluid lamellar bilayers (DLPC, DMPC, DOPC). Tryptophan fluorescence experiments 
suggest that the peptide resides in a more hydrophobic environment for the fluid membranes, 
indicative of deeper penetration into the bilayer. The rate of diffusion of the amyloid-beta 
peptide over the 2-D membrane surface has been shown to be slower in the gel phases (243), 
consistent with a recent study which showed that diffusion rates for membrane-associated 
peptides are strongly linked to the underlying lipid self-diffusion rates (311)  For the amyloid-
beta peptide, a reduction in diffusion was linked with a retardation in fibril growth. Here, a 
similar effect was noted for the saturated hydrocarbon chains, aggregation of SST in the gel 
phase was slower than that in the fluid lamellar phase.  However, the effect is more minor than 
that of the lipid solubility as evidenced by the large difference in aggregation rates for saturated 
DLPC and unsaturated DOPC. A similar effect was noted by (309) for α-synuclein; while the 
binding of α-synuclein was greatest to fluid membranes, this was not correlated with 
aggregation rate (309).   
To summarise, a combination of CD, intrinsic tryptophan fluorescence, ThT assays, SAXS and 
AFM results suggest that membrane surface charge is the parameter which enhances fibril 
formation most, in line with published literature on toxic amyloid-forming peptides. Saturated 
chain lipids appear to enhance fibrillisation while unsaturated lipids inhibit fibrillisation, and 
this effect is correlated with deeper penetration of the peptide into the unsaturated bilayer due 
to reduced lateral pressure. Aggregation of peptides may be enhanced on the membrane surface 
(as opposed to deeper in the bilayer) due to the probability of contact with other surface-
associated peptides resulting in amyloid formation. A more minor effect is seen with lipid 
solubility; shorter chain lipids appear to have the fastest aggregation rates, potentially linked 
to the reciprocal transfer of lipids out of the bilayer. The short chain, saturated lipid DMPC is 
a particularly interesting case study, with an extremely high volume of fibrils formed with 
highly heterogeneous contour lengths.  
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Figure 3.13. An illustration of SST-14 fibril interacting with fluid DMPC bilayer, inspired by 
AFM image (Figure 3.9b) 
Statistical analysis of the AFM data suggests that the DMPC lipid bilayer is disrupted and a 
lipid monolayer sheath is formed around the growing SST fibrils obscuring their natural twisted 
morphology. Presumably, this bilayer disruption is made possible by the highly soluble nature 
of the short chain DMPC lipids. The reason this effect is not also observed by SAXS for the 
equally short chain length DLPC is unclear and warrants further study. Here it is worth 
highlighting the power of combining high-throughput ensemble techniques like SAXS and 
macromolecular imaging techniques such as AFM. By taking this approach, we were able to 
screen the entire library of lipids and identify unusual behaviour in the DMPC lipids. An in-
depth statistical analysis of DMPC and SST co-aggregation then allowed us to detect fibrils 
with two sub-populations of diameters with a difference corresponding to one lipid monolayer 
thickness. The fibrils appeared to have a distinct “pearl necklace” formation seen in AFM and 
its interaction with DMPC bilayer is shown in a schematic representation (not to scale, Figure 
3.13). If we did not take such a statistical approach to high-resolution macromolecular imaging 
in order to determine the diameter of our fibrils, and instead relied on ensemble techniques for 
colloidal analysis (i.e. Dynamic Light Scattering) these sub-populations with subtle differences 
in fibril diameter would have been indistinguishable.  
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CHAPTER 4 
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4. The interaction between the cyclic neurohypophysial hormone-like peptides 
Vasopressin (AVP-9) and Oxytocin (OT-9) and model membranes 
4.1 Introduction 
The neurohypophysial hormones AVP-9 and OT-9 (312) are part of a family of structurally 
and functionally related peptide hormones with a conserved intramolecular ring, comprised of 
6 amino acid (aa) residues and a C-terminal extension of 3 aa residues (250). They are formed 
as large precursor proteins that are consequently processed to give rise to mature nonapeptides. 
These peptides differ in the amino acids at positions 3 and 8 (Figure 4.1), contributing to 
significant differences in their activity (313). Neurohypophysial hormones are involved in 
sexual behaviours and social recognition and contribute to neuropsychiatric disorders including 
intellectual disability (ID), autism spectrum disorders (ASDs) and bipolar disorder (BD) (250, 
251). The primary role of AVP is in the regulation of blood pressure and urine concentration 
(313-315). It is also responsible for the stability of body temperature (316) and the stimulation 
of adrenocorticotropin secretion (317). OT is involved in labor and lactation and plays an 
indirect, facilitatory role in the release of luteinising hormone (LH) (313).  
 
Figure 4.1. The amino acid sequences for neurohypophysial hormones (a. AVP and b. OT) 
(adapted from (21)) 
Studies have concluded that neurohypophysial hormones contain sequences which are likely 
to form aggregates due to mutations (250) resulting in the formation of functional amyloids in 
secretory granules(77). Immunohistochemical studies conducted on mouse pituitary tissue 
have confirmed the existence of amyloid-like fibrils of OT-9 and AVP-9 in secretory granules 
located in the posterior lobe of the pituitary (99, 100). AVP receptors are typically found 
located in the same brain regions as Aβ fibrils and in vivo studies conducted by Jing and co-
AVP-9 OT-9 
  
63 
 
workers, have reported that AVP can prevent Aβ induced impairment (101). More recently, 
Atosiban, a nonapeptide drug which is an OT-9 antagonist and shares most of its features, has 
been reported to self-assemble into 7-nm wide amyloid fibrils above a critical concentration of 
2-10% (w/w) (100). Atosiban is also an inhibitor of OT-9 and AVP-9 receptors and is directed 
to delay premature labor (318). 
In Chapter 3, we demonstrated that interaction with lipid membranes significantly impacted 
the rate of fibrillisaton and fibril morphology for the functional amyloid-forming peptide SST.  
The lipid composition was shown to modulate this effect, with a surface charge, and lipid chain 
saturation both playing an important role. Herein, the effect of lipid composition on the 
formation of fibrils has been investigated for AVP-9 and OT-9, which exhibit a high degree of 
structural resemblance (319). These peptides are “cyclic” with Cys residue at positions 1 and 
6, linked by a disulphide bond and tripeptide tail (21, 319). They are similar to SST-14 in their 
cyclic structure but differ in their disulphide link (Cys1-Cys6 for OT and AVP; Cys3-Cys14 for 
SST) and the fact that they consist of a smaller number of amino acids overall. The peptide 
cyclicity may play an important role in the interaction of these peptides with the lipid 
membrane and their subsequent aggregation. Saturated lipids with chain length from C12 to 
C18 were investigated, as well as the singly unsaturated C18 lipid DOPC. The effect of 
cholesterol and the anionic lipids DMPS and DOPS were also investigated. Results were 
reasoned in terms of the structure of the peptide, as well as the effect of membrane parameters 
including membrane surface charge and fluidity, hydrocarbon chain packing, and lipid 
solubility on the fibrillisation of functional amyloid-forming peptides.  
While the effect of lipid membranes on fibrillisation has not been characterised for these 
peptides, studies carried out by Sikorska et al. and co-workers have confirmed that 
neurohypophysial hormone-like peptides, do interact with lipid membranes. Electrostatic and 
hydrophobic interactions between AVP/OT and anionic liposomes composed of a 
DPPC:DPPG mixture were found to determine the overall conformation of the peptide (313). 
Both AVP and OT showed no change in conformation in water however, in a liposome 
(DPPC:DPPG) an increase in β-sheets and reduction in disordered, random coil structure was 
reported (313).  
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4.2 Materials and Methods 
4.2.1 Liposome preparation 
The preparation and analysis are described in Chapter 2, section 2.2.1. 
4.2.2 Preparation of Functional amyloid-forming peptides (FAFP’s) 
150 mM NaCl was added to a weighed fraction of OT and AVP. The solution was vortexed for 
a few seconds for smaller aliquots or a minute for bigger aliquots to produce solutions having 
a final concentration ranging from 0.01% w/w to 5% w/w. 
4.2.3 Thioflavin T (ThT) Binding Assay  
The concentration of AVP and OT in the buffer is described in 4.2.2, and in liposomes, 0.5% 
w/w OT and 5% w/w AVP was used (preparation and analysis described in Chapter 2, section 
2.2.1). ThT assay protocol is described in Chapter 2, section 2.2.2. 
4.2.4 Atomic Force Microscopy (AFM)  
0.5 % (w/w) solution of OT fibrils or fibrils + liposomes (OT + DMPC) and 5 % (w/w) solution 
of AVP fibrils or fibrils + liposomes (AVP + DMPC+DMPS) at ratio (1:97). Imaging protocol 
is described in Chapter 2, section 2.2.4 and statistical analysis not possible with a low number 
of fibril (<500). 
4.2.5 Circular Dichroism (CD) 
A weighed fraction of 0.1% w/w or 1 mg mL-1 AVP or OT was dissolved in buffer (MilliQ 
water). An equimolar (1:1) mixture of both peptides at similar concentration was also studied. 
The peptides were co-incubated in liposomes (DOPC, DOPC/Chol, DOPC/DOPS, DLPC, 
DMPC, DPPC and DSPC) at an appropriate ratio (1:97) with a slight change to the re-hydration 
buffer and are described in Chapter 2, section 2.2.1. The protocol for CD measurements and 
spectra analysis are described in Chapter 2, section 2.2.5.  
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4.3 Results 
4.3.1 Effect of the lipid bilayer on the secondary structure of cyclic 
neurohypophysial hormones  
The secondary structure of the cyclic nonapeptides OT-9 and AVP-9 at 1 mg mL-1 (0.1% w/w) 
was determined using a benchtop CD in the presence and absence of liposomes. An equimolar 
(1:1) mixture of both peptides was also studied, as they are known to both originate from the 
same secretory granules. Spectra for all three samples in the absence of liposomes are presented 
in Figure 4.2. The spectra for both AVP and OT are characterised by a large negative band at 
195nm and 198nm, respectively, consistent with a disordered, random coil structure in 
agreement with a recent study on these peptides in water (313).    
The CD spectrum of an equimolar ratio of AVP and OT (1:1) is also dominated by a negative 
band around 195 nm, consistent with a disordered structure, indicating that the conformation 
of the peptides does not change significantly on mixing. The estimation of secondary structure 
for these peptides is complicated due to limitation of the UV range not accessible in most 
bench-top CD compared to synchrotron CD (chapter 3). Therefore, dichroweb analysis had 
resulted in large errors in data-fitting (NRMSD > 0.250). 
 
 
Figure 4.2. Secondary structures of OT-9, AVP-9 and AVP:OT (1:1) at 1 mg mL-1 analysed 
using Circular Dichroism (CD)  
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The CD spectra of OT following incubation with liposomes based on saturated chain lipids are 
presented in Figure 4.3 after 3 hours incubation (Figure 4.3a) and 72 hours incubation (Figure 
4.3b). No significant changes to the CD spectrum observed for OT-9 in water were observed 
following incubation of up to 72 hours with liposomes indicating either that the peptide has 
limited interaction with the lipid bilayer, or that this interaction does not result in a 
conformational change of the peptide.  
The CD spectra of OT following incubation with DOPC-based liposomes of various 
compositions are presented in Figure 4.3 after 3 hours incubation (Figure 4.3c) and 72 hours 
incubation (Figure 4.3d). Changes to the CD-spectra were observed for the majority of samples 
consistent with changes to the secondary structure following incubation with the lipid 
membrane. Following 3 hours incubation with DOPC, and mixtures of DOPC with Chol or 
DOPS, the minimum at 198 nm becomes less intense and moves to a higher wavelength (~200 
- 204nm), consistent with an increase in β-sheets and an associated reduction in the proportion 
of the structure that is the random coil. The effect is dependent on the lipid composition and is 
more pronounced for the lipid bilayer doped with the anionic lipid DOPS, presumably due to 
an electrostatic interaction with the positively charged OT peptide. For charged liposomes, 
these effects appear to become more pronounced with time (Figure 4.3d).  A similar effect was 
noted for the addition of OT to charged DPPC-DPPG liposomes and was also correlated with 
an increase in β-sheets at the expense of random coil structure (313).   
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Figure 4.3. (a) CD spectra for 1 mg mL-1 (0.01% w/w) OT-9 co-incubated with saturated lipid 
vesicles after 3 hours, (b) after 72 hours, (c) CD spectra for 1 mg mL-1 OT-9 co-incubated with 
vesicles doped with various lipid compositions after 3 hours and (d) after 72 hours   
Similar to results obtained with OT-9, co-incubation of AVP-9 with saturated chain lipids did 
not result in any significant changes to the CD spectra even at 72-hour period, again suggesting 
no conformational changes to the peptide after interaction with the saturated chain membrane 
(Figure 4.4a-b). 
Upon three hours incubation of AVP-9 with DOPC-based liposomes of various compositions, 
a slight shift in the CD-spectrum was observed for all samples, (Figure 4.4c). The minimum at 
198 nm becomes more intense and moves towards higher wavelength (~200nm). A second 
minimum at 205 -210 nm was observed, particularly for DOPC-Chol and DOPC-DOPS 
samples, which is consistent with an increase in β-sheets and the associated reduction in the 
proportion of structure that is a random coil as previously observed for AVP upon interaction 
with charged liposomes (313). This observation is in agreement with the known effect of 
cholesterol and charge on some toxic amyloid-forming peptides; both have been shown to 
a) b) 
c) d) 
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induce conformational changes, e.g. in α-synuclein (284, 320). Although the effect becomes 
slightly more noticeable with time, particularly for cholesterol doped liposomes, (Figure 4.4d), 
in general, the conformation of AVP is not significantly affected by interaction with uncharged 
liposomes. A similar effect was noted by Sikorska et al. (313), who found that the conformation 
of AVP did not change following interaction with liposomes. An NMR study by this group 
suggested that the positively charged Arg residue at position 8 of the AVP peptide promotes 
the same extended conformation of the C-terminus regardless of whether the peptide is in 
solution or in SDS micelles (321). A similar effect has been reported upon transfer of AVP to 
hexafluoroacetone (structure-stabilising co-solvent) (322, 323). 
 
Figure 4.4. (a) CD spectra for 1 mg mL-1 (0.01% w/w) AVP-9 co-incubated in saturated lipid 
vesicles after 3 hours, (b) after 72 hours, (c) CD spectra for 1 mg mL-1 AVP-9 co-incubated in 
vesicles doped with various lipid compositions after 3 hours and (d) after 72 hours 
 
a) b) 
c) d) 
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Since AVP and OT are found in the same secretory granules, the peptide conformation for the 
equimolar mixture was investigated in lipid vesicles (99). Upon incubation, we note no change 
in conformation for (AVP:OT) in saturated lipid vesicles, (Figure 4.5a or b), or unsaturated 
DOPC liposomes of various compositions, (Figure 4.5c or d) up to 72 hrs incubation.   
  
Figure 4.5. (a) CD spectra for 1 mg mL-1 (0.01% w/w) AVP:OT (1:1) co-incubated in saturated 
lipid vesicles after 3 hours, (b) after 72 hours, (c) CD spectra for 1 mg mL-1 AVP:OT (1:1) co-
incubated in vesicles doped with various lipid compositions after 3 hours, (b) after 72 hours 
4.3.2 Effect of the lipid bilayer on the kinetics of fibril growth of OT-9 
The kinetics of aggregation was characterised using a ThT fluorescence assay for OT and AVP 
in the presence and absence of liposomes of various compositions. The increase in ThT relative 
fluorescence with time is plotted in Figure 4.6 for OT-9 dissolved in 150 mM NaCl at various 
concentrations. No lag phase was observed however, a strong growth phase was observed from 
t=0. This growth phase can be used to calculate the rate constant for aggregation (kagg) by fitting 
a mono-exponential decay to the data (98). 
a) b) 
c) d) 
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In the absence of the lipid bilayer, ThT binding was detected for OT-9 at all concentrations 
studied (0.1 – 5% w/w) (Figure 4.6a), suggesting that OT-9 readily aggregates into -sheet rich 
structures. This is interesting when compared to SST-14 (Chapter 3), where aggregates were 
only observed above a critical concentration of 2.5% (w/w). A decrease in half-time and 
increase in kagg with increasing concentration was observed (Table 4.1), although a lag phase 
was not observed at any concentration.  
The evolution of ThT relative fluorescence with time for OT-9 0.5% (w/w) incubated with 
liposomes of various lipid compositions, including saturated chain lipids of various lengths 
(DLPC (C12); DMPC (C14); DPPC (C16) and DSPC (C18)) and the unsaturated lipid DOPC 
(C18:1) is presented in Figure 4.6b. Co-incubation of OT-9 with liposomes formed from 
saturated chain lipids resulted in a significant increase in the intensity of the fluorescence 
plateau phase, relative to aggregation in buffer (Figure 4.6b), indicating an increase in the 
amount of beta-sheet rich assemblies formed. The final fluorescence intensity of plateau was 
significantly higher in the presence of longer chain lipids (DPPC/ DSPC) compared to shorter 
chain lipids (DLPC/DMPC) suggesting that gel-phase (DPPC/DSPC) promotes aggregation of 
this peptide more than fluid-phase (DLPC/DMPC) bilayers. This observation contrasts with 
that seen for SST-14, where aggregation was increased in the presence of shorter-chain lipids.   
In contrast, the presence of liposomes formed from the unsaturated DOPC did not have a 
significant effect on aggregation.  The final fluorescence intensity was similar to that observed 
in the buffer, although the kagg value for the growth phase had increased (Table 4.2) and was 
similar to that seen for some saturated chain liposomes (Figure 4.6c).  
The effect of cholesterol (doped at 30mol% within DOPC and DMPC bilayers) was also 
investigated. Addition of cholesterol did not significantly affect the kagg values (Table 4.2), 
although a slight increase in fluorescence intensity was observed in the presence of cholesterol 
in both cases (Figure 4.6c). Addition of cholesterol was observed to have a similar effect on 
fibrillisation of SST-14. 
As for SST-14, the addition of lipids having a charged PS headgroup to the bilayer had the 
greatest effect on aggregation. The intensity of the fluorescence plateau was highest in the 
presence of charged liposomes, indicating that the vesicles containing lipids with a charged 
headgroup promoted the formation of −sheet containing assemblies to a greater extent than 
another lipid compositions tested. Interestingly, the fluorescence intensity (Figure 4.6d) are 
similar for charged liposomes formed from either DOPC or DMPC suggesting that the effect 
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of charge is dominant, and counteracts the observed effect of unsaturated liposomes to either 
slow down or have no effect on fibril growth. This observation is consistent with our results 
for SST-14 in Chapter 3, as well as the known effect of charge on the fibrillisation of toxic 
amyloids (5) and the recently studied functional amyloid TasA (8).  
 
 
Figure 4.6. (a) Thioflavin T (ThT) assay for OT-9 in buffer over a 1-week period, (b) ThT assay 
for OT-9 at 0.5% (w/w) co-incubated with unsaturated (DOPC) and saturated (DLPC, DMPC, 
DPPC and DSPC) vesicles with increase in chain length, (c) ThT assay for OT-9 at 0.5% (w/w) 
co-incubated with unsaturated and saturated vesicle doped with cholesterol and (d) ThT assay 
for OT-9 at 0.5% (w/w) co-incubated with unsaturated and saturated vesicle doped with 
charged lipids (DMPS/DOPS)  
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Table 4.1. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for OT-9 in the buffer over 1 week 
OT % 
(w/w) 
Lag Phase 
(hours) 
t50 or (t1/2)2 
(hours) 
kagg (s-1)
 1 Final fluorescence 
intensity of plateau 
phase (x106) 
0.1 0 5.4 0.11 6.9 
0.5 0 5.0 0.14 12.7 
5 0 0.5 0.69 20.1 
One-phase association1 and half-time2 
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Table 4.2. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for OT-9 at 0.5% (w/w) in buffer and vesicles doped with various 
lipid compositions over 1 week 
Conditions Lag phase 
(hours) 
t50 or (t1/2)2 
(hours) 
kagg (s-1) 1 Final fluorescence 
intensity of plateau 
phase (x106) 
NaCl 0 0.5 0.1401 12.7 
 Unsaturated 
DOPC 0 0.9 0.2831 14.3 
 
 Effect of chain length or bilayer thickness 
DLPC 0 0.5 0.3471 21.3 
 
DMPC 0 0.5 0.3741 21.4 
 
DPPC 0 0.5 0.3321 27.0 
 
DSPC 0 1.0 0.3761 26.3 
 
 Effect of Cholesterol 
70DOPC+30CHOL 0 0.2 0.2491 16.1 
 
70DMPC+30CHOL 0 0.5 0.2181 24.6 
 Effect of Charge 
65DOPC+35DOPS 0 0.5 0.2581 24.6 
 
65DMPC+35DMPS 0 0.5 0.3591 23.7 
 
One-phase association1 and half-time2 (324) 
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4.3.3 Effect of the lipid bilayer on the kinetics of fibril growth for AVP 
A similar study was carried out on AVP-9, which differs from OT-9 only in the amino acids at 
positions 3 and 8 (Figure 4.1). 
Table 4.3. Shows the position, polarity, charge and hydrophobic amino acid residues for OT 
and AVP 
 OT-9 AVP-9 
Position 3 8 3 8 
Amino acid residue Phe Arg Ile Leu 
Polarity Non-polar Polar Non-polar Non-polar 
Charge Neutral +ve Neutral Neutral 
Hydrophobic side-
chain 
Yes No Yes Yes 
 
For AVP-9 in solution, overall low fluorescence intensity was observed over 1 week, (Figure 
4.7a), even at the highest concentration of 5% (w/w) suggesting that no appreciable aggregation 
occurred over this time period.  
Following incubation of AVP-9 with liposomes formed from saturated chain lipids, no 
significant changes in fluorescence intensity were observed (Figure 4.7b). A small increase in 
fluorescence intensity was observed for the longest chain lipids (DPPC and DSPC) suggesting 
that a small number of −sheet containing assemblies may have formed for these samples.  A 
similar effect was noted for liposomes formed from the unsaturated lipid DOPC, and mixtures 
of DOPC and Chol (Figure 4.7c).   
However, upon addition of 35 mol% of the charged lipid DMPS to DMPC liposomes, an 
appreciable increase in fluorescence was noted over approximately 1 week indicating that the 
presence of the charged liposome has accelerated aggregation for this peptide (Figure 4.7d).  
Interestingly, a similar effect was not observed for charged liposomes formed from a mixture 
of DOPC and DOPS. We note that the intensity of the fluorescence plateau and kagg values 
(Table 4.3) are significantly lower compared to those for OT-9 (Table 4.2).    
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Figure 4.7. (a) ThT assay for AVP-9 in buffer over a 1-week period, (b) ThT assay for AVP-9 
at 5% (w/w) co-incubated with unsaturated and saturated vesicle with an increase in chain 
length, (c) ThT assay for AVP-9 at 5% (w/w) co-incubated with unsaturated and saturated 
vesicle doped with cholesterol and (d) ThT assay for AVP-9 at 5% (w/w) co-incubated with 
unsaturated and saturated vesicle doped with charge 
We further investigated the effect of bilayer charge by varying the percentage of the charged 
lipid DMPS from 5 to 35 mol% in the DMPC bilayer. A characteristic growth curve consistent 
with amyloid fibril formation was observed at all levels of charge (Figure 4.8). A consistent 
increase in final fluorescence intensity of the plateau phase with increasing % of DMPS was 
observed, suggesting that more fibrils are formed as the bilayer charge increases. In addition, 
kagg values increase slightly 0.020 s
-1 (5 mol% DOPS) to 0.032 s-1 (35 mol% DOPS) (Table 
4.4).  
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Figure 4.8. ThT assay for AVP-9 at 5% (w/w) co-incubated with saturated vesicle doped with 
an increase in the concentration of the charged lipid DMPS (5 – 35 mol%) 
Table 4.4. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for AVP-9 at 5% (w/w) in DMPC vesicles doped with DMPS at (5-
35 mol%) 
Conditions Lag Phase 
(hours) 
t50 or (t1/2)2 
(hours) 
kagg (s-1)1 Final fluorescence 
intensity of plateau 
phase (x106) 
DMPC 0 0 0 0.007 
95DMPC+5DMPS 0 36.5 0.0200 0.047 
85DMPC+15DMPS 0 26.8 0.0222 0.066 
75DMPC+25DMPS 0 14.8 0.0281 0.12 
65DMPC+35DMPS 0 3.76 0.0325 0.16 
One-phase association1 and half-time2 
4.3.4 AFM a surface technique used to study aggregate deposited from solution 
both in the absence and presence of liposomes 
AFM analysis was carried out on OT fibrils formed in the presence or absence of DMPC lipid 
vesicles. For OT fibrils formed in the buffer, a small number of short fibrils were observed via 
AFM (Figure 4.9). Such fibrils contrast with those formed by SST in the buffer, which is much 
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longer and more numerous and display the typical amyloid-like unbranched twisted fibrillar 
structures.  
Upon co-incubating OT with DMPC vesicles, large amorphous aggregates are detected (Figure 
4.10), which we believe are due to co-assemblies of lipids and a non-fibrillar beta sheet 
containing OT assemblies that form planer films upon adsorbing to the positively charged mica 
substrate. No fibrils could be detected at this concentration (0.5% w/w).   
 
Figure 4.9. Topographic images of (a) short OT fibrils at 0.5% (w/w) in aqueous solution and 
(b) image of a single OT fibril  
 
Figure 4.10. Topographic image showing no OT fibrils detected with DMPC 
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No fibrils were detected in the AFM analysis on AVP in buffer (Figure 4.11a) in agreement 
with the ThT assay results. As for the OT samples, large planar films were also detected for 
AVP co-incubated with charged DMPC+DMPS vesicles (Figure 4.11b). Like in the case of OT 
we suggest these films are due to co-assemblies of non-fibrillar aggregates of AVP and anionic 
lipid vesicles which have been converted to planar films due to strong electrostatic interactions 
with the cationic mica substrate.     
 
Figure 4.11. Topographic images of (a) 5 % (w/w) AVP in aqueous solution and (b) AVP 
incubated with DMPC+DMPS vesicles  
4.4 Discussion 
In this chapter the effect of lipid membranes on the aggregation of two cyclic peptides, OT-9 
and AVP-9 was investigated. Despite differing only in the amino acids at position 3 and 8 
(Table 4.3), aggregation of these peptides was markedly different. ThT assay results suggest 
that OT aggregates readily at all concentrations studied, with fast aggregation rates and no lag 
period observed. In contrast, no appreciable increase in fluorescence intensity was observed 
for AVP, except in the presence of highly anionic liposomes.   
The significant increase in propensity for aggregation for OT relative to AVP may reflect the 
phenylalanine (Phe) amino acid at position 3, compared to Isoleucine (Ile) for AVP.  Previous 
studies have shown that the substitution of a single amino acid can have a significant effect on 
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the aggregation propensity of a peptide. Chiti et al. have demonstrated that aggregation rates 
can span a range of up to 1000 following an amino acid mutation, with aggregation rates up to 
30 times faster and 15 times slower than the wild-type peptide observed (325). The effects of 
a specific mutation were shown to correlate strongly with the hydrophobicity and charge of the 
peptide, as well as the resultant secondary structure (325). Here, the substitution of the Phe 
residue can promote π – π stacking interactions, and leads to increased hydrophobicity of the 
peptide, driving aggregation. Furthermore, Phe is known to be critical amyloid forming amino-
acid, and the short Phe-Phe sequence is known to be the minimal amyloid-forming peptide 
sequence within Aβ (326).  
AFM data indicate that neither of these peptides forms the typical amyloid-like twisted fibrillar 
structures, with only a few short fibril-like structures observed for OT, and no aggregates 
observed for AVP.  This is consistent with a study by Beuret and co-workers, who were unable 
to stain pro-AVP-9 aggregates in the secretory granules of the endoplasmic reticulum (ER) 
(327).  It is possible that the AFM washing steps used, typical for the formation of large fibrils, 
may have washed off the smaller AVP fibrillar aggregates. Further AFM studies are therefore 
required to confirm the morphology of the beta-sheet rich aggregates observed in the ThT 
assays. In contrast, numerous fibrils were observed via AFM for SST, and these had the 
characteristic amyloid-like unbranched twisted fibrillar structures. Both the fluorescence 
plateau value and the rate constant for aggregation were significantly higher for OT than for 
SST at the same concentration (5% w/w).  In addition, no lag period was observed for OT is 
probably indicative of a lack of nucleation phase (transition from monomers to oligomers), 
while a lag period of approximately 12 hours was observed for SST. Typically, amyloid kinetic 
growth curves possess a lag phase whereby the concentration of non-fibrillar, but insoluble, 
oligomers are increasing to a sufficient level where it can seed the exponential growth of 
fibrillar structures (328). The lack of observable lag phase, high ThT plateau, and absence of 
fibrils observed in the AFM images suggests a rapid formation of many beta-sheet containing 
aggregates of OT that are not capable of seeding the exponential growth of fibrillar structures. 
This is presumably due to increased solubility of these OT aggregates. Such aggregates have 
previously been hypothesised as an off-pathway product of the amyloid fibril mechanism (329, 
330).   
The lack of OT fibrils seen here by AFM, despite the relatively high intensity of the ThT assay 
fluorescence plateau, suggests that the dominant OT aggregates formed, are non-fibrillar beta-
sheet containing assemblies (ThT is sensitive to all β-sheet containing assemblies, not just 
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fibrillar structures). Despite the absence of fibrils, the effect of the lipid bilayer on the rate and 
extent of aggregation for OT was qualitatively similar to that observed for SST in the previous 
chapter. Bilayers formed from saturated chain lipids appeared to promote aggregation for OT, 
with an increase in the rate constant for aggregation and the intensity of the ThT fluorescence 
plateau for saturated chains from C12 to C18. This is qualitatively similar to the behaviour of 
SST in the presence of liposomes. However, for SST, the short-chain lipids DLPC and DMPC 
had the greatest effect on fibril growth, while for OT, the longer-chain lipids DPPC and DSPC 
promote aggregation more. While saturated chain lipids did not significantly enhance 
aggregation of AVP, we do, however, note that the longer-chain lipids also appeared to have 
the most promoting effect on aggregation for AVP. A previous study on Aβ (1-42) has also 
suggested that this peptide interacts more with gel-like bilayers (including DPPC), thereby 
enhancing aggregation (331). This may suggest that the mechanism of aggregation may differ 
depending on whether fibrils or amorphous aggregates are formed. The increase in aggregation 
for AVP and OT appears to be driven by a general increase in the interaction of the peptide and 
the bilayer. In contrast, the typical amyloid-fibril formation mechanism observed for SST may 
involve a reciprocal transfer of lipids from the membrane to the growing amyloid (37).   
For OT and AVP, bilayers formed from the unsaturated chain lipid DOPC did not promote 
aggregation. A similar effect was observed for SST and appeared to be strongly correlated with 
the depth of penetration of the peptide into the bilayer, as determined via intrinsic tryptophan 
fluorescence from the Trp residue in SST. While a similar analysis was not possible for OT or 
AVP due to the absence of the Trp amino acid in both peptides, it is likely that a similar effect 
occurs for these peptides. In general, insertion of a peptide having some hydrophobic character 
into a lipid bilayer can be modified by the lateral pressure profile in the bilayer. Highly 
branched, or saturated hydrocarbon chains, are associated with higher lateral pressure in the 
bilayer which can prevent insertion of the hydrophobic segment of the peptide into the bilayer 
(332). The reduced lateral pressure associated with the DOPC bilayer can result in deeper 
penetration of the peptide, and this was confirmed for SST. This indicated that aggregation is 
promoted by a more peripheral association of the peptide with the lipid membrane. This 
association does not seem to promote a significant conformational change in either OT or AVP. 
This is in contrast to a previous study on interactions between OT and AVP, and their receptors, 
which suggested that the peptide only adopts the bioactive conformation required for receptor 
docking following association with the membrane (313). There is no evidence. Therefore, that 
membrane-associated conformational change drives fibril growth. Rather, the data seem to 
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point towards the “molecular crowding” mechanism where a high local concentration of 
peptides at the membrane surface may be driving the increase in the rate of aggregation.   
For all three cyclic peptides studied to date, the addition of anionic lipids to the bilayer drives 
the greatest increase in rate consistent with a strong electrostatic interaction between the 
cationic peptide and the anionic bilayer. A similar observation is seen with AVP and the 
charged bilayer DPPC:DPPG (309, 313). The secondary structure of OT-9 also modified in the 
presence of DOPC/DOPS liposomes, with a transition from random coil towards β-sheets 
observed. Some studies suggest that this reflects the tyrosine (Tyr) side chain being more 
exposed to the outside environment (313, 333).  
In summary, significant differences were noted in the aggregation of all three cyclic peptides 
investigated in Chapters 3 and 4, despite two of these peptides having a similar amino acid 
sequence, structure and location within the secretory granules. Previous studies have shown 
that transplanting a small sequence stretch of six amino acids into a non-amyloid forming 
protein, can result in a protein which is capable of forming amyloid fibrils (334). Herein, a 
variation of a single amino acid has been shown to have a marked influence on the ability of a 
peptide to form amyloid fibrils or other assemblies. This is consistent with single homomutants 
of the amyloid-forming protein α-synuclein being responsible for significant changes in 
aggregation, toxicity and mortality in familial cases of Parkinson’s disease (335, 336). This 
change does not seem to be influenced by interactions with the lipid membrane, which are 
similar for both peptides. We suggest that the role of the membrane may be to speed up the rate 
of aggregation by bringing the peptides into contact on the lipid membrane surface. However, 
intrinsic peptide-peptide interactions still appear to fundamentally drive aggregation or 
otherwise.    
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CHAPTER 5 
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5. Effect of lipid composition on fibrillisation in linear functional amyloid-
forming peptides, Substance P-11 (SP-11) and Deslorelin-10 (Des-10) 
5.1 Introduction 
In the previous two Chapters, I have shown that interaction with the lipid bilayer drives 
fundamental changes in the kinetics of amyloid formation and the aggregate morphology for 
three functional amyloid-forming peptides, somatostatin, oxytocin and vasopressin. All of 
these peptides have a cyclic structure, which has been shown to stabilize certain peptides (337, 
338). In contrast, linear peptides have been reported in some cases to adopt a more flexible 
conformation (339). While the driving force for self-assembly of linear and cyclic peptides are 
mainly hydrophobic and π-π stacking interactions between tryptophan residues (339, 340). 
Fundamental differences in linear and cyclic peptides may affect their aggregation and 
fibrillisation.  For example, a TEM study by Choi et al. and co-workers demonstrated that linear 
peptides were inclined to aggregate into irregular objects, while cyclic peptides preferred to 
form stable regular spheres (339).  
In this chapter, I have investigated the effect of the lipid bilayer on the fibrillisation of two 
linear peptides, SP-11 (SP), and Des-10 (Des), Figure 5.1. The 11 amino-acid peptide, SP, is a 
linear peptide (341) that belongs to a neuropeptide group called tachykinins, (254, 255) (Figure 
5.1). It has a cationic charge of +3 at neutral pH (256). Its activity spans across the central and 
peripheral nervous system (257); it is involved in different functions including pain 
transmission (254), regulation of blood flow (258) and gastrointestinal motility (259). SP may 
have neuroprotective properties and play a role in inhibiting amyloid formation for the Aβ 
peptide in AD, as well as preventing brain ageing-related memory decline (255, 260-262). 
Reduced levels of SP have been observed in the brain and spinal fluid of Alzheimer’s disease 
(AD) patients (35). Administration of SP was found to reduce the potassium channels 
overexpressed by Aβ in a rat model of AD (35). In addition, Kowall and co-workers reported 
that SP, co-administered with Aβ peptide into the cerebral cortex of rat, prevented amyloid-
induced neuronal loss (342). 
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Figure 5.1. An illustration of the linear structure and amino acid sequence of (a) SP-11 and (b) 
Des-10 (adapted from (22) (23)) 
SP is probably aggregated in vivo within storage granules (343). Aggregation of SP has been 
reported by Choo et al. at concentrations > 10 mg ml-1 (344).  NMR studies also demonstrated 
aggregation of SP at both basic and acidic pH (104). In contrast, Chassaing and co-workers 
found that aggregation only occurred at neutral pH in the presence of NaCl (345). It was 
reported to aggregate into larger fibrils which were detected by electron microscopy (346). 
Recently, a structural study of the SP assembly process (using a combination of SAXS and 
FTIR) by Dharmadana and co-workers (Dharmadana et al., 2019, manuscript in preparation) 
has demonstrated that SP can self-assemble into nanotubes.    
In solution, SP has been reported as being reasonably disordered, (254, 347-349). It has been 
suggested that the presence of two proline (pro) residues at positions 2 and 4 does not allow 
long-range hydrogen bonds, thereby promoting a random-coil conformation for this peptide in 
solution (349). However, a range of secondary structures has been reported for SP, from 
unfolded to aggregates or β-sheets (254). X-ray and neutron diffraction studies have also 
revealed β-sheet structures for aggregated SP (263). CD studies have shown that SP can adopt 
a partial α-helix in the presence of amphipathic mediators with negatively charged head groups; 
no helix has been reported in the presence of positively charged head groups (254, 256, 301). 
The interaction of cationic peptides with membranes or micelles is greatly dependent upon the 
charge distribution along the peptide chain and nature of the headgroup (350). In fact, this has 
been claimed to be an essential prerequisite for the biological activity of SP (351, 352).    
Des-10 (Des) is a decapeptide synthetic analogue of Luteinising hormone-releasing hormone 
(LHRH), which is also a linear peptide (253). Des-10 consists of modified amino acid residues 
at positions 6 (replacing Gly with D-Trp) and at position 10 swapping Gly with ethylamide 
(Figure 5.1). Synthetic Des-10 is 144 times more potent that native LHRH (353), whose short 
half-life (~hours) prevents its use in targeting cancer cells (354, 355). Des-10 is stated to induce 
b) Des-10 
a) SP-11 
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ovulation by targeting the pituitary-gonadal axis, which regulates the follicle stimulating 
hormone (FSH) and luteinising hormone (LH) (264). (264, 265). Des also suppresses 
testosterone which leads to a reduction in sperm count and eventually deteriorating the testes 
(102, 356). 
The secondary structure of Des is reported to be disordered (265), with no evidence of β-sheets 
or aggregates reported to date. While no aggregation has been investigated for Des, Triptorelin, 
which is another LHRH analogue with a highly similar sequence to Des, has been reported to 
form small nanotubes at low pH or large nanotubes at high pH (24).  
The lack of secondary structure in several peptide hormones, including SP-11and Des-10, has 
led to the suggestion that the peptide must undergo some conformational change to allow it to 
be recognised by the receptor; i.e. the conformation of the peptide in solution may not be the 
active conformation in vivo. It has been previously observed that interaction with a lipid bilayer 
may induce a more biologically relevant conformation for SP (357). Some studies have 
indicated that SP aggregates in contact with a lipid bilayer, resulting in a loss of penetrability 
of the lipid vesicles (256, 358). 
In this chapter, I have therefore investigated both the secondary structure and the aggregation 
process for SP and Des, in the presence of lipid membranes (liposomes of various lipid 
compositions). Saturated lipids with chain length C12 to C18, as well as singly unsaturated 
C18 DOPC were investigated. The effect of cholesterol and the anionic lipid DMPS and DOPS 
were also studied. Based on results from Chapters 3 and 4, the following membrane parameters 
were investigated: membrane surface charge, bilayer thickness and fluidity, the degree of 
unsaturation in the bilayer and addition of cholesterol. To the best of our knowledge, 
information is limited on linear peptides aggregating or forming amyloids upon interacting 
with eukaryotic membrane or model systems.  
5.2 Materials and Methods 
5.2.1 Liposome preparation 
Liposomes were prepared as described in Chapter 2, section 2.2.1.  
5.2.2 Preparation of Functional amyloid-forming peptides (FAFP’s) 
150 mM NaCl was added to a weighed fraction of SP and Des. The solution was vortexed for 
a few seconds for smaller aliquots or a minute for bigger aliquots to produce solutions having 
a final concentration ranging from 0.01% w/w to 10% w/w. 
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5.2.3 Thioflavin T (ThT) Binding Assay  
ThT assay was carried out as described in Chapter 2, section 2.2.3. 
5.2.4 Atomic Force Microscopy (AFM)  
10 % (w/w) solution of SP fibrils or fibrils + lipid (SP + DMPC) and 10 % (w/w) solution of 
Des fibrils or fibrils + lipid (Des + DMPC) at ratio (1:97). Imaging was carried out as described 
in Chapter 2, section 2.2.4 and statistical analysis not possible with a low number of fibril 
(<500). 
5.2.5 Circular Dichroism (CD) 
A weighed fraction of 0.03% w/w or 0.3 mg mL-1 Des-10 was dissolved in MilliQ water 
(buffer), and liposomes at ratio (1:97) were prepared as described in Chapter 2, section 2.2.1 
with a slight change to the re-hydration buffer, Milli-Q water was used instead of 150 mM 
NaCl. The measurements and analysis are described in Chapter 2, section 2.2.5.  
5.2.6 Synchrotron Circular Dichroism (SR-CD) (ASTRID II facility in Aarhus 
Denmark) sample measurements and characterisation 
SRCD sample preparation for SP-11 is followed as described in 5.2.5. The measurements and 
analysis are described in Chapter 2, section 2.2.6. 
5.3 Results 
5.3.1 Interaction with the lipid bilayer changes the secondary structure of SP-11 
and Des-10  
Substance P 
The secondary structure of SP-11 at 0.3 mg mL-1 (0.03% w/w) was studied using SRCD in the 
presence and absence of liposomes. The CD spectrum for SP-11 in water (Figure 5.2) contains 
a double minimum at 200 nm and 193 nm, consistent with a secondary structure which is a 
mostly random coil (unfolded), with some beta-sheet structures. This was confirmed by 
dichroweb analysis on this sample which yields 72% random coil and 26% β-sheets and turns 
(Table 5.1), in agreement with previous FTIR and CD studies on SP-11 (254, 359) (360) (290, 
361). (Note that SP concentrations used for FTIR studies are one or two orders of magnitude 
more than those used for CD experiments).  
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Figure 5.2. Secondary structures of SP-11 at 0.3 mg mL-1 (0.03 % w/w) analysed using 
Synchrotron Circular Dichroism (SR-CD), and Des-10 at 0.3 mg mL-1 analysed using Circular 
Dichroism (CD) 
The CD spectra of SP-11 following three hours incubation with liposomes of various 
compositions is shown in Figure 5.3a. Dichroweb analysis, which was only possible for 
selected samples due to large errors in data-fitting (NRMSD > 0.250) is provided in Table 5.1. 
For all uncharged liposomes, a decrease in the intensity of the minimum at 200 nm was 
observed, with a concomitant increase in the small maximum at 193 nm, consistent with an 
increase in β-sheets structures. Dichroweb analysis (Table 5.1) confirmed an increase in the 
percentage of β-sheets and turns, to approximately 50-60%, and a corresponding decrease in 
the percentage of unordered structure from approximately 70% to approximately 30-40%.  No 
major differences were observed between saturated and unsaturated lipids or following the 
addition of cholesterol. The change in secondary structure is most pronounced for the charged 
liposome (DOPC doped with 35 mol% DOPS) (Figure 5.4a).  Dichroweb analysis suggests that 
SP forms a partial alpha-helix following interaction with the anionic bilayer. This is in 
agreement with previous CD studies demonstrating that SP forms a partial helix in the presence 
of negatively charged amphiphiles including SDS micelles (254), and lipids having anionic PG 
or PS headgroups (254, 346), No significant increase in α-helical structure has been reported 
in the presence of positively charged headgroups (343). Similarly, Shang et al. and co-workers 
have also reported this observation of conformational change to α-helix using CD (362). 
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After 72 hours, it is indicative that a slight increase in the positive maximum at approximately 
195 nm is observed for SP incubated with DOPC+DOPS (Figure 5.3b). This can also be 
confirmed from dichroweb analysis, which shows an increase in % α-helical structure (Table 
5.1), suggesting that with time, the α-helix structure is favoured. This observation has 
previously been reported for α-synuclein with SDS (363).  
 
Figure 5.3. (a) SR-CD spectra for SP-11 at 0.3 mg mL-1 (0.03 % w/w) co-incubated in vesicles 
after 3 hours, (b) SR-CD spectra for SP-11 co-incubated in vesicles after 72 hours  
 
 
 
 
 
 
 
 
 
a) b) 
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Table 5.1. Secondary structure of SP-11 in liposomes analysed using Dichroweb with Contin-
LL algorithm method 
 
Deslorelin 
The secondary structure of Des-10 was studied using the bench-top CD in the presence and 
absence of liposomes, Figure 5.4. Due to large errors in data-fitting (NRMSD > 0.250), 
dichroweb analysis was not possible for these samples.  
The CD spectrum for the peptide in its native conformation (Figure 5.2), has a well-defined 
minimum at 218 nm, and a double minimum at ~203 nm and ~198 nm, which could suggest a 
turn or bent-like conformation, along with some random coil. By analogy with Triptorelin, 
which shares the same sequence as Des but with the addition of a glycine amino acid, a globular 
conformation was observed at higher pH values (pH > 7.5), while a more extended β-sheets 
based conformation was observed at pH < 6.5, with a turn. (24)  A similar observation has been 
reported with LHRH (278, 364). Recently, Kapoor et al. and co-workers have reported no 
major broadening of band or shift in the peak for Des using IR, which indicates no significant 
structural perturbation (265).  
 
Samples 
Helix
% 
Sheet
% 
Turns
% 
Unordered
% 
NRMSD Ref Set 
After 3 hours 
Pure SP 3 14 12 72 0.092 7 
DMPC+SP 5 28 25 43 0.202 1 
DOPC+SP 5 37 25 33 0.259 1 
65DOPC:35DOPS+SP 15 16 30 40 0.222 1 
70DOPC:30CHOL+SP 6 38 23 33 0.213 1 
After 72 hours 
Pure SP 4 13 14 70 0.098 7 
DMPC+SP 5 26 25 44 0.185 1 
65DOPC:35DOPS+SP 17 14 29 40 0.231 1 
70DOPC:30CHOL+SP 8 36 22 35 0.188 1 
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Following three hours incubation of Des-10 with liposomes with various compositions, 
changes to the spectra may be observed, (Figure 5.4a). For DOPC liposomes and DOPC/Chol 
liposomes, the double minimum at ~203 nm and ~198 nm is replaced by a single minimum and 
moves to higher wavelengths, which may suggest an increase in β-sheet structures. Changes to 
the DMPC spectrum are more minor, suggesting that this interaction has had less effect on the 
Des conformation. In contrast, the addition of charged liposomes had the biggest effect, 
presumably due to electrostatic interactions with the cationic peptide, although the spectrum is 
complex and difficult to deconvolute.   
 
Figure 5.4. (a) CD spectra for Des-10 at 2 mg mL-1 (0.2% w/w) co-incubated in vesicles after 
3 hours, (b) CD spectra for Des-10 co-incubated in vesicles after 72 hours 
 
 
 
 
a) b) 
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5.3.2 Effect of the lipid bilayer on the kinetics of aggregation for SP-11 and 
Des-10  
The fluorescent dye Thioflavin T (ThT) specifically binds to the β-sheets structures present in 
amyloid fibrils, resulting in an increase in its fluorescence intensity. ThT fluorescence binding 
assays were used to monitor the kinetics of aggregation for SP and Des in solution, and in the 
presence of liposomes. The increase in ThT relative fluorescence with time is plotted in Figure 
5.5a for SP at various concentrations in NaCl solution. No increase in fluorescence was 
detected at any concentration studied, indicating that aggregation into β-sheet rich structures 
was not observed.   
The increase in ThT relative fluorescence for SP (5 mol%) incubated with liposomes of various 
lipid compositions, including saturated chain lipids of various lengths (DLPC (C12); DMPC 
(C14); DPPC (C16) and DSPC (C18)) and the unsaturated lipid DOPC (C18:1) is shown in 
Figure 5.5b. An increase in ThT fluorescence, characteristic of the growth of aggregates rich 
in β-sheets was observed for some samples. An initial lag phase (absent for some samples), 
characterised by a weak increase in ThT fluorescence, was followed by a strong growth phase. 
This growth phase can be used to calculate the rate constant for aggregation (kagg) by fitting a 
mono-exponential function (characteristic of first-order kinetics) to the data, as described in 
(98). Values of kagg, t1/2, lag phase and final fluorescence intensity of plateau phase are provided 
in Table 5.2. Incubation with saturated chain lipids resulted in the formation of aggregates, 
while the unsaturated lipid DOPC did not cause an increase in fluorescence. The intensity of 
the fluorescence plateau was highest for the longer-chain lipids DPPC and DSPC, and lower 
for the shorter-chain lipids, DLPC and DMPC, suggesting that the greatest number of fibrils 
are formed with DPPC and DSPC liposomes. There appeared to be no correlation between 
chain length and the value of kagg or t1/2, similar to the trend observed for SST in chapter 3. 
These results show that the presence of saturated lipids initiates the SP aggregation process.  
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Figure 5.5. ThT assay performed over 1-week period for (a) SP-11 in NaCl, (b) 10% w/w or 5 
mol% SP-11, co-incubated with unsaturated and saturated vesicle with an increase in chain 
length, (c) SP (5 mol%) co-incubated with DMPC, DMPC doped with cholesterol and (d) SP 
(5 mol%) co-incubated with DOPC, DOPC vesicle doped with cholesterol and DOPC doped 
with DOPS  
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Table 5.2. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SP at 10% (w/w) in NaCl and vesicles doped with various lipid 
compositions over 1 week 
Conditions Lag phase 
(hours) 
t50 or (t1/2) 
(hours)3 
kagg (s-1)1or2 Final fluorescence 
intensity of 
plateau phase 
(x106) 
 Buffer 
NaCl No fitting 
 Unsaturated 
DOPC No fitting 
 Effect of chain length or bilayer thickness 
DLPC 0 19 0.0371 0.22 
DMPC 12 66 0.0182 0.15 
DPPC 0 35 0.021 0.58 
DSPC 0 26 0.031 0.55 
 Effect of Cholesterol 
70DOPC+30CHOL 0 31 0.0221 0.37 
70DMPC+30CHOL No fitting  
 Effect of Charge 
65DOPC+35DOPS No fitting 
65DMPC+35DMPS 0 13 0.1571 0.61 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
Addition of cholesterol to the DMPC and DOPC liposomes did not have a consistent effect on 
fibril growth.  A decrease in fluorescence plateau was seen for DMPC/Chol liposomes, relative 
to pure DMPC (Figure 5.5c), while a slight increase was observed for DOPC/Chol liposomes, 
relative to pure DOPC. 
Addition of the anionic lipid DMPS to the DMPC bilayer resulted in the highest fluorescence 
plateau value observed suggesting the greatest number of fibrils were formed with this 
combination (Figure 5.5d). This is also in agreement with the highest kagg (0.157 s
-1) (Table 
5.2). This indicates that electrostatic interactions play a role in the interaction between the 
highly charged SP (+3) and anionic bilayer. However, the characteristic ThT growth curve was 
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not observed at early time-points, with a large decrease in fluorescence intensity observed.  
This seems to be an artefact of the ThT assay for SP, and was observed for samples (e.g., SP 
in solution) even when the sample did not form appreciable aggregates.   
Similarly, a ThT assay was used to detect the formation of β-sheets rich aggregates for Des-10 
in the presence and absence of liposomes, Figure 5.6. The fluorescence intensity remained low 
throughout 1 week for Des-10 in NaCl, suggesting that no aggregation occurred (Figure 5.6a).  
The ThT assay for Des-10 incubated with liposomes of various lipid compositions, including 
saturated chain lipids of various lengths (DLPC (C12); DMPC (C14); DPPC (C16) and DSPC 
(C18) and unsaturated lipid DOPC is shown in (Figure 5.6b). As for SP, an appreciable increase 
in fluorescence was observed for saturated chain lipids, while little to no fluorescence was 
observed in the presence of the unsaturated lipid DOPC. The highest fluorescence of the final 
plateau phase was obtained for Des-10 with the short-chain lipids DLPC and DMPC (Figure 
5.6b). These lipids also had slightly lower (t1/2) or half-time values (20.5 and 23.8 hours),  
although there was no strong correlation between kagg values and chain length (Table 5.3). 
The effect of cholesterol on the DOPC and DMPC lipid bilayers was also investigated. In Des-
10, it can be seen that the final fluorescence intensity of the plateau region is reduced compared 
to pure DMPC (Figure 5.6c). This can be confirmed from the increase in half-time (23.8 to 
30.1 hours) (Table 5.3). This is suggesting that cholesterol has reduced the fibrillisation of Des-
10 compared to pure DMPC. In contrast, the addition of cholesterol to DOPC had little effect 
on the final fluorescence plateau value.   
In contrast to all other peptides studied, the addition of anionic DMPS into DMPC bilayers did 
not increase fibrillisation kinetics (Figure 5.6d). Rather, this lipid appeared to have an 
inhibiting effect. In contrast, an appreciable increase in the final fluorescence intensity of the 
plateau region was observed for unsaturated DOPC doped with DOPS. This also resulted in 
the highest kagg value (0.089 s
-1), compared to other bilayers.   
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Figure 5.6. ThT assay performed over 1-week period for (a) Des-10 in NaCl, (b) 10% w/w or 
5 mol% Des-10, co-incubated with unsaturated and saturated vesicle with an increase in chain 
length, (c) Des (5 mol%) co-incubated with DMPC, DMPC doped with cholesterol and (d) 
Des-10 (5 mol%) co-incubated with DOPC, DOPC vesicle doped with cholesterol and DOPC 
doped with DOPS  
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Table 5.3. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for Des at 10% (w/w) in NaCl and vesicles doped with various lipid 
compositions over a 1-week period 
Conditions Lag phase 
(hours) 
t50 or (t1/2) 
(hours)3 
kagg (s-1)1or2 Final fluorescence 
intensity of plateau 
phase (x106) 
 Buffer 
NaCl No fitting 
 Unsaturated 
DOPC 12 95 0.0032 0.083 
 Effect of chain length or bilayer thickness 
DLPC 0 21 0.0331 0.40 
DMPC 0 24 0.0231 0.34 
DPPC 0 28 0.0251 0.12 
DSPC 0 28 0.0201 0.14 
 Effect of Cholesterol 
70DOPC+30CHOL 0 46 0.0151 0.084 
70DMPC+30CHOL 0 30 0.0291 0.16 
 Effect of Charge 
65DOPC+35DOPS 0 78 0.0891 0.15 
65DMPC+35DMPS Fitting not possible 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
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5.3.3 Clear morphological differences are observed between aggregates formed 
in the buffer and those incubated with liposomes 
Atomic Force Microscopy (AFM) analysis was carried out on SP-11 and Des-10 using 
deposited layers, (Figure 5.7b and 5.9a-b). In solution, needle-like fibrillar structures were 
observed for SP, Figure 5.7a. TEM analysis carried out on similar structures (Durga 
Dharmadna, unpublished PhD thesis, RMIT University) were determined to have a fibrillar 
morphology, with the lateral alignment of fibrils into bundles. SAXS analysis (Durga 
Dharmadna, unpublished PhD thesis, RMIT University) demonstrated that these structures 
have a characteristic nanotube symmetry. In contrast, no aggregate structures were detected for 
SP-11 co-incubated with DMPC vesicles, (Figure 5.7b) consistent with ThT assay, which 
displayed relatively weak fluorescence intensity in the presence of DMPC liposomes. Due to 
the small number of fibrils (<500), fibre app analysis on SP-11 could not be performed.  
 
Figure 5.7. Atomic force microscopy (AFM) analysis of SP fibrils at 10% (w/w) and SP fibrils 
co-incubated with DMPC lipid vesicles, (a-b) topographic images of (a) SP fibrils displaying 
needle-like fibrillar structure and (b) SP co-incubated with DMPC vesicles 
AFM images of Des-10 in solution show numerous multilaminar crystalline structures in the 
absence of DMPC vesicles, (Figure 5.8a). The lack of appreciable fluorescence intensity in the 
ThT assay suggests that these structures have a low binding affinity to ThT dye molecules. 
These multi-laminar structures can be seen clearly with adhesion and deformation channels. 
These nanotubes assemblies are also reported with triptorelin (24) as shown in Figure 5.10a. 
In contrast, in the presence of DMPC vesicles, typical amyloid-like structures with twists can 
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be seen (Figure 5.9a). These twists can be clearly seen in the deformation channel (Figure 
5.9b). As for SP, due to the small number of fibrils (<500), fibre app analysis was not possible. 
 
Figure 5.8. Topographic images of (a) Des fibrils at 10% (w/w) in the absence of DMPC 
vesicles assemblies can be seen better in the adhesion or (b) deformation channels 
 
Figure 5.9. Topographic images of Des fibrils in DMPC displaying a regular looking amyloid 
(a) with periodic twisting structure (b) the twists can be clearly seen in the deformation channel   
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5.4 Discussion 
In contrast, to the earlier cyclic peptides studied, the formation of amyloid fibril structures was 
not detected for either SP or Des-10 in solution. ThT assay results did not detect any 
appreciable increase in fluorescence consistent with the formation of β-sheets rich aggregates, 
and only a few needle-like fibril structures were detected for SP in solution. In contrast, recent 
work on SP in NaCl solution has found that this peptide aggregates into nanotubes, with the 
internal nanotube symmetry, confirmed via SAXS measurements (Durga Dharmadana, 
Unpublished PhD Thesis, RMIT University).   
Addition of liposomes did affect the kinetics of aggregation, with a clear increase in 
fluorescence for some samples. However, these aggregates were not observed in AFM images. 
Addition of saturated liposomes tended to increase the aggregation rate, as has been 
consistently seen for all peptides studied. CD studies suggest that the peptide conformation 
changes less following interaction with the saturated liposome DMPC than with liposomes 
based on the unsaturated DOPC lipid. This may suggest that the aggregation mechanism again 
depends on a more peripheral attachment of the peptide to the membrane surface, with deeper 
penetration and/or conformational change tending to reduce the tendency to aggregate. This 
may also explain why the final fluorescence plateau is highest for the longer-chain lipids DPPC 
and DSPC.  Both of these lipids adopt a gel-like bilayer with close packing of the hydrocarbon 
chains which may prevent the peptide from inserting too deeply into these bilayers.   
The lack of interaction between SP and liposomes based on neutral lipids may reflect the high 
net positive charge of SP (+3), is inducing charge repulsion which can lead to relatively weak 
hydrogen bonds (349). Keire and Fletcher (1996), also found no change in conformation of SP 
following interaction with anionic or zwitterionic micelles (365). It has been suggested that SP 
adopts an extended conformation at the surface of the bilayer, forming hydrogen bonds with 
its neighbours (254) and such observation is also reported with linear AMPs (366).  
AFM results show that Des-10 aggregates into multi-laminar structures in solution, although 
ThT binding to these aggregates was not observed. Previous studies on the analogue of Des-
10, triptorelin is also reported to self-assemble into nanotubes (24). For triptorelin, at pH values 
<8, bundles of these nanotubes were observed to laterally associate into fibres (24). The 
formation of the nanotubes was shown to be highly pH dependent and related to the protonation 
state of the Histidine residue (pKa = 6.1)  of Triptorelin (24). At high ph values (>8) Triptorelin 
was found to adopt a globular conformation partially stabilised by an H-bond between the 
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histidine and serine residues, as well as aromatic packing between the histidine residues. At 
lower pH (<6.5) the histidine residue becomes protonated disrupting these interactions, and 
promoting the formation of β-sheets, within nanotube bundles. For Des-10, which also contains 
His and Ser residues in close proximity, similar differences between aggregates may be 
observed depending on pH. While this was not explicitly investigated during the thesis, at pH 
values close to neutral, the His residue should be protonated and promote the formation of 
nanotubes. The aggregates detected for Des-10 via AFM are potentially consistent with bundles 
of nanotubes although there is no definitive evidence for this.    
Interestingly, the addition of liposomes results in a completely different aggregate morphology, 
as determined via AFM.  The twisted aggregates observed are consistent with twisted or helical 
ribbons.  Such structures have been proposed as structural intermediates during the formation 
of nanotubes, Figure 5.10 (25). It is possible that the addition of lipids could be preventing 
lateral association of the protofilaments into nanotubes, resulting in the system remaining in 
the twisted or helical ribbon intermediate stage. This theory is consistent with SST results 
presented in Chapter 3, where lipids were observed to decorate the amyloid fibrils in a pearl 
necklace arrangement.    
 
Figure 5.10. Illustrations of (a) an electron micrograph image of triptorelin in water (24) and 
(b) nanotube self-assembly (25)   
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As for SP, the addition of liposomes had a significant effect on aggregation kinetics, as 
determined by ThT binding assays. In common with SP, the addition of saturated chain lipids 
tended to increase the final fluorescence plateau suggesting a greater volume of aggregates 
were formed. While this effect was consistently seen for 9 duplicate samples it is an anomalous 
result and at present we do not have an explanation. Although, saturated charged surface 
(DMPC/DMPS) did not show any appreciable rise in fluorescence intensity, suggests that the 
interaction is dependent on the headgroup. However, for Des-10, the shorter chain lipids 
(DLPC/DMPC), which adopt a fluid-lamellar phase at room temperature, appear to promote 
more aggregation than the gel-phase longer lipids DPPC and DSPC. This is the opposite effect 
to that observed for SP and suggests that the aggregation mechanism may be distinct for each 
peptide.   
Overall results suggest that while Des-10 and SP do not form typical amyloid-like fibrils, they 
may form structures consistent with nanotubes observed to self-assemble in analogies of these 
peptides. Although a typical amyloid formation is not observed, interaction with lipid 
membranes appears to promote or inhibit aggregation in a similar manner to that observed for 
amyloid formation, suggesting that these interactions may be independent of the exact 
mechanistic pathway. 
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CHAPTER 6 
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6. Effects of Stilbenes on functional amyloid-forming peptide Somatostatin-14 
(SST-14) 
6.1 Introduction 
Resveratrol (RSV), which is a stilbene and a natural polyphenol (Figure 6.1a) that is found in 
red wine and several plant species (28, 367), has received significant interest due to its immense 
pharmacological activities including antineuroinflammatory against neurodegenerative and 
cardiovascular diseases (139, 249, 368-370).  
However, RSV is poorly soluble in water, demonstrating passive diffusion via plasma 
membranes (371). To overcome this solubility issue, lipid-based carriers like liposomes serve 
as an excellent vehicle for delivering hydrophobic molecules (28, 372). Lipid membranes and 
polyphenols are suggested to interact mainly through hydrogen bonding and hydrophobic or 
electrostatic interactions (373, 374), due to the amphiphilic nature of phospholipids, although 
the hydrophobic interaction is strongest (375-377). A study conducted by Fei et al. 2018, 
showed that RSV increases the surface area per lipid, subsequently decreasing its membrane 
thickness, which is the opposite effect observed with cholesterol (26). Neves et al. 2016, has 
reported broader Bragg peaks and lower D-spacing or lattice parameter for DMPC (1,2-
dimyristoyl-sn-glycero-3-phosphocholine) in the presence of 10 mol% RSV using small-angle 
x-ray scattering (SAXS) and wide-angle x-ray scattering (WAXS) (375). RSV has a high 
affinity for the lipid part of the membrane which is determined by its corresponding partition 
coefficient (LogP) (defined as, the logarithmic ratio of the concentration of solute between two 
solvents in a biphasic system). Partition coefficient values for RSV in a range of lipid bilayers 
have been reported as 2.63 in DMPC (378), 3.07 in DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine) and 3.11 in DSPC (1,2-distearoyl-sn-glycerophosphocholine) vesicles (26, 
379).  
Moreover, lipid biomembranes show mainly two phases, depending on the composition, water 
content and temperature (380). The fluid lamellar phase (Lα) is known to be the most common 
lipid arrangement in cells. However, a more ordered or gel phase (Lβ) can also coexist with a 
fluid phase (381). It is widely accepted that the hydroxyl groups (OH) of RSV is responsible 
for interacting with head groups of phospholipids (26, 382, 383). Selvaraj et al. 2013, showed 
that high doses of RSV localise within the outer leaflet of the bilayer (384), although their 
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precise location and orientation remains a mystery. Molecular docking studies have suggested 
that the ideal orientation of RSV is nearly planar (surface-level) (Figure 6.2) in the bilayer 
(385), but previous studies have shown that it can also be tilted in the bilayer (386) and others 
have claimed that it is located at the phospholipid-water interface (383, 387). Numerous 
literature studies have examined the location of RSV within the model membrane using variety 
of techniques like differential scanning calorimetry (DSC), nuclear magnetic resonance 
spectroscopy (NMR), X-ray, neutron diffraction, electron spin resonance spectroscopy (ESR) 
and molecular dynamic simulations (MDS) (382, 383, 385, 386).  
 
Figure 6.1. Shows the structure of stilbenes (a) RSV (26), (b) TMS (27) and (c) TS (27) 
Addition of RSV can impact the physicochemical properties of the bilayer. For example, on 
DMPC and model membranes consisting of a mixture of phosphatidylcholine (PC), 
sphingomyelin (SM) and Chol (375, 388, 389). Fei et al. 2018, have suggested that increasing 
the concentration of RSV (0 to 33 mol%) reduces the chain melting temperature (Tm) of DPPC 
and DSPC (26). Sarpietro et al. 2007, have also shown similar observation, upon interacting 
RSV with DMPC (387). Moreover, a consistent decrease in Tm is also reported with 
POPC/POPS (1-palmitoyl-2-oleoyl-sn-glycerophosphocholine/phosphoserine) monolayer 
membranes (390).  
 
RSV 
Chol 
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Figure 6.2. Diagram showing RSV location in the bilayer of DPPC/Chol (adapted from (28)) 
RSV has been shown to inhibit amyloid formation, for Islet Amyloid Polypeptide (IAPP) (391) 
and Amyloid-beta (Aβ) aggregation (3, 146, 392, 393). Literature information is scarce to 
confirm whether RSV can protect cells via direct inhibition of the interaction between IAPP 
toxic species (266, 391, 394, 395) and little is known about the mechanism with which RSV 
interacts with amyloids. Though some light is shed with present nuclear magnetic resonance 
(NMR) studies, which has reported that Lysine (Lys) at peptide position 1 and Histidine (His) 
at peptide position 18 of a nonphysiological analogue of IAPP is involved in the binding of 
RSV (396). The resonance recorded from NMR spectra revealed the largest change for His-18 
occurred during titration with RSV. Therefore, it was concluded that His-18 was critical for 
RSV-IAPP interaction. However, Hsien et al. 2015 have reported that phenylalanine (Phe) at 
position 15 also has an important role in the interaction between RSV and IAPP (391). The 
aromatic rings of polyphenols have been reported to be involved in the binding and interaction 
with cationic charged sites in IAPP (391).     
In this chapter, we compare the effect of RSV, with that of two other stilbene derivatives: trans-
3,5,4’-trimethoxy stilbene (TMS) (Figure 6.1b) and trans-stilbene (TS) (Figure 6.1c), which 
differ mainly in their functional groups. The topological polar surface areas and octanol-water 
partition coefficients (obtained using the Molinspiration Cheminformatics (MC) software 
(397)) for all three polyphenols are listed in Table 6.1.  
Table 6.1. Shows the topological polar surface area (tPSA) and partition coefficient (clogP) 
values for stilbenes    
Stilbenes tPSA (A2) clogP 
RSV 60.68 2.99 
TMS 27.70 4.59 
TS 0.00 4.50 
 
TMS has demonstrated to be more potent than RSV, concerning its anticancer and anti-
inflammatory properties in many cell systems (398-401). However, its effect on amyloid 
aggregation has not been investigated.     
The effect of these stilbenes, both in solution and within a lipid bilayer, on the fibrillisation of 
SST-14 has been investigated in this chapter.  SST-14 is a cyclic functional amyloid-forming 
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peptide; its amyloid formation and secondary structure conformation in vesicles have been 
explored in depth in Chapter 3. The use of RSV and two additional stilbene-based analogues 
of RSV allows for the comparison of the effects of different functional groups, and membrane 
interactions, on the effect of stilbenes on amyloid formation.  To our knowledge, this is the first 
study to look at the impact of a series of stilbenes on functional amyloid aggregation. The 
conformation of SST in the presence of the stilbenes both in solution and bilayer-based was 
investigated using circular dichroism (CD). Intrinsic tryptophan fluorescence measurements 
provided information on the local environment of the SST. Thioflavin-T (ThT) assays were 
used to assess the impact of the stilbenes on fibril growth, while AFM images provided 
complementary images on the number of the morphology of formed fibrils deposited on a 
substrate. In this work, saturated chain lipids (DLPC-C12, DMPC-C14, DPPC-C16 and DSPC-
18) and charge (DMPS/DOPS) were mainly used, since we have demonstrated in Chapter 3, 
that saturated chain lipids and the anionic charge are responsible for inducing the highest rate 
of fibril formation in SST-14. 
6.2 Materials and Methods 
6.2.1 Liposome preparation 
The preparation and analysis are described in Chapter 2, section 2.2.1. 
6.2.2 Preparation of stilbenes and liposome doped with stilbenes (RSV, TMS and 
TS)  
The stilbenes were doped in liposomes (DLPC, DMPC, DPPC, DSPC, DMPC/Chol, 
DOPC/DOPS) at a ratio of 18:1, co-dissolved in chloroform/ethanol mixture (2:1, v/v) in glass 
vials. Mol% is defined as, 100 𝑋 
Moles of RSV
moles of RSV + moles of lipid
. The preparation of vesicles doped 
with stilbenes and analysis of size using DLS are described in Chapter 2, section 2.2.1. 
6.2.3 Preparation of Functional amyloid-forming peptides (FAFP’s) 
150 mM NaCl was added to a weighed fraction of SST-14at 5% w/w.  
6.2.4 Thioflavin T (ThT) Binding Assay  
A weighed fraction of stilbenes (RSV, TS and TMS) was prepared in DMSO and added to 
SST-14 at 5% (w/w) at a ratio of 1:33 and stilbenes doped with liposomes is described in 
section 6.2.2. The experimental procedure and analysis are described in Chapter 2, section 
2.2.2.    
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6.2.5 Tryptophan Fluorescence 
The sample preparation is described in Chapter 3, section 3.2.7 with addition and preparation 
of RSV and TMS described in 6.2.4. The ratio (SST-14 + lipid + stilbenes) is at (33:1:18), and 
the protocol is similar to Chapter 3, section 3.2.7 and experimental protocol and analysis are 
described in Chapter 2, section 2.2.3. 
6.2.6 Circular Dichroism (CD) 
A weighed fraction of 0.01% w/w or 0.1 mg mL-1 SST was dissolved in buffer (Milli-Q water) 
and co-incubated in liposomes doped with RSV (33:1:18) (procedure described in 6.2.2 with a 
minor change, Milli-Q water used instead of 150 mM NaCl to rehydrate vesicles). The 
experimental protocol and analysis of CD spectra are described in Chapter 2, section 2.2.5.  
6.2.7 Atomic Force Microscopy (AFM) 
5 % (w/w) solution of SST fibrils were used and sample preparation is described in section 
6.2.4 and SST + lipid + stilbenes (33:1:18) and experimental protocol described in Chapter 2, 
section 2.2.4 and no statistical analysis performed due to low fibril number (<500).  
6.3 Results 
6.3.1 Addition of RSV to liposomes 
DLS data confirm that addition of RSV to liposomes of various lipid compositions has only a 
minor impact on the particle size and distribution, Figure 6.3-6.5 (Table included in appendix 
S8.6 to S8.8).   
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Figure 6.3. Shows the Dynamic light scattering (DLS) curves for pure saturated chain vesicles 
and saturated vesicles doped with 5 mol% RSV (a) DLPC, (b) DMPC, (c) DPPC and (d) DSPC 
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Figure 6.4. DLS curve for pure DMPC+Chol vesicle and vesicle doped with 5 mol% RSV 
Figure 6.5. DLS curve for (a) Pure DOPC+DOPS vesicle and vesicle doped with 5 mol% 
RSV and (b) Pure DMPC+DMPS vesicle and vesicle doped with 5 mol% RSV 
6.3.2 SST-14 interaction with the lipid bilayer doped with RSV  
CD measurements were performed to investigate conformational changes of SST-14 with or 
without RSV in the bilayer. Note that a typical peptide concentration 0.1 mg mL-1 was used in 
these experiments. As amyloid formation only occurs at concentration above 50 mg mL-1 for 
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SST (Chapter 3), SST-14 in water, is mainly in a random coil conformation with some β-sheets 
and turns (Figure 6.6a), which is in agreement with the literature (98, 402).   
Following the addition of RSV in solution (i.e. in the absence of lipids), no significant shift in 
the spectrum relative to pure SST (in water) is observed, suggesting that no major 
conformational change had occurred. However, a reduction in the small shoulder at ~196 nm 
could indicate a minor reduction in β-sheet structure. Addition of saturated chain liposomes 
doped with RSV, (DLPC-C12, DMPC-C14, DPPC-C16 and DSPC-C18), and the presence of 
cholesterol also produced only minor changes to the spectra, (Figure 6.6a and b). The minimum 
at 203nm is observed to move to slightly higher wavelength, consistent with a small increase 
in β-sheet structure. This is in contrast to the behaviour of pure SST, where a more significant 
increase in β-sheets and reduction in random coil structures were observed following 
incubation with saturated chain liposomes. It suggests that the presence of RSV embedded 
within the bilayer may inhibit interaction with SST. 
Incubation with a charged bilayer (both in the presence and absence of RSV) was shown to 
impact the CD spectrum to the highest degree (Figure 6.6c). The minimum at 203nm shifts to 
higher wavelengths (β-sheets), presumably due to electrostatic interaction with the positively 
charged peptide. 
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Figure 6.6. (a) CD spectra for SST-14 0.01% w/w (0.1 mg mL-1) co-incubated in saturated 
vesicles doped with 5 mol% RSV, (b) CD spectra for SST-14 co-incubated in DMPC bilayer 
doped with cholesterol and 5 mol% RSV and (c) CD spectra for SST-14 co-incubated in 
bilayers (DMPC & DOPC) doped with anionic charge (DMPS & DOPS) and 5 mol% RSV 
a) 
b) 
c) 
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Intrinsic fluorescence from the Trp residue in the SST peptide may be used to provide 
additional information on the local environment around the peptide. In Chapter 3, I showed 
that the depth of penetration of the SST into the lipid bilayer depended on the lipid composition.   
Here, the hydrophobicity of the local environment of the tryptophan residue present in SST-14 
was studied in buffer and RSV using intrinsic tryptophan fluorescence assay. A significant red 
shift, i.e. to the higher wavelength (Figure 6.7) was observed for SST co-incubated with RSV 
compared to SST in solution. This suggests that interaction with the RSV has caused the Trp 
residue to be more hydrophilic. This could suggest that, a change in peptide conformation 
however, not observed via CD.    
 
Figure 6.7. SST-14 environment in bilayer and bilayer doped with RSV, measured by 
Tryptophan Fluorescence 
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A corresponding red shift or higher λ max is observed upon addition of SST to bilayers doped 
with RSV (5 mol%) (Figure 6.7). This suggests that the presence of the RSV prevents the SST 
from penetrating into the lipid bilayer, in contrast to the CD results which suggested that the 
interaction was less pronounced. As for SST in liposomes (no RSV), the effect is dependent on 
the lipid composition of the bilayer. However, in the presence of RSV, the deepest penetration 
seems to be into the DPPC and DSPC bilayers. This is again in contrast to bilayers without 
RSV, where charged bilayers tended to result in the deepest penetration of the peptide.    
6.3.3 Effect of RSV on fibrillisation of SST-14  
ThT fluorescence binding assays were used to monitor the kinetics of SST-14amyloid fibril 
formation in the presence of RSV, both in solution and doped within a lipid bilayer.   
A significant reduction in the final fluorescence intensity of the plateau phase was observed 
following addition of RSV in solution (Figure 6.8) suggesting fewer fibrils are formed. This is 
in agreement with literature reports on the effect of RSV on fibrillisation of toxic amyloid 
species like Aβ and IAPP (146, 391). However, a slight decrease in the lag phase and increase 
in kagg was observed (Table 6.2) relative to in buffer, suggesting that the rate of fibril growth 
actually increased in the presence of the RSV.   
The effect of RSV doped within liposomes formed from saturated hydrocarbon chains was also 
investigated Figure 6.9.  In the absence of RSV, these liposomes were shown to have a strong 
promoting effect on fibrillisation of SST in Chapter 3. For liposomes doped with RSV, clear 
differences in behaviour were observed between the short-chain lipids (DLPC, DMPC) which 
from fluid bilayers and the longer-chain lipids (DPPC, DSPC) which form gel-phase bilayers. 
For all saturated chain lengths, the presence of RSV in the bilayer reduced the intensity of the 
final fluorescence plateau relative to the bilayer without RSV, indicating that the RSV is acting 
against the strong promoting effect of the bilayer, and acting to inhibit fibril growth as seen in 
solution.  However, for the longer chain lipids (DPPC and DSPC) RSV-doped bilayers also 
increased the lag time, suggesting that they are inhibiting nucleation.  In contrast, no reduction 
in lag time is seen for the shorter-chain lipids, relative to the bilayer without RSV. This backs 
up the theory presented in Chapter 3 that a different aggregation mechanism may be at play for 
the longer-chain lipids.   
As observed throughout the thesis, the effect of cholesterol doped within the bilayer was not 
significant, Figure 6.10, with similar behaviour to that seen for the pure saturated chain lipids.  
For charged liposomes, a similar effect was also observed, Figure 6.11.  However, while the 
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overall fluorescence plateau was reduced in the presence of RSV, the rate of aggregation 
remains very fast, indicating that the effect of the charged bilayer is dominant in this case. This 
effect may also be due to acid-base interaction between RSV and the negatively charged 
bilayer. 
 
Figure 6.8. Shows the ThT assay curves for 5% (w/w) SST-14 incubated in buffer (NaCl) vs 
stilbenes co-dissolved using DMSO 
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Figure 6.9. Shows the ThT assay curves for 5% (w/w) SST-14 co-incubated in saturated chain 
lipids doped with 5 mol% RSV (a) DLPC, (b) DMPC, (c) DPPC vesicles and (d) DSPC   
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Table 6.2. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) co-incubated in the buffer, RSV, saturated chain 
lipids and saturated chain lipids doped with 5 mol% RSV 
Conditions Lag 
phase 
(hours) 
t50 or (t1/2) 
(hours)3 
kagg (s-1)1or2 Final fluorescence 
intensity of plateau 
phase (x106) 
 Buffer 
SST 12 51 0.01862 2.7 
SST+RSV 0 12 0.04021 1.3 
 Effect of chain length or bilayer thickness 
SST+DLPC 0 6.3 0.05891 3.8 
SST+DLPC+RSV 5 mol% 0 1.9 0.2231 2.2 
SST+DMPC 0 13 0.03801 6.2 
SST+DMPC+RSV 5 mol% 0 2.4 0.1351 2.2 
SST+DPPC 24 41 0.06312 4.9 
SST+DPPC+RSV 5 mol% 24 15 0.0212 1.9 
SST+DSPC 12 28 0.05112 4.8 
SST+DSPC+RSV 5 mol% 24 36 0.04252 2.0 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
 
Figure 6.10. Shows the ThT assay curves for 5% (w/w) SST-14 co-incubated in the buffer and 
DMPC/Chol vesicles doped with 5 mol% RSV 
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Table 6.3. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) co-incubated in the buffer and DMPC/Chol 
vesicles doped with 5 mol% RSV 
Conditions Lag phase 
(hours) 
(t1/2) or t50 
(hours)3 
kagg (s-1) 1or2 Final 
fluorescence 
intensity of 
plateau 
phase (x106) 
SST 12 51 0.01862 2.7 
SST+RSV 0 12 0.04021 1.3 
SST+DMPC+CHOL 0 23 0.03021 11.0 
SST+DMPC+CHOL+RSV 5 mol% 0 14 0.02011 5.2 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
 
 
Figure 6.11. Illustrations of: (a) ThT assay curves for 5% (w/w) SST-14 co-incubated in buffer 
and DOPC/DOPS vesicles doped with 5 mol% RSV (b) ThT assay curves for 5% (w/w) SST-
14 co-incubated in buffer and DMPC/DMPS vesicles doped with 5 mol% RSV 
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Table 6.4. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) co-incubated in buffer and DOPC/DOPS and 
DMPC/DMPS vesicles doped with 5 mol% RSV 
Conditions Lag 
phase 
(hours) 
(t1/2) or t50 
(hours)3 
kagg (s-1) 1or2 Final 
fluorescence 
intensity of 
plateau 
phase (x106) 
SST 12 51 0.01862 2.7 
SST+RSV 0 12 0.04021 1.3 
SST+DOPC+DOPS 0 2.6 0.3251 5.6 
SST+DOPC+DOPS+RSV 5 mol% 0 0.5 Fitting not 
possible 
9.8 
SST+DMPC+DMPS 0 0.3 0.2191 12.3 
SST+DMPC+DMPS+RSV 5 mol% 0 1.0 0.4771 8.7 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
RSV has been shown to inhibit aggregation, both in solution, and doped within a lipid bilayer, 
where it appears to act against the promoting effect of the lipid bilayer.   
A similar study was then carried out on two additional stilbene analogues of RSV, TS (TS) and 
TMS (TMS). Both of these molecules have a much lower topological polar surface area than 
RSV, and a higher octanol-water partition coefficient, suggesting that they are more likely to 
reside within the lipid bilayer environment of the liposomes.   
6.3.4 SST-14 interaction with the lipid bilayer doped with tri-methoxy RSV and 
trans-stilbene  
DLS data show some changes to the liposome hydrodynamic particle size and distribution upon 
the addition of stilbenes, TS and TMS which has impacted the size of the vesicles slightly 
compared to RSV (Figure 6.12) (in appendix Table S8.6).  However, as these changes are not 
consistently to higher or lower average liposome size, it is likely these represent some 
experimental variation in liposomes size which is unlikely to affect the results.   
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Figure 6.12. Shows the Dynamic light scattering (DLS) curves for pure saturated chain vesicles 
and saturated vesicles doped with 5 mol% stilbenes (a) DLPC, (b) DMPC, (c) DPPC and (d) 
DSPC 
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Figure 6.13. SST-14 environment in bilayer and bilayer doped with stilbenes, measured by 
Tryptophan Fluorescence 
The hydrophobicity of the local environment of the tryptophan residue present in SST-14 was 
studied in TMS using intrinsic tryptophan fluorescence assay (Figure 6.13). (Note that data for 
TS are not available). As for RSV, a significant red shift, i.e. to the higher wavelength (Figure 
6.13) was observed for SST co-incubated with TMS in solution, suggesting a conformational 
change has occurred upon interaction with TMS. Again, the addition of the liposomes caused 
a corresponding blue shift or decrease in λ max. This blue shift is greater in the presence of 
TMS, which may be related to the higher hydrophobicity of this molecule compared to RSV. 
Variations between the different lipid compositions were reduced compared to that for pure 
bilayers or RSV-doped bilayers. However, the data again suggest that the SST peptide has 
interacted with the lipid bilayer, with some penetration of the peptide into the bilayer.   
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6.3.5 Effect of the stilbenes TMS and TS on fibrillisation of SST-14  
ThT fluorescence binding assays were used to monitor the kinetics of SST-14 amyloid fibril 
formation in the presence of TMS and TS, both in solution and doped within a lipid bilayer.   
A significant reduction in the final fluorescence intensity of the plateau phase was observed 
following addition of either TMS or TS in solution (Figure 6.14) suggesting fewer fibrils are 
formed, in agreement with results for RSV and previous data on the effect of RSV on the 
fibrillisation of toxic amyloid-forming peptides (146, 391). However, in contrast to RSV, both 
TMS and TS increased the lag phase to 24 and 54 hours, respectively. TS also significantly 
reduced the value of kagg (0.003 s
-1) (Table 6.5) relative to in buffer (0.019 s-1), suggesting that 
it not only reduced the final volume of fibrils formed, but also the rate of fibril growth.   
The effect of TMS and TS doped within liposomes formed from saturated hydrocarbon chains 
was also investigated Figure 6.15.  In the absence of the stilbenes, these liposomes are known 
to have a strong promoting effect on fibrillisation of SST.  For all saturated chain liposomes 
doped with TS, the intensity of the final fluorescence plateau was reduced (or remained 
relatively constant) relative to the bilayer without TS, similar to what was seen for RSV.  
However, the addition of TMS within these bilayers resulted in an increase to the fluorescence 
plateau, the opposite effect to that of TMS in solution. This effect was very marked, with the 
plateau increasing by approximately an order of magnitude relative to SST in solution. 
Addition of TMS to the bilayer also reduced the lag time, suggesting that it both increases the 
nucleation rate and the final volume of fibrils formed. In contrast, the effect of bilayer-
encapsulated TS again depended on the lipid chain length. For short-chain lipids, the addition 
of TS reduced the lag rate whereas for longer chain lipids it increased the lag rate.   
Aggregation rate constants (kagg) did not vary considerably between the liposomes with and 
without stilbenes suggesting that while the peptide-bilayer interactions may impact nucleation 
rates and volume of fibrils formed, they have a lesser effect on the actual rate of growth of the 
fibrils.   
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Figure 6.14. Shows the ThT assay curves for 5% (w/w) SST-14 incubated in buffer (NaCl) vs 
stilbenes co-dissolved using DMSO 
Table 6.5. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) in buffer vs stilbenes 
Conditions Lag 
phase 
(hours) 
(t1/2) or t50 
(hours)3 
kagg (s-1) 1or2 Final fluorescence 
intensity of plateau 
phase (x106) 
SST 12 51 0.01861 2.7 
SST+RSV 5 mol% 0 12 0.04021 1.3 
SST+TS 5 mol% 54 104 0.003412 0.3 
SST+TMS 5 mol% 24 46 0.02782 1.7 
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Figure 6.15. Shows the ThT assay curves for 5% (w/w) SST-14 co-incubated in saturated chain 
lipids doped with 5 mol% stilbenes (a) DLPC, (b) DMPC, (c) DPPC vesicles and (d) DSPC   
 
 
  
124 
 
Table 6.6. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) co-incubated in the buffer, stilbenes, saturated 
chain lipids and saturated chain lipids doped with 5 mol% stilbenes 
Conditions Lag 
phase 
(hours) 
t50 or (t1/2) 
(hours)3 
kagg (s-1)1or2 Final fluorescence 
intensity of plateau 
phase (x106) 
 Buffer 
SST 12 51 0.01862 2.7 
SST+RSV 0 12 0.04011 1.3 
SST+TS 54 104 0.003412 0.3 
SST+TMS 24 46 0.02782 1.7 
 Effect of chain length or bilayer thickness 
SST+DLPC 0 6.3 0.05891 3.8 
SST+DLPC+RSV 5 mol% 0 1.9 0.2231 2.2 
SST+DLPC+TS 5 mol% 0 7.6 0.06601 3.1 
SST+DLPC+TMS 5 mol% 6 23 0.03192 21.2 
SST+DMPC 0 13 0.03801 6.2 
SST+DMPC+RSV 5 mol% 0 37 0.1351 2.2 
SST+DMPC+TS 5 mol% 0 26 0.01581 8.3 
SST+DMPC+TMS 5 mol% 0 33 0.02081 19.4 
SST+DPPC 24 41 0.06312 4.9 
SST+DPPC+RSV 5 mol% 24 56 0.0212 1.9 
SST+DPPC+TS 5 mol% 12 36 0.02762 3.1 
SST+DPPC+TMS 5 mol% 0 21 0.04871 9.1 
SST+DSPC 12 28 0.05112 4.8 
SST+DSPC+RSV 5 mol% 24 37 0.04252 2.0 
SST+DSPC+TS 5 mol% 12 32 0.02802 3.9 
SST+DSPC+TMS 5 mol% 0 21 0.03051 7.3 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
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The DLS data is showing a hydrodynamic particle size and distribution which suggests that 
stilbenes have intercalated well within the bilayer (Figure 6.16) (in appendix Table S8.7). 
 
Figure 6.16. DLS curve for pure DMPC+Chol vesicle and vesicle doped with 5 mol% stilbenes 
Addition of cholesterol to the liposomes did not significantly affect the results. As for samples 
without cholesterol, the greatest fibril growth is observed with TMS (Figure 6.17) doped in 
DMPC/Chol, which shows the highest final fluorescence intensity before reaching a plateau. 
This is also consistent with the highest kagg value (0.06 s
-1) and the lowest t1/2 (11 h) (Table 
6.7).   
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Figure 6.17. Shows the ThT assay curves for 5% (w/w) SST-14 co-incubated in the buffer and 
DMPC/Chol vesicles doped with 5 mol% stilbenes 
Table 6.7. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) co-incubated in the buffer and DMPC/Chol 
vesicles doped with 5 mol% stilbenes 
Conditions Lag 
phase 
(hours) 
(t1/2) or t50 
(hours)3 
kagg (s-1) 1or2 Final fluorescence 
intensity of plateau 
phase (x106) 
SST 12 51 0.01862 2.7 
SST+RSV 0 12 0.04021 1.3 
SST+TS 54 104 0.003412 0.3 
SST+TMS 24 46 0.02782 1.7 
SST+DMPC+CHOL 0 23 0.03021 11.0 
SST+DMPC+CHOL+RSV 5 mol% 0 14 0.02011 5.2 
SST+DMPC+CHOL+TS 5 mol% 12 30 0.03882 9.6 
SST+DMPC+CHOL+TMS 5 mol% 0 11 0.06061 15.2 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
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6.3.6 SST-14 interaction with anionic charged lipid bilayer doped with tri-
methoxy RSV and trans-stilbene 
The DLS data is suggesting only minor changes to the particle size distribution on the addition 
of TMS or TS (Figure 6.18) (in appendix Table S8.8). 
 
Figure 6.18. DLS curve for (a) Pure DOPC+DOPS vesicle and vesicle doped with 5 mol% 
stilbenes and (b) Pure DMPC+DMPS vesicle and vesicle doped with 5 mol% stilbenes 
Even for the anionic bilayers, which strongly promote fibril formation, a significant increase 
in the final fluorescence intensity of the plateau phase (Figure 6.19) is observed upon 
incorporating TMS. This is suggesting that hydrophobic and electrostatic interactions are 
strongly promoting aggregation in SST-14.  
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Figure 6.19. Illustrations of: (a) ThT assay curves for 5% (w/w) SST-14 co-incubated in buffer 
and DOPC/DOPS vesicles doped with 5 mol% stilbenes (b) ThT assay curves for 5% (w/w) 
SST-14 co-incubated in buffer and DMPC/DMPS vesicles doped with 5 mol% stilbenes 
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Table 6.8. Shows the lag phase, half-time, aggregation rate constant and the final fluorescence 
intensity of plateau phase for SST at 5% (w/w) co-incubated in the buffer and DOPC/DOPS 
and DMPC/DMPS vesicles doped with 5 mol% stilbenes 
Conditions Lag phase 
(hours) 
(t1/2) or t50 
(hours)3 
kagg (s-1) 1or2 Final fluorescence 
intensity of plateau 
phase (x106) 
SST 12 51 0.01862 2.7 
SST+RSV 0 12 0.04021 1.3 
SST+TS 54 104 0.00342 0.3 
SST+TMS 24 46 0.02782 1.7 
SST+DOPC+DOPS 0 2.6 0.3251 5.6 
SST+DOPC+DOPS+RSV 5 
mol% 
0 0.5 Fitting not 
possible 
9.8 
SST+DOPC+DOPS+TS 5 
mol% 
0 17 0.03161 6.9 
SST+DOPC+DOPS+TMS 5 
mol% 
0 2.4 0.2181 9.9 
SST+DMPC+DMPS 0 0.3 0.2191 12.3 
SST+DMPC+DMPS+RSV 5 
mol% 
0 1.0 0.4771 8.7 
SST+DMPC+DMPS+TS 5 
mol% 
0 1.5 0.4211 10.8 
SST+DMPC+DMPS+TMS 5 
mol% 
0 2.2 0.3331 21.1 
One-phase association1, Plateau followed by one-phase association2 and half-time3 
Since it has been reported that RSV has no significant absorption within the range of ThT 
fluorescence (391), nevertheless this does not imply that it will not interfere with ThT assays. 
Thus, complementary AFM study was conducted to confirm that results are not influenced by 
interference between ThT and stilbenes.  
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6.3.7 Clear morphological differences are observed between fibrils formed in the 
buffer and RSV doped with lipid vesicles 
In Chapter 3, we concluded that SST aggregates into typical amyloid-like unbranched twisted 
fibrillar structures in solution.  In contrast, the fibrils formed by SST co-incubated with DMPC 
vesicles were much longer and had slightly greater stiffness, suggesting that SST fibrils form 
heterogeneous structure, likely due to an uneven coating of lipids decorating the fibrils. 
AFM images were obtained of SST samples incubated with the three stilbene derivatives in 
solution and encapsulated within DMPC bilayers.   
Following the incubation of SST-14 fibrils in RSV (absence of lipid) no fibrils were detected, 
(Figure 6.20a) in agreement with ThT assay results which showed a decrease in the 
fluorescence intensity. Both techniques suggest that RSV had indeed inhibited SST fibril 
formation (Figure 6.8). However, in the presence of a bilayer doped with RSV, fibrils were 
observed tightly associated into clusters of lipid aggregates (Figure 6.20b).  The few individual 
fibrils that can be detected are much shorter fibrils, indicating that RSV had impacted fibril 
growth also when encapsulated within the bilayer.  
 
Figure 6.20. AFM analysis of SST-14 fibrils at 10% (w/w) with RSV, topographic images of 
(a) SST-14 with 5 mol% RSV displaying little or fibrils and (b) SST-14 co-incubated with 
DMPC vesicles doped with 5 mol% RSV displaying much shorter fibrils  
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AFM analysis of SST-14 fibrils in TS (absence of lipids) again showed no evidence of fibrils, 
but tiny aggregates clumped together (Figure 6.21a) which is also in agreement with the lowest 
fluorescence intensity observed with ThT assay (Figure 6.14). Whereas, long SST fibrils 
showing twists (Figure 6.21b) were observed in DMPC vesicles doped with TS. This is 
consistent with the ThT assay which indicated that fibrils were still formed in the presence of 
the TS-doped liposomes (Figure 6.15b), albeit at a lower volume. AFM images suggest that 
incubation with TS in DMPC bilayer had little effect on SST fibril morphology.  
 
Figure 6.21. AFM analysis of SST-14 fibrils at 10% (w/w) with TS, topographic images of (a) 
SST-14 with 5 mol% TS displaying little or no fibrils and (b) SST-14 with DMPC vesicles 
doped with 5 mol% TS displaying neat long fibrils  
Lastly, AFM analysis of SST-14 fibrils in TMS (absence of lipids) shows little or no fibrils 
(Figure 6.22a), which also be compared to the lower fluorescence intensity observed with ThT 
assay (Figure 6.14). However, SST co-incubated with DMPC bilayer doped with TMS shows 
long SST fibrils (Figure 6.22b) suggesting that TMS has little effect on SST fibril morphology. 
This, in fact, agrees with the highest final fluorescence intensity observed in the plateau region 
compared to SST+DMPC+TMS (Figure 6.15b).  
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Figure 6.22. AFM analysis of SST-14 fibrils at 10% (w/w) with TMS, topographic images of 
(a) SST-14 with 5 mol% TMS displaying little or no fibrils and (b) SST-14 with DMPC vesicles 
doped with 5 mol% TMS displaying neat long fibrils  
6.4 Discussion 
RSV an active phytochemical present in many plants and wine has received much research 
attention due to its ability to decrease cognitive impairment and amyloid neuropathology. The 
exact mechanism by which RSV exerts neuroprotective effects continues to be defined. RSV 
has been shown to inhibit fibrillisation of toxic amyloid-forming peptides including IAPP and 
Aβ (3, 391, 394). In this chapter, RSV and two stilbene analogues TMS and TS, were shown 
to inhibit fibril formation in solution for the functional amyloid-forming peptide, SST. A 
significant decrease in the intensity of the fluorescence plateau was observed in the presence 
of all three stilbenes. Although RSV has no significant absorption in the wavelength range of 
ThT fluorescence, some issues have been previously observed in using ThT assays to monitor 
inhibition of amyloid fibril formation by inhibitors. For example, RSV has been shown to 
reduce the ThT intensity of pre-formed A fibrils, and it has been suggested that it might 
displace the bound ThT from the fibrils (403). While we have no evidence that RSV interferes 
with ThT binding to SST fibrils, AFM images were nevertheless used as a complementary 
technique to reflect deposited fibrils and in the presence of the stilbenes was significantly 
reduced, with little to no fibrils observed.   
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Both TMS and TS increased the lag phase, while RSV actually decreased the lag phase 
suggesting that nucleation of this functional amyloid occurred faster in the presence of RSV, 
in contrast to what has been seen for toxic amyloid formation. This suggests there may be 
fundamental differences between the peptide-TMS/peptide-TS interactions, and the peptide-
RSV interaction. Previously RSV has been shown to interact with the toxic amyloid-forming 
peptide IAPP through the His-18 and Lys-1 residues (403). Interactions between aromatic side-
chains and amyloid inhibitors, including polyphenols, have also been previously observed 
(404).  Finally, π-cation interactions have been shown to stabilise globular proteins (405). SST 
contains a positively charged Lys residue (pKa = 10.5) at approximately neutral pH, as well as 
the aromatic amino acids Phe (3) and Trp all of which could interact with the stilbene inhibitors 
studied.   
 
Figure 6.23. Diagrammatic illustrations of how RSV inhibits SST fibrillisation by disturbing 
the lipid monolayer by a dual effect approach (adapted from (29))  
Addition of the stilbene inhibitor into a lipid bilayer did not result in the same trends as in 
solution suggesting that the interaction method may be different.  In solution, the stilbenes will 
interfere with fibrillisation by direct interactions with the peptide, which modify the peptide-
peptide interactions necessary for fibrillisation. However, in a bilayer, these molecules may 
affect fibrillisation in two ways. 1. By Binding directly to the peptide (similar to in solution), 
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the stilbene may prevent the peptide from interacting with the membrane (This mechanism was 
suggested by Evers et al. and is shown in Figure 6.23 (29) 2. By insertion into the lipid bilayer, 
the stilbene may change the physiochemical properties of the bilayer such that the interaction 
with the peptide is modified. The theoretical partition coefficients of RSV in DMPC, DPPC 
and DSPC vesicles have been calculated as 2.63, 3.07 and 3.11, respectively (378). The 
percentage of membrane-bound RSV was reported 93%, 97% and 98% in DMPC, DPPC and 
DSPC membranes respectively (378). The low topological polar surface areas associated with 
all three stilbenes indicate that all three will associate with the lipid bilayer to some extent. The 
tPSA is lowest for TS suggesting that this molecule may have most bilayer-association 
(although TMS has a slightly higher octanol-water partition coefficient). DLS data indicate that 
encapsulation of these molecules into the lipid bilayer did not impact the size distribution of 
liposomes. This is expected to affect chain packing within the lipid bilayer although this was 
not directly investigated during the thesis. RSV has been previously observed to act as a spacer, 
causing an increase in disorder lipid molecules in the bilayer (381). RSV molecule is also 
reported to bind near the head group region of the phospholipid, which induces an increase in 
surface area per lipid and subsequently decreasing membrane thickness (26). 
Both TS and RSV appeared to inhibit fibrillisation in the bilayer, similar to what was observed 
in solution, acting against the generally promoting effect of the saturated lipid bilayers studied.  
This was the case, even for charged bilayers, which are strongly promoting.  While the 
fluorescence plateau was reduced relative to that seen with the bilayer alone, it was still higher 
than that observed in the absence of a bilayer, suggesting that the promotion effect of the bilayer 
is dominant.  It is possible that increasing the concentration of RSV in the bilayer may act to 
reduce fibrillisation even more. However, TMS actually promoted fibrillisation when 
encapsulated in the lipid bilayer, with higher fluorescence plateau values.   
In fluid short-chain bilayers (DLPC and DMPC), the stilbenes reduced the lag time, suggesting 
nucleation is actually faster in the presence of these ‘inhibitors’. However, AFM images 
suggest that the fibrils formed in the presence of stilbene-doped DMPC bilayers can be shorter 
or aggregated into clusters (as for RSV doped DMPC) suggesting that the faster nucleation 
may have led to an off-aggregation pathway.  In contrast, in gel bilayers (DPPC, DSPC), while 
TMS and RSV still reduce the lag time, TS increases the lag time, similar to what is observed 
in solution. As TS has a high logP value and a tPSA of essentially zero, it is not likely that this 
effect is via free TS in solution.   
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In summary, RSV, which is known as an inhibitor of toxic amyloid formation, was also shown 
to act as an inhibitor of fibrillisation for the functional amyloid-forming peptide SST. Two 
stilbene derivatives of RSV, TMS and TS, which are not polyphenols were shown to have a 
greater inhibiting effect in solution. The effect of the stilbenes, when encapsulated in a bilayer, 
was not always the same as that in solution suggesting that peptide inhibition may result from 
a different mechanism.  
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7. Conclusion and Future work 
Fundamental differences in aggregation were observed between the different peptides in 
solution. For the three cyclic peptides studied, SST forms typical long amyloid-like unbranched 
twisted fibrillar structures in solution, oxytocin formed a small number of very short fibrils, 
and no fibrils were detected via AFM or the ThT assay for vasopressin. It is particularly 
interesting to note the differences in fibrillisation between oxytocin and vasopressin, as these 
peptides are structurally similar, and differ only in the amino acids at positions 3 and 8. The 
increase in aggregation propensity for oxytocin may reflect the substitution of the 
Phenylalanine amino acid for Isoleucine for at position 3, as this is known to promote π – π 
stacking interactions, and increase the hydrophobicity of the peptide. The linear peptides 
Substance P and Deslorelin displayed markedly different aggregation behaviour than the cyclic 
peptides.  Needle-like fibrillar structures were observed for Substance P, while numerous 
multi-laminar crystalline structures were observed for Deslorelin.  Similar structures have been 
observed in solution for Substance P, and for LHRH, an analogue of Deslorelin and confirmed 
via SAXS to have internal nanotube, rather than fibril, symmetry.   
For all peptides studied, both cyclic and linear, co-incubation with a lipid bilayer was observed 
to impact both the rate of aggregation and the morphology of fibrils formed.  While there were 
obvious differences between the different peptides, some clear trends emerged throughout the 
thesis. The effect of surface charge in the lipid bilayer was dominant for all peptides studied.  
Strong electrostatic interactions between the typically cationic peptides, and an anionic bilayer, 
were found to drive the highest volume of fibrils formed in each case.  In fact, AVP only formed 
fibrils in the presence of an anionic bilayer, with either no, or a very small volume of fibrils 
formed in solution, or in the presence of uncharged bilayers.  For this peptide we demonstrated 
that the final volume of fibrils formed was proportional to the overall charge on the bilayer.   
In general, lipid bilayers formed from saturated chain lipids tended to increase the rate of 
aggregation, and the volume of fibrils formed. In contrast, unsaturated chain lipids tended to 
inhibit fibrillisation, decreasing the rate of aggregation, increasing the lag time, and reducing 
the total volume of fibrils formed.  For the peptide SST this was clearly linked to the interaction 
between the peptide and the lipid bilayer.  Intrinsic tryptophan fluorescence studies indicated 
that the peptide penetrated more into the unsaturated DOPC bilayer than into the saturated 
chain bilayers, presumably due to the increase in lateral bilayer pressure associated with the 
saturated chains. We suggest that the peptide-peptide interactions necessary for fibrillisation 
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are promoted by a more peripheral attachment of the peptide to the membrane surface, but 
inhibited by deeper penetration into the bilayer.   
The effect of chain length varied among the different peptides.  For all peptides studied, no 
significant differences in the kagg values were observed among the different saturated chain 
lipids, suggesting that the actual rate of growth of the peptide fibril did not depend on the lipid 
environment.  This is consistent with a mechanism where the lipid bilayer acts as a nucleation 
site for peptide-peptide interactions but does not accelerate the actual growth process.  For SST, 
the lag period was shortest for the short-chain bilayers DLPC and DMPC, however for the 
other peptides studied, the lag period was typically zero suggesting no differences in the ability 
of the different saturated chains to promote nucleation.  However, significant differences were 
observed between the different chain lengths in terms of the final volume of fibrils formed.  For 
SST and Deslorelin, most fibrils were formed in the presence of the short-chain lipids DLPC 
and DMPC.  However, for OT, AVP and SP, most fibrils were formed for the longer-chain 
lipids DPPC and DSPC.  This suggests that the mechanism by which the lipid membrane 
promotes an increased volume of fibrils formed may differ depending on the peptide.  This 
does not seem to depend on whether the peptide is linear or cyclic, or the morphology of the 
aggregates formed (fibrils vs nanotubes). The effect may be related to lipid solubility (the short 
chain lipids are typically more soluble as expected) and suggests that the membrane-mediated 
mechanism of fibrillisation may involve a reciprocal transfer of lipids from the bilayer to the 
growing fibril.  It may also be related to lipid chain packing.  The shorter-chain lipids DLPC 
and DMPC form a fluid lamellar phase at room temperature, while the longer chain lipids form 
a gel lamellar phase.  However, we suggest that the effect of a gel vs fluid bilayer is more 
minor, as DOPC also forms a fluid lamellar phase at room temperature, yet is not observed to 
promote fibril growth for any peptide studied.   
The morphology of the aggregates formed was also affected by the presence of the lipid bilayer.  
For SST, evidence of lipid coating of the fibrils was seen.  The fibrils were more heterogeneous 
and had a tendency to be longer. The typical twisted morphology of the fibrils in solution was 
also obscured due to the lipid coating. For Des, which appears to form bundles of nanotubes in 
solution, addition of lipids results in a completely different aggregate morphology. We suggest 
that the twisted aggregates observed are twisted or helical ribbons, which are suggested to be 
structural intermediates during the formation of nanotubes.  In this case, the lipid coating may 
be preventing lateral association of the protofilaments into nanotubes.  
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While the peptides studied clearly interact with the lipid bilayer in all cases, a reciprocal 
structural effect on the lipid bilayer was not observed for SST, in either the bulk lamellar phase 
or in liposomes.  This is in contrast to the behaviour of toxic amyloid-forming peptides which 
cause major structural perturbations to the lipid bilayer, and may partially explain the reduced 
toxicity of functional amyloids.   
In Chapter 6 we showed that the polyphenol resveratrol, which is known to inhibit fibril 
formation for toxic amyloid-forming peptides, also inhibited fibrillisation for the functional 
amyloid-forming peptide, SST. Two stilbene derivatives of resveratrol, trans-3,5,4’-
trimethoxystilbene (TMS) and trans-stilbene (TS), were also shown to inhibit fibril formation 
in solution, despite not being polyphenols. In a lipid bilayer environment, the behaviour of 
these molecules, which are reasonably soluble in the lipid bilayer, was not the same as in 
solution.  In fact, TMS, which inhibits fibrillisation in solution, consistently and strongly 
promoted fibrillisation in a bilayer environment.  In solution the stilbene molecules presumably 
modify peptide-peptide interactions by direct interaction with the peptide itself.  However, in 
a lipid bilayer, the stilbene may modify fibrillisation by changing the physicochemical 
properties of the bilayer such that the peptide-lipid interaction is modified.   
In summary, we have shown that the lipid bilayer, and stilbene additives, have a significant 
effect on the fibrillisation of five different functional amyloid-forming peptides. This 
represents a significant increase to the body of literature in this area, as only a single 
experimental study has, to date, investigated this effect. We suggest that intrinsic peptide-
peptide interactions are the ultimate driving force behind fibrillisation. However, the lipid 
membrane may promote fibrillisation by facilitating peptide-peptide interactions on the 
membrane surface or inhibit fibrillisation when peptide insertion into the bilayer is deep enough 
to preclude such interactions. The mechanism by which this occurs remains unresolved.  Future 
work will involve direct visualisation of the peptide-lipid interactions using confocal 
microscopy with fluorescently tagged lipids. This could allow for direct visualisation of any 
reciprocal transfer of bilayer lipids into the growing fibril.   
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Appendix 
Table S8.1. Analysis of hydrophobicity, net charge, and % charged amino acids of SST-14 
using PEPTIDE 2.0 (34) 
Peptides 
Mw 
(kDa) 
 
Structure 
Amino 
acid 
residues 
Net 
charge 
 
Charged amino 
acids % 
Hydrophobic 
residue% 
Somatostatin 1.60 
 
Cyclic 
14 +2 
 
14 
36 
Vasopressin 1 
 
Cyclic 
9 +2 
 
33 
22 
Oxytocin 1 
 
Cyclic 
9 +1 
 
22 
22 
Substance P 1.3 
 
Linear 
11 +3 
 
45 
55 
Deslorelin 1.3 
 
Linear 
10 +1 
 
44 
50 
 
 
Figure S8.1. Shows the DLS curves for liposomes doped with various lipid compositions 
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Table S8.2. Shows the hydrodynamic size of liposomes doped with various compositions 
Sample Avg size-nm 
DOPC 130 
DOPC+Chol 148 
DOPC+DOPS 135 
DMPC 135 
DMPC+Chol 125 
DMPC+DMPS 125 
DLPC 128 
DPPC 89 
DSPC 108 
 
Table S8.3. Quantitative analysis of the CD spectra for SST incubated in liposomes 
Liposomes Wavelength (nm) 
After 3 hours 
DOPC 205 
65DOPC+35DOPS  
After 72 hours 
DOPC 204 
DMPC weak intensity 
65DOPC+35DOPS 210 
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Table S8.4. Shows the effect of concentration on kagg, half-time and lag phase for SST in NaCl
 
% (w/w) 
Lag phase 
(hours) 
t50 or (t1/2) 
(hours)3 
kagg (s-1)
 2 
0.01 absent 0 0 
0.05 absent 0 0 
0.1 absent 0 0 
0.5 absent 0 0 
1 absent 0 0 
2.5 58 112 0.0036712 
5 12 51 0.017882 
Plateau followed by one-phase association2 and half-time3 
Table S8.5. Quantitative analysis of the CD spectra for SP incubated in liposomes after 72-
hours 
Liposomes Wavelength (nm) 
After 72 hours 
DOPC Weak intensity 
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Table S8.6. Shows the hydrodynamic size of saturated lipid vesicles with the presence and 
absence of stilbenes at 5 mol% 
Sample Avg size-nm 
DLPC 128 
DLPC+RSV 122 
DLPC+TS 164 
DLPC+TMS 91 
DMPC 135 
DMPC+RSV 148 
DMPC+TS 164 
DMPC+TMS 85 
DPPC 89 
DPPC+RSV 106 
DPPC+TS 97 
DPPC+TMS 72 
DSPC 108 
DSPC+RSV 121 
DSPC+TS 122 
DSPC+TMS 95 
 
Table S8.7. Shows the hydrodynamic size of DMPC+Chol vesicles with the presence and 
absence of stilbenes at 5 mol% 
Sample Avg size-nm 
DMPC+Chol 125 
DMPC+Chol+RSV 122 
DMPC+Chol+TS 5mol% 118 
DMPC+Chol+TMS 5mol% 115 
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Table S8.8. Shows the hydrodynamic size of anionic charged vesicles with the presence and 
absence of stilbenes at 5 mol% 
Sample Avg size-nm 
DOPC+DOPS 135 
DOPC+DOPS+RSV 122 
DOPC+DOPS+TS 115 
DOPC+DOPS+TMS 98 
DMPC+DMPS 125 
DMPC+DMPS+RSV 91 
DMPC+DMPS+TS 89 
DMPC+DMPS+TMS 105 
 
 
 
Figure S8.2. ThT curve fit for SST (5% w/w) in NaCl 
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Figure S8.3. ThT curve fit for SST (5% w/w) in DOPC 
 
Figure S8.4. ThT curve fit for SST (5% w/w) in DLPC 
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Figure S8.5. ThT curve fit for SST (5% w/w) in DMPC 
 
Figure S8.6. ThT curve fit for SST (5% w/w) in DPPC 
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Figure S8.7. ThT curve fit for SST (5% w/w) in DSPC 
 
Figure S8.8. ThT curve fit for SST (5% w/w) in DOPC+Chol 
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Figure S8.9. ThT curve fit for SST (5% w/w) in DMPC+Chol 
 
Figure S8.10. ThT curve fit for SST (5% w/w) in DOPC+DOPS 
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Figure S8.11. ThT curve fit for SST (5% w/w) in DMPC+DMPS 
 
 
Figure S8.12. ThT curve fit for OT (0.1% w/w) in NaCl 
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Figure S8.13. ThT curve fit for OT (0.5% w/w) in NaCl 
 
Figure S8.14. ThT curve fit for OT (5% w/w) in NaCl 
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Figure S8.15. ThT curve fit for OT (0.5% w/w) in DOPC 
 
Figure S8.16. ThT curve fit for OT (0.5% w/w) in DOPC+Chol 
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Figure S8.17. ThT curve fit for OT (0.5% w/w) in DOPC+DOPS 
 
Figure S8.18. ThT curve fit for OT (0.5% w/w) in DLPC 
0 50 100 150 200
0
1×107
2×107
3×107
Time (hours)
F
lu
o
re
s
c
e
n
c
e
Kagg = 0.2583 s
-1
0 50 100 150 200
0
5×106
1×107
1.5×107
2×107
2.5×107
Time (hours)
F
lu
o
re
s
c
e
n
c
e
Kagg = 0.3466 s
-1
  
173 
 
 
Figure S8.19. ThT curve fit for OT (0.5% w/w) in DMPC 
 
Figure S8.20. ThT curve fit for OT (0.5% w/w) in DMPC+Chol 
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Figure S8.21. ThT curve fit for OT (0.5% w/w) in DMPC+DMPS 
 
Figure S8.22. ThT curve fit for OT (0.5% w/w) in DPPC 
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Figure S8.23. ThT curve fit for OT (0.5% w/w) in DSPC 
 
Figure S8.24. ThT curve fit for AVP (5% w/w) in 95DMPC+5DMPS 
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Figure S8.25. ThT curve fit for AVP (5% w/w) in 85DMPC+15DMPS 
 
Figure S8.26. ThT curve fit for AVP (5% w/w) in 75DMPC+25DMPS 
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Figure S8.27. ThT curve fit for AVP (5% w/w) in 65DMPC+35DMPS 
 
Figure S8.28. ThT curve fit for Des (10% w/w) in DOPC 
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Figure S8.29. ThT curve fit for Des (10% w/w) in DOPC+Chol 
 
Figure S8.30. ThT curve fit for Des (10% w/w) in DOPC+DOPS 
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Figure S8.31. ThT curve fit for Des (10% w/w) in DLPC 
 
 
Figure S8.32. ThT curve fit for Des (10% w/w) in DMPC 
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Figure S8.33. ThT curve fit for Des (10% w/w) in DPPC 
 
Figure S8.34. ThT curve fit for Des (10% w/w) in DSPC 
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Figure S8.35. ThT curve fit for Des (10% w/w) in DMPC+Chol 
 
Figure S8.36. ThT curve fit for SP (10% w/w) in DLPC 
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Figure S8.37. ThT curve fit for SP (10% w/w) in DMPC 
 
Figure S8.38. ThT curve fit for SP (10% w/w) in DPPC 
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Figure S8.39. ThT curve fit for SP (10% w/w) in DSPC 
 
 
Figure S8.40. ThT curve fit for SP (10% w/w) in DOPC+Chol 
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Figure S8.41. ThT curve fit for SP (10% w/w) in DMPC+DMPS 
 
Figure S8.42. ThT curve fit for SST (5% w/w) in resveratrol (RSV) 
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Figure S8.43. ThT curve fit for SST (5% w/w) in trans stilbene (TS) 
 
Figure S8.44. ThT curve fit for SST (5% w/w) in trimethoxy resveratrol (TMS) 
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Figure S8.45. ThT curve fit for SST (5% w/w) in DLPC+RSV 
 
Figure S8.46. ThT curve fit for SST (5% w/w) in DLPC+TMS 
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Figure S8.47. ThT curve fit for SST (5% w/w) in DLPC+TS 
 
Figure S8.48. ThT curve fit for SST (5% w/w) in DMPC+RSV 
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Figure S8.49. ThT curve fit for SST (5% w/w) in DMPC+TS 
 
Figure S8.50. ThT curve fit for SST (5% w/w) in DMPC+TMS 
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Figure S8.51. ThT curve fit for SST (5% w/w) in DMPC+Chol+RSV 
 
Figure S8.52. ThT curve fit for SST (5% w/w) in DMPC+Chol+TS 
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Figure S8.53. ThT curve fit for SST (5% w/w) in DMPC+Chol+TMS 
 
Figure S8.54. ThT curve fit for SST (5% w/w) in DMPC+DMPS+RSV 
0 50 100 150 200
0
5×106
1×107
1.5×107
2×107
Time (hours)
F
lu
o
re
s
c
e
n
c
e
Kagg = 0.06057 s
-1
0 50 100 150 200
0
2×106
4×106
6×106
8×106
1×107
Time (hours)
F
lu
o
re
s
c
e
n
c
e
Kagg = 0.4770 s
-1
  
191 
 
 
Figure S8.55. ThT curve fit for SST (5% w/w) in DMPC+DMPS+TS 
 
Figure S8.56. ThT curve fit for SST (5% w/w) in DMPC+DMPS+TMS 
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Figure S8.57. ThT curve fit for SST (5% w/w) in DOPC+DOPS+TS 
 
Figure S8.58. ThT curve fit for SST (5% w/w) in DOPC+DOPS+TMS 
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Figure S8.59. ThT curve fit for SST (5% w/w) in DPPC+RSV 
 
Figure S8.60. ThT curve fit for SST (5% w/w) in DPPC+TS 
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Figure S8.61. ThT curve fit for SST (5% w/w) in DPPC+TMS 
 
Figure S8.62. ThT curve fit for SST (5% w/w) in DSPC+RSV 
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Figure S8.63. ThT curve fit for SST (5% w/w) in DSPC+TS 
 
Figure S8.64. ThT curve fit for SST (5% w/w) in DSPC+TMS 
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